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An abnormal serotonin (5-HT) system has been thought to underlie the 
aetiology of depression and drugs that target the 5-HT system are clinically effective 
at alleviating depression. Antidepressants can affect circadian (24 hour) rhythms, 
some of which are abnormal in depression. Central serotoninergic function, which 
displays a marked circadian rhythm, is under the control of terminal 5 -HTj3  
autoreceptors. This thesis addresses the hypothesis that prolonged antidepressant 
treatment differentially alters the control the 5-HTig receptor exerts on synthesis 
and release through the light-dark cycle.
The basal synthesis rate of 5-HT varied significantly in the hypothalamus, 
hippocampus, frontal cortex and striatum over the light-dark cycle. RU24969, a 5- 
HTia/ib agonist, significantly decreased the rate of 5-HT synthesis in all brain 
regions. The degree of inhibition over the light-dark cycle varied significantly in the 
hippocampus, frontal cortex and striatum. The response was pharmacologically 
characterised as being mediated by a 5-HTjb receptor. The variation in the 
RU24969-induced decrease in 5-HT synthesis was significantly altered by chronic 
treatment with two antidepressant drugs; desipramine a noradrenaline uptake 
inhibitor and paroxetine a serotonin uptake inhibitor.
In vivo microdialysis was used to investigate 5-HT 1 3  control of 5-HT release 
in the anterior hypothalamus of anaesthetised rats at mid light and end light The 
release-suppressing effects of RU24969 were significantly greater when measured at 
end light compared to mid light After chronic antidepressant treatment, as above, 
the effect of RU24969 was significantly attenuated only at end light
The results agree with the proposed hypothesis, indicating that chronic 
antidepressant treatment affects 5 -HTj3  control of release and synthesis in a phase- 
dependent manner. A new model is proposed to explain how antidepressant drugs 
might alleviate depression with a circadian abnormality by their interaction with 5 - 
HT1B autoreceptors.
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Chapter 1 Introduction
This thesis is concerned with the interplay between serotonin (5- 
hydroxytryptamine, 5-HT), circadian (24 hour) rhythms and depression and 
antidepressant drugs. The introduction, therefore, aims to provide an overview of the 
central serotoninergic system and factors affecting it, depression and the role of 5-HT 
in affective disorder and finally, the effect of antidepressant drugs on the 5-HT system 
and circadian rhythms.
Serotonin
Since its discovery in the central nervous system by Twarog and Page in the 
early 1950s serotonin (5-hydroxytryptamine, 5-HT) has been implicated in many forms 
of mental illness.
Serotonin can act as both an inhibitory and excitatory neurotransmitter and so 
5-HT is thought to have a modulatory action in a variety of functions such as feeding, 
motor function, anxiety, sleep and hormonal release.
The central serotoninergic system arises from a group of cell bodies, which lie 
on or adjacent to the midline of the caudal brainstem through to the midline, called the 
raphe nuclei (RN). Formerly these nuclei were classified as B1-B9, but they are now 
divided into the superior and the inferior group (Jacobs and Azmitia 1992). The 
superior group, which comprises the dorsal and median raphe nuclei (DR and MR 
respectively), is the most important since it provides ascending innervation to virtually 
all brain regions. Whilst the inferior group projects to the ventral horn and substantia 
gelatinosa of the spinal cord.
Some target regions receive innervation from both the median and dorsal RN, 
but the degree of innervation can differ significantly, whilst others receive projections 
from only one of the RN, figure 1 shows a cross-section through the rat brain showing 
the location of the superior and inferior raphe groups and the preferential projections of 
































Figure 1. A. Coronal section through the rat brain indicating the location of the superior and inferior 
raphe nuclei. B. Schematic diagram of ascending 5-HT fibres from the median and dorsal raphe 
projecting to specific brain regions of interest to this thesis, based on Azmitia and Segal (1978).
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There is evidence that the fibres that project from the DR and MR differ significantly 
(Tork 1990). Fibres from the DR are thin, branch diffusely in their target region, have 
small heterogenous varicosities ranging in size and make undefined synaptic contacts. 
In contrast, fibres originating from the MR are thick and non-varicose, but branches 
contain round or oval varicosities, and make well-defined synapses with target cells. 
The DR system is more sensitive to neurotoxins such as p-chloroamphetamine (PCA) 
and 3,4-methylenedioxymetamphetamine (MDMA) than the MR (Dewar et al. 1992).
The RN themselves receive a number of projections from other brain regions 
(neurotransmitters indicated in brackets), the superior vestibular nucleus (acetylcholine; 
ACh), the nucleus of the solitary tract (adrenaline), the locus coeruleus and 
subcoeruleus (noradrenaline; NA), the substantia nigra and ventral tegmental area 
(dopamine; DA) and the periaqueductal grey (neuropeptides). The MR and DR receive 
a major innervation firom the lateral habenular nucleus which contains excitatory amino 
acids (EAA); this pathway synapses both directly onto MR and DR cell bodies and y- 
aminobutyric acid (GABA) intemeurons.
Serotonin synthesis
Since serotonin is hydrophilic at physiological pH, and therefore cannot cross 
the blood-brain barrier, it must be synthesised in the brain firom dietary 1-tryptophan (1- 
try); for a schematic diagram of the synthesis of 5-HT see figure 2. The level of 
circulating 1-try is determined by the catabolic liver enzyme tryptophan pyrrolase and 
under normal conditions, 90% of plasma 1-try is bound non-covalently to serum 
albumin; the d-isomer is not bound. L-tryptophan is actively transported across the 
blood-brain barrier by the neutral amino acid carrier, so the transport of 1-try is open to 
competition from other neutral amino acids such as tyrosine and leucine. L-try is taken 
into neuronal cells and glia by a carrier-mediated and non-saturable diffusion process. 
Brain 1-try levels vary between l-10pM (Knowles and Pogson 1984). Newly 
accumulated 1-try is considered to be preferentially converted to 5-HT, which has lead 
to the proposition that brain 1-try is distributed to two compartments. The first is a high
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capacity uptake system which accounts for 60% 1-try influx into the brain, where the 
uptake is subject to competition from large neutral amino acids, the second a low 
capacity system which is non-competitive.
L-try is converted to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase 
(EC 1.14.16.4, 1-tryptophan; tetrahydropteridine oxygen oxidoreductase; TrOH), a 
mixed function oxidase which is only found in 5-HT synthesising neurons. The gene 
encoding brain TrOH has recently been cloned and sequenced (Kim et al. 1991). TrOH 
contains 444 amino acids, has a MW of about 51kDa and is 50% homologous to 
tyrosine hydroxylase, the rate limiting step in the biosynthesis of dopamine and 
noradrenaline. Greatest homology rests in the middle and C-terminal regions of the 
enzymes, indicating that these regions contain the catalytic domain whilst the N- 
terminal is responsible for substrate recognition. The conversion of 1-try to 5-HTP is 
considered to be the rate-limiting step in the biosynthesis of 5-HT and requires 
molecular oxygen and reduced tetrahydrobiopterin (BH4 ) as co-factors. Under normal 
conditions the enzyme is unsaturated since rat brain 1-try levels range between 1 and 
lOpM and the Km of TrOH for 1-try is 50pM (Boadle-Biber 1993). In the conversion 
of 1-try to 5-HTP one molecule of oxygen is reduced to water for hydroxylation at the 
5 position, the electrons being donated by BH4 . The unstable quinoid dihydrobiopterin 
produced is immediately converted back to BH4  by a NADH-linked quinoid 
dihydropteridine reductase.
Once 5-HTP has been synthesised it is decarboxylated to 5-HT by the non­
specific aromatic amino acid decarboxylase (EC 4.1.1.28; AADC), almost immediately. 
The enzyme requires pyridoxal-5'-phosphate (vitamin Bg) as a co-factor. The 5-HT is 
formed in the cytoplasm and actively taken up by a specific 5-HT transporter driven by 
a pH gradient into dense core vesicles where it binds with high affinity to a specific 
serotonin-binding protein which is released with serotonin on exocytosis. 
Unsequestered 5-HT is degraded intraneuronally.
After 5-HT is released from the nerve terminal, and has acted on its target 









Figure 2. Schematic diagram of the pathway for the synthesis of 5-hydroxytryptamine from 1- 
tryptophan in the brain. L-tryptophan, derived from the diet, is converted to 5-hydroxytryptophan by 
tryptophan hydroxylase. 5-Hydroxytryptophan is then decarboxylated by the non-specific 1-aromatic 
amino acid decarboxylase to 5-hydroxytryptamine, which is, in turn, degraded to 5- 
hydroxyindoleacetic acid by monoamine oxidase.
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specific sodium-dependent transporter (Shaskan and Snyder 1970), which has recently 
been cloned (Hoffman et al. 1991). Inside the neuron 5-HT is degraded to 5- 
hydroxyindole aldehyde (5-HIA) by monoamine oxidase (EC 1.4.3.4.; MAO), which is 
located on the external wall of mitochondria. There are two isoforms of MAO, A and 
B. Classically MAO-A and -B can be distinguished by their substrate preference and 
brain distribution. MAO-A oxidises serotonin, dopamine and noradrenaline and is 
found in catecholaminergic neurons, whilst MAO-B prefers trace amines such as 
phenylethylamine and methylhistamine and is located in serotoninergic neurons (Kwan 
et al. 1992; Richards et al. 1992). This apparent discrepancy has recently been 
addressed. It has been proposed that at physiological concentrations of 5-HT, MAO-A 
degrades trace substances that might interfere with the storage, release and degradation 
of 5-HT. Once 5-HIA is formed it is degraded to either 5-hydroxy-trytophol by alcohol 
dehydrogenase or 5-hydroxyindoleacetic acid (5-HLAA) by aldehyde dehydrogenase, 
depending on the energy state of the neuron. 5-HLAA moves across the blood brain 
barrier by an acid transport process and is excreted in the urine.
Factors affecting serotoninergic neurotransmission
The degree of control, and relative importance, that any of the factors listed 
below exert on 5-HT neurotransmission is currently under debate.
Precursor availability
One factor that may control the synthesis rate of 5-HT in the brain is the 
availability of its precursor 1-try. In vitro studies using hypothalamic slices have shown 
that increasing the perfusing concentration of 1-try increases both the basal and 
stimulated release of 5-HT (Schaechter and Wurtman 1990). This effect is dose- 
dependent (Lookingland et al. 1986) using 1-try concentrations within the normal 
circadian range (Femstrom and Wurtman 1971). These findings have been partially 
confirmed by in vivo studies. Peripheral injection of 1-try can increase the level of 5-HT 
in dialysate samples in the ventral hippocampus of anaesthetised rats (Gartside et al. 
1992a) or the cortex of freely moving rats (Carboni et al. 1986). Peripheral
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administration of 5-HTP also increases dialysate 5-HT in the anaesthetised rat 
hypothalamus dose-dependently and the output was calcium-dependent (Gartside et al. 
1992b). Interestingly decreasing the level of 1-try, by increasing the concentration of 
other large neutral amino acids which compete with 1-try for uptake, decreases 5-HT 
levels in vitro (Schaechter and Wurtman 1990) and in vivo (Gartside et al. 1992a). One 
study in vivo has shown no increase in dialysate 5-HT levels after 1-try administration, 
although an increase in 5-HIAA was observed after the maximal dose of 1-try (Shaip et 
al. 1992). However the amount of 5-HT released per pulse was increased after 1-try 
administration and the increase was proportionally greater at higher stimulation 
frequencies of the DR (Sharp et al. 1992). Studies using positron emission topography 
in living dog brain have shown that increasing plasma 1-try concentrations increases 5- 
HT synthesis rate in a linear fashion (Diksic et al. 1991), thereby providing convincing 
evidence that 5-HT synthesis rate can be affected by the plasma 1-try level.
The function of the newly synthesised 5-HT is currently under debate. There is 
evidence that it is degraded intraneuronally (Lookingland et al. 1986; Shaip et al. 
1992), spills out of the neuron (Trulson and Jacobs 1976), or is functional (Schaechter 
and Wurtman 1990, Gartside et al. 1992a; Sharp et al. 1992). It has been suggested 
(Sharp et al. 1992) that when the increase in 1-try is within the circadian range the 5- 
HT produced is metabolised intraneuronally. At higher levels synthesis rate outstrips 
the degradation capability of the neuron and the 5-HT enters the releasable pool.
5-HT neuronal firing
Nearly all experiments investigating raphe 5-HT neuronal firing have been 
performed in unanaesthetised, head-restrained cats. Raphe neurons show a highly 
regular, slow discharge pattern in anaesthetised animals (Jacobs and Azmitia 1992) 
which appears to be an inherent property of the neurons since it persists in vitro. This 
rhythm is present from an early stage in development and can be accounted for by 
membrane ionic conductances (Jacobs and Azmitia 1992). The firing rate of the 5-HT 
neurons is related to the state of arousal of the animal, both in rats (Imeri et al. 1994) 
and cats (Trulson and Jacobs 1979; Wilkinson et al. 1991). The phenomenon has been
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studied best in cats. During REM sleep cells fire at 0-0.3 spikes/sec; this increases in 
slow wave sleep to 0.3-1.5 spikes/sec , 1.5-2.0 spikes/sec when the cat is drowsy, 2.- 
3.0 spikes/sec during quiet waking, 3.0-5.0 spikes/sec during active waking and 4.0-7.0 
spikes/sec when the cat is physically aroused. Using the technique of in vivo 
microdialsysis, Wilkinson and colleagues (1991) have demonstrated that changes in 
neuronal firing affect the terminal release of 5-HT. The firing rate of raphe 5-HT 
neurons is remarkably resistant to stimuli Increased temperature or blood pressure, 
pain, changes in glucose availability, restraint or the introduction of a dog into the cat's 
vicinity all have no effect on the firing rate (Jacobs and Azmitia 1992). Stimulation of 
the RN has been reported to increase 5-HT synthesis (Petersen et ai 1989), whilst 
decreasing RN firing rate decreases synthesis (Invemizzi et a i 1991).
5-HT autoreceptors and heteroreceptors
An autoreceptor is a receptor located somatodendritically or terminally on a 
neuron and is only responsive to the neurotransmitter released from the same neuron. 
This is shown diagramatically in figure 3. If neurons A and B release the same 
neurotransmitter, the blue receptor located on neuron A is an autoreceptor for neuron 
A but a post-synaptic receptor for neuron E .
Figure 3. Diagram to show the distinction between autoreceptors and heteroreceptors. The blue 
receptor on neuron A is an autoreceptor for that neuron, but a post-synaptic receptor for neuron B. The 
green receptor on neuron A is sensitive to the neurotransmitter released from neuron C, but not 
sensitive to the neurotransmitter released from neuron A, and is therefore a heteroreceptor.
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Cell body autoreceptor
The somatodendritic 5-HT autoreceptor in the RN has been characterised as a 
5-HTja receptor (O’Connor and Kmk 1992). It is negatively coupled to adenylate 
cyclase and linked to the opening of a K+ channel and closing of a Ca++ channel; 
stimulation of the autoreceptor therefore hyperpolarises the neuron.
Electrophysiological recording of dorsal raphe cell firing in vivo (Fletcher et al. 1993) 
and in vitro (Lanfiimey et al. 1993) has shown that the selective 5-HTj^ agonist, 8 - 
hydroxy-2-(Di-/i-propylamino)tetralin (8 -OH-DPAT), decrease the neuronal firing rate 
in a dose-dependent manner. The effect can be antagonised by the novel, selective 5- 
HTja antagonist (±)WAY100135 (Fletcher et al. 1993; Lanfumey et al. 1993). 
Application of 8 -OH-DPAT, either directly or peripherally, can decrease both the 
terminal release of 5-HT as measured by in vivo microdialysis (Hjorth and Sharp 1991; 
Bonvento et al. 1992; Routledge et al. 1993) or differential pulse voltammetry 
(Marsden and Martin 1986) and synthesis rate (Invemizzi et al. 1991; Fletcher et al. 
1991) in vivo. The effect on release and synthesis rate are antagonised by WAY100135 
(Fletcher et al. 1991; Routledge et al. 1993). Administered alone WAY100135 has no 
effects on 5-HT neuronal firing (Fletcher et al. 1993), indicating that 5-H T^ 
autoreceptors do not display autoinhibitory tone. Thus the somatodendritic 5-HTj^ 
autoreceptor can influence 5-HT synthesis and terminal 5-HT release.
Terminal 5-HT autoreceptor
Famebo and Hamberger (1974) were one of the first teams to demonstrate that 
5-HT agents could decrease [3 H]5-HT released from cortical slices in vitro. Their 
findings were subsequently confirmed by other workers in hypothalamic synaptosomes 
(Cerrito and Raiteri 1979) and cortical slices (Gothert and Weinheimer 1979). All these 
workers showed that exogenously applied 5-HT decreased [3 H]5-HT release and that 
5-HTj antagonists applied alone could increase this release and block the effects of 5- 
HT. Other 5 -HT2  antagonists tested e.g. cyproheptidine, methysergide, pizotifen and 
mianserin (Cerrito and Raiteri 1979; Baumann and Waldmeier 1981) were found to be 
ineffective, helping to define the receptor subtype mediating the inhibition.
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Further characterisation of the terminal 5-HT autoreceptor as a 5-HTj receptor 
was performed by correlating ligand binding profiles with the ligand's effects on the 
stimulated overflow of [3 H]5-HT from hypothalamic synaptosomes (Martin and 
Sanders-Bush 1982). Since these workers used a synaptosomal preparation they could 
be sure that the effects of agonists were mediated by presynaptic receptors not an 
indirect effect due to stimulated release of another neurotransmitter from a different 
population of neurons which impinge upon, and affect, serotonin release. Subsequendy 
the autoreceptor was defined as a 5-HT 1 3  receptor by the same techniques (Engel et 
aL 1986) and by superfusion alone (Middlemiss 1984; 1985).
The rat brain 5-HT1B receptor has been cloned and characterised (Voigt et al. 
1991). The receptor has a molecular weight of 43kDa, as has been reported for most G 
protein coupled receptors. The terminal 5-HT1B autoreceptor is negatively coupled to 
adenylate cyclase (Bouhedal et al. 1988) by a pertussis-sensitive G-protein (Passarelli 
et al. 1988). Stimulation of the 5-HT1B autoreceptor leads to a decrease in cyclic 
adenosine monophosphate (cAMP) and therefore reduced protein kinase A (PKA) 
activity. There are three protein kinase target sites within the third intracellular loop of 
the 5-HTiB receptor, two for PKA at residues Thr 248 and Thr 309, and one for 
protein kinase C at residue Thr 243 (Voigt et al. 1991). The receptors are linked to 
adenylate cyclase by an inhibitory G-protein (Gj) which is composed of three subunits, 
a , p and y. Under basal conditions the G protein is bound in a complex with guanine 
diphosphate (GDP). When 5-HT or other agonists bind to the receptor it causes a 
conformational change and the GDP dissociates. Guanine triphosphate (GTP) 
immediately binds to the site left vacant by GDP, which induces a conformational 
change and the complex of the a-subunit and GTP (a.GTP) dissociates from the 
neurotransmitter-receptor complex. The a.GTP is then free to inhibit adenylate 
cyclase. The a  subunit possesses intrinsic GTPase action and catalyses the conversion 
of GTP to GDP. The resultant a.GDP complex has high affinity for the py subunits and 
they reassociate to the basal state (Helper and Gilman 1992).
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Cell body heteroreceptors
A heteroreceptor is a receptor that is not sensitive to the neurotransmitter 
released by the neuron on which it is present, see figure 3 above. Several 
heteroreceptors have been found to influence 5-HT neuronal firing; GABA^ and 
GABAg (Becquet et al. 1990; Levine and Jacobs 1992), aj-adrenoceptors (Baraban 
and Aghajanian 1980; Freedman and Aghajanian 1987) and cholecystokining receptors 
(Boden et al. 1991).
Terminal heteroreceptors
Several heteroreceptors located on serotoninergic terminals which can 
modulate 5-HT release have been identified e.g. c^-adrenoceptors (Gothert et al. 1981; 
Tao and Hjorth 1992), further classified as an a^-adrenoceptor (Gobbi et al. 1990; 
Hjorth and Tao 1992), GABAg (Schlicker et al. 1984; Gray and Green 1987), H3 - 
receptors (Schlicker et al. 1988), muscarinic and nicotinic acetylcholine receptors 
(Hery et al. 1977a; Ennis and Cox 1982; Marchi et al. 1986), NPY (Schlicker et al. 
1991). Stimulation of all these heteroreceptors decreases the output of 5-HT.
Circadian rhythms
In its true definition, the term "circadian" is used to define rhythms which 
oscillate over 24 hours in the absence of any external cues, zeitgebers. However, 
circadian is often used to describe rhythms which vaiy over 24 hours in the presence of 
a light-dark cycle, the major zeitgeber in experimental animals. Almost every aspect of 
5-HT function, from synthesis to release, has been shown to vary over 24 hours. The 
circadian aspects will be divided according to their position in the scheme of synthesis 
and turnover. For simplicity I have only described peaks and troughs as being in the 
dark phase or in the light phase, for precise timings see table 1 at the end of this 
section.
L-Tryptophan
The level of free 1-try in plasma have a circadian rhythm, although conflicting 
zeniths and nadirs have been published. The level is either maximal early in the light 
phase and minimal early in the dark phase (Redfem and Martin 1985) or peaks at mid
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dark with the trough occurring at mid light (Hery et al. 1977b). The rate of 1-try 
transport across the blood-brain barrier has not been measured over 24 hours. Since 
transport is a competitive process it might be assumed that the amount of 1-try entering 
the brain is determined by its ratio to competing large neutral amino acids.
The uptake of 1-try into cortical synaptosomes shows a distinct pattern, the 
peak being at the transition from light to dark and the trough was 3 hours after 
lights off (Loizou and Redfem 1986). The Vmax peaked at the end of the dark phase 
and fell to a trough in the first 3 hours of the dark phase (Loizou and Redfem 1986). 
As the authors point out, since the normal plasma concentration range of 1-try is 1 to 
lOpM, the uptake system would appear to buffer any fluctuation in 1-try levels and 
keep a constant rate of entry of 1-try into the neuron. The uptake of pH]-try into 
hypothalamic or brainstem slices is greater during the light phase (Hery et al. 1972). 
The same results was obtained after intracistemal administration of pH]-try. These 
results are consistent with the finding that the circadian rhythm in brain 1-try is not 
dependent on diet. If the food supply is restricted to a few hours in the light period 
then the rhythm in brain 1-try is not significantly different from mice allowed free access 
to food (Morgan and Yndo 1973).
In a comprehensive survey of 1-try levels in homogenates from seven different 
brain regions at mid light and mid dark, Pietraszek and colleagues (1992) consistently 
found lower levels in the light phase. This is consistent with the findings of Hery and 
colleagues (1977b). The concentration of 1-try measured in hypothalamic homogenates 
of individually housed rats (Greco et al. 1988) showed a circadian variation directly 
opposite to that observed by Redfem and Martin (1985).
Tryptophan hydroxylase
One of the initial indications that the synthesis of 5-HT displayed a circadian 
rhythm was the demonstration that the conversion of pH] try to pH] 5-HT was lower 
during the dark phase (Hery et al. 1972). However the authors point out that the 
variation is due to a rhythm in the uptake of pH]l-try. The activity of TrOH was found 
by Kan and colleagues (1977) to display a circadian rhythm. Differing rhythms were
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demonstrated in TrOH activity in sonicates from individual raphe nuclei and the 
striatum. Their findings have been questioned since brain sonicates are thought to 
contain an endogenous inhibitor of TrOH (McLennan and Lees 1978). Since then some 
workers have found rhythms in TrOH activity in different brain regions; peak activity in 
the brainstem is during the light phase and lowest in the dark phase (Cahill and Ehret 
1981), whilst pineal activity peaks in the night (Ehret et al. 1991). Others have failed to 
detect any rhythm in the striatum and midbrain (McLennan and Lees 1978). However, 
McLennan and Lees did find that the Km of TrOH for BH4  was 72% higher in the light 
phase. Measurement of the rate of accumulation of 5-HTP after its decarboxylation has 
been inhibited gives a good indication of the activity of TrOH. A significant variation in 
the rate of accumulation has been found in nine brain regions, however the position of 
the peaks and troughs differed significantly (Poncet et aL 1993). In the dorsal and 
central raphe nuclei, locus coeruleus, cortex and ventrolateral medulla both peaks and 
troughs occurred in the dark phase. In the raphe pallidus, paraventricular nucleus and 
suprachiasmatic nucleus (SCN) accumulation was greatest in the light phase. The 
dorsomedian medulla was unique in that peak accumulation occurred at the end of the 
dark phase (Poncet et al. 1993).
5-HTP decarboxylase
Only one study has assessed the activity of 5-HTP decarboxylase over 24 
hours. A circadian rhythm in activity was demonstrated with a peak at 1700h and a 
trough at 0900h (Hillier and Redfem 1976). When pyridoxal phosphate, the co-factor, 
was added to the medium the enzyme's activity increased by 100%. The increase was 
the same at the two time points tested, implying that the rhythm observed was not due 
to differing levels of the active enzyme. The authors speculated that there could either 
be a variation in 1-try entry into the neuron or that there is competition for the enzyme 
by other large neutral amino acids since the decarboxylase is not specific.
Tissue 5-HT level
Generally 5-HT levels have been found to be higher in the light phase e.g. in the 
hypothalamus, striatum and hippocampus (Pietraszek et al. 1992), SCN (Cagampang
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and Inouye 1994), frontoparietal cortex (Hery et al. 1977b), central raphe nucleus and 
dorsomedian medulla (Poncet et al. 1993). 5-HT concentrations are highest in the dark 
phase in the dorsal raphe nucleus, ventrolateral medulla and SCN (Poncet et al. 1993), 
with the amplitude being greatest in the SCN.
5-HT release
The release of 5-HT is greatest in the dark phase when measured in the SCN 
(Faradji et al. 1983; Hutson et al. 1984; Martin and Marsden 1985; Glass et al. 1992), 
paraventricular nucleus (Martin and Marsden 1985) and hippocampus (Kalen et al. 
1986) in vivo. This is in direct opposition to the peak synthetic activity suggesting that 
5-HT is synthesised and then stored for release during the nocturnal animal's active 
period. However, in vitro [3 H]5-HT release was greater during the light phase (Blier et 
al. 1989). The difference may be accounted for by the experimental technique; Blier 
and co-workers compared the amount of [3 H]5-HT released after electrical stimulation 
at only two time points, one in the light phase and one in the dark phase. There is a 
circadian rhythm in the uptake of [3 H]5-HT (Meyer and Quay 1976) so more [3 H]5- 
HT may have been taken up at one time point than the other.
Reuptake of 5-HT
Meyer and Quay (1976) demonstrated a rhythm in [3 H]5-HT uptake into SCN 
slices and hypothalamic homogenates; peak uptake occurred at the transition from light 
to darkness and the trough at the transition from darkness to light A circadian rhythm 
in the number of uptake sites has been demonstrated (Wirz-Justice et al. 1983). These 
workers found there were more uptake sites during the dark phase. Both these results 
suggest that uptake of 5-HT is greatest when release is highest. However the ligand 
used for binding studies, imipramine, is now considered to label a heterogenous 
population of uptake sites, one high affinity (the 5-HT uptake site) and one low affinity 
(Marcusson and Boss 1990).
5-HIAA concentration
5-HIA A levels in the cerebellum, hypothalamus, striatum, hippocampus and 
cortex are lower during the light phase (Pietraszek et al. 1992; Imeri et al. 1994). In the
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frontoparietal cortex, though, levels are at their maximum early in the dark phase and 
minimal late in the light phase (Hery et al. 1977b).
Receptor rhythms
A circadian rhythm in the number of 5-HTj^ and 5-HT1B binding sites has 
been demonstrated in the cerebral cortex (Akiyoshi et al. 1991; Weiner et al. 1992). In 
addition a seasonal rhythm in 5-HTj, 5-HT1A and 5 -HT2  binding has been shown 
(Weiner et al. 1992). The number of 5-H T^, 5-HT1B receptors is higher during the 
dark phase than the light phase (Prosser et al. 1993), however this study did not 
distinguish between pre- and post-synaptic 5-HTiB receptors. The strength of the in 
situ hybridisation signal for 5-HT1A, 5-HT1B ,5 -HT2 c and 5 -HT2  receptors in the SCN 
has been found to be the same when measured at four time points in the light-dark 
cycle (Roca et al. 1993). Although this does not preclude a variation in membrane 
receptor numbers.
Serotoninergic neurons in the SCN, lateral geniculate nucleus (LGN) and 
hippocampus display a circadian rhythm in their sensitivity to iontophoretically applied 
5-HT (Mason 1986), with a greater reduction in neuronal firing during the night. The 
recovery of the neuron from the 5-HT-ind
ed suppression of firing also differed significantly. Recovery was more rapid near the 
onset of the subjective night and slowest near the onset of the subjective day (Mason 
1986). This is probably linked to circadian rhythm in the uptake of 5-HT (Meyer and 
Quay 1976). Depletion of 5-HT by parachlorophenylalanine (90-95%), which spares 
the actual 5-HT neurons, did not affect the circadian variation in sensitivity (Mason 
1986). However electrolytic lesion of the SCN abolished the variation in sensitivity and 
decreased the sensitivity to iontophorised 5-HT in the LGN and hippocampus.
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Table 1. Summary o f published data on circadian rhythms in 5-HT function
Parameter Peak Trough Brain region Reference
tryptophan free CT17 free CT6 plasma Hery etal. 1977b
total CT21 total CT10
free CT1 free CT7 plasma Redfern and Martin 1985
total CT1 total CT13
Tissue tryptophan CT6 CT18 brainstem slice Hery et al 1972
CT6 CT12- hypothalamus slice
CT20 CT10 cerebral cortex sonicate Hery etal. 1977b
CT12 CT1 hypothalamic homogenate Greco et al. 1988
uptake 1-try cortical synaptosome Loizou and Redfern 1986
CT23.5 CT15 Vv max
CT23.5 CT15 Km
TrOH activity CT8 CT16 brainstem Hery etal. 1972
CT8 CT14 hypothalamus
CT8 CT12 cortex
TrOH activity CT1 CT11 dorsal raphe slice Kan et al. 1977
CT8 CT18 striatal slice
Ion +0h loflf +3h brainstem homogenate Cahill and Ehret 1981
CT19 CT15 dorsal raphe Poncet etal. 1993
CTO CT12 ventral medulla
CT18 CT15 dorsomedial medulla
CT19 CT15 cortex
CT19 CT19 paraventricular nucleus
CT19 CT7 suprachiasmatic
Parameter Peak Trough Brain Region Reference
Tissue 5-HT level CT12 CT4/16 hypothalamic homogenate Greco etal. 1988
CT19 CT7 dorsal raphe Poncet etal. 1993
CT19 CT3/15 suprachiasmatic nucleus








CT2/10 CT8 hippocampus Kalen etal. 1989
CT14 CT11 paraventricular nucleus Stanley et al. 1989







Meyer and Quay 1976
Uptake sites CT23 CT11 suprachiasmatic nucleus slice Wirz-Justice et al. 1983
Binding
5-HT1A CT6 CT15
cerebral cortex Akiyoshi et al. 1989
5-HT1r CT3 CT18
assagscss------m  ■ a—aaagcaaaaa .
Table 1. Summary of the published data on circadian rhythms in the serotoninergic system. CT refers to circadian time after lights on in the animal colony if the animals
were on a 12:12 light-dark cycle. In the case of Cahill and Ehret 1981. rats were subjected to an 8:16 light-dark cycle so the maximum and minimum is expressed as time 
after lights on (Ion) or lights off (loff). Some authors referred to in the text have not been included in the table because the timing of lighting cycles was not included in 
their paper or they compared differences at only one time point in each phase of the light-dark cycle.
Depression
Depression is one of the most common forms of mental illness. The term 
depression covers a wide variety of illnesses and symptoms vary among patients. 
Sufferers complain of some or all of the following symptoms: hopelessness or 
helplessness; little interest in activities previously found pleasurable; fatigue; decreased 
concentration and thinking; indecision; worthlessness; excessive or inappropriate guilt; 
weight changes; sleep and circadian rhythm abnormalities.
There are two basic divisions of clinical depression; unipolar and bipolar. 
Unipolar depression affects, at any one time, 2-3% of males and 5-9% of females, and 
carries a lifetime risk of 8-12% for men and 20-26% of women (Horton 1991). Bipolar 
depression is less common, with a lifetime risk of 1 % for both men and women. 
Unipolar sufferers show the symptoms described above, whilst bipolar depressives 
fluctuate between this state and bouts of mania. In the manic phase patients 
misperceive reality; hallucinate; hold bizarre beliefs and display strange behaviour, feel 
elated, carefree, overconfident and euphoric; overestimate their attractiveness, 
intelligence and abilities and possess unlimited energy. Bipolar depression shows a 
stronger hereditary trait, so offspring of bipolar depressives who themselves have 
depression are more likely to be bipolar depressives. Depression with physical 
symptoms and no apparent cause is termed endogenous depression, whilst reactive 
depression can be triggered by external events and anxiety.
Monoamine theory of depression
Thirty years after its formulation by Schildkraut the "monoamine theory of 
depression" is still commonly evoked to explain the aetiology of depression. The theory 
is based on an observation in the 1960s that patients treated with reserpine, a 
monoamine depletor, showed symptoms very similar to those observed in depression. 
The effects of reserpine could be blocked by pre-treatment with antidepressant drugs, 
which had just been discovered. However by no means all depressed patients respond 
to antidepressant drugs targeted to the central monoaminergic systems and it should be
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borne in mind that the monoamine hypothesis is not the only theory concerning the 
cause of depression; other neurotransmitter candidates are ACh, DA and opiates. It is 
therefore possible that the symptoms of depression can arise as a result of a range of 
biochemical abnormalities.
Evidence for 5-HT involvement in depression
Having mentioned differing neurotransmitter hypotheses of depression, there is 
considerable evidence linking a malfunction in serotoninergic neurons with depressive 
illness. For instance there is a significant decrease in plasma tryptophan in depressed 
patients (Cowen et al. 1989; Pietraszek et al. 1991). Delgado and colleagues (1990) 
have shown that if the plasma level of total 1-try in depressed patients in remission is 
rapidly depleted (by 87%) the majority of depressed patients relapse into depression. 
Their state improves gradually when they were returned to a regular diet, while control 
patients showed no response to 1-try depletion (Delgado et al. 1990). The number of 
cortical 5-HT transporters is decreased in the cortex and hippocampus taken from 
depressed suicide victims (Leake et al. 1991; Little et al. 1993). The density of 5 -HT2  
receptors in the frontal cortex and 5-HT1D (the human equivalent of the rat 5-HT1B 
receptor) receptors has been reported to be increased in depressed suicide victims 
(Stanley and Mann 1983; Lowther et al. 1991). However Cheetham and colleagues 
(1990) have shown that there is no change in hippocampal 5 -H T ^  receptor binding in 
depressed suicide victims. Most binding studies in post-mortem human brain do not 
categorise the victim's type of depression. This, taken together with variations in post­
mortem delay, age, sex, method of suicide may explain the differences in findings.
Another approach used is the neuroendocrine challenge test. This test depends 
on the ability of drugs which affect the 5-HT system to produce specific effects on 
plasma hormone levels. These effects cannot be specifically tied down to one step in 
the synthesis and turnover sequence of events. Administration of 1-try decreases plasma 
prolactin and growth hormone (GH) levels. The 1-try-induced decrease in plasma 
prolactin was even greater in non-melancholic depressed patients compared to healthy
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volunteers, while in melancholic and psychotic depressed patients 1-try administration 
increased plasma prolactin concentration (Price et al. 1991). The 1-try-induced increase 
in plasma GH concentration was less in unipolar, non-melancholic and non-psychotic 
patients compared to control subjects (Price et al. 1991). The findings imply that 
changes in 5-HT function may differ according to the type of depression. Another 
neuroendocrine study has shown that the 5-HT ̂ -mediated induction of 
adrenocorticotrophic hormone (ACTH) and cortisol secretion was less pronounced in 
unipolar depressives than controls (Lesch et al. 1990).
Circadian rhythms in depression
The term circadian describes a rhythm which oscillates over 24 hours, the 
rhythm is independent of external cues (such as a light-dark cycle) and will therefore 
persist in isolation.
Most, but by no means all, depressed patients complain of early morning 
wakening, which indicates a possible malfunction of the circadian system. In addition 
there is evidence of abnormalities in other circadian rhythms in some depressed 
patients, as outlined below. It is therefore possible that there may be at least one form 
of depression which is associated with circadian rhythm abnormality.
The amplitude of the circadian rhythm in plasma tryptophan is decreased in 
depressed patients compared to controls (Candito et al. 1992). In depressed patients, 
the acrophase (i.e. the peak level over 24 hours) in the noradrenaline metabolite 3- 
methoxy-4-hydroxyphenylglycol (MHPG) in plasma is phase advanced (de Met et al. 
1984). Heart rate shows a significant circadian variation in normal subjects, however 
depressed patients show two distinct differences in this circadian variation. One group 
still possess a circadian rhythm but with a reduced amplitude, whilst a second group 
have no circadian rhythm (Taillard et al. 1990).
The circadian rhythm in the plasma concentration of prolactin, corticotrophin, 
cortisol, GH, thyrotrophin, ACTH, melatonin, as well as body temperature, heart rate 
sleep timing and structure have all been shown to be abnormal in depressed patients
20
compared to control subjects (Hallonquist et al. 1986; van Cauter and Turek 1986; 
Goetze and Tolle 1987; Daimon et al. 1992). The changes though have been reported 
variously to take the form of phase advance, phase delayed, and both reduction or 
increase in the amplitude of the rhythm. The differences may be due to the 
heterogeneity of the patients or difficulties inherent in collection of data. One of the 
most consistent finding is a phase advance in the onset of REM sleep, early morning 
wakening, peak ACTH and the nocturnal elevation in prolactin and GH (van Cauter 
and Turek 1986).
There are many hypotheses put forward to explain the circadian abnormalities 
which can be divided into two categories. The circadian system requires a pathway 
from the external environment to the pacemaker, the pacemaker itself and pathways 
from the pacemaker to target regions. The first set of hypotheses propose a variety of 
malfunctions of the pacemaker itself, e.g. internal desynchronisation, loss of amplitude, 
phase advance, inappropriate entrainment and dysregulation. In the second category 
Healy and Williams (1988) have hypothesised that there is no abnormality in the central 
clock, in fact a normally-functioning clock is a pre-requisite for the hypothesis, but that 
the transmission of information about the environment to the clock is abnormal.
Antidepressant Drugs
Antidepressants are clinically effective in alleviating depression only after 
repeated administration for more than about 14 days. There are 3 major classes of 
antidepressant drugs;
1. Uptake inhibitors: As the name implies these block the reuptake of neurotransmitters 
released into the synaptic cleft. The concentration of the neurotransmitter then builds 
up with consequent changes in pre- and post-synaptic receptor sensitivity and/or 
number. These can be non-specific e.g. amitriptyline which blocks the uptake of 
noradrenaline, dopamine, 5-HT and ACh or specific e.g. desipramine, which selectively 
blocks noradrenaline reuptake or nomifensine which is selective for dopamine reuptake. 
More recently highly selective inhibitors of 5-HT, termed SSRI (selective serotonin
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reuptake inhibitors), have been introduced which are clinically very effective, e.g. 
paroxetine, fluoxetine, sertraline, fluvoxamine.
2. Monoamine oxidase inhibitors (MAOI): These prevent the breakdown of recaptured 
monoamines by irreversibly inhibiting the activity of MAO e.g. phenelzine, 
trancypromine. The administration of these drugs is hampered by quite serious side 
effects termed the "cheese reaction". Administration of MAOI blocks the activity of 
MAO in the gut wall and liver and therefore increases the circulating level of normally 
innocuous dietary amines, mainly tyramine. This results in a sympathomimetic effect, 
tyramine displacing noradrenaline from vesicles, leading to hypertension which 
produces headaches and even intracranial haemorrhage. Many foods contain tyramine, 
but one of the highest concentration is found in cheese. Within the last few years, 
selective monoamine oxidase-A inhibitors have been introduced. Called reversible 
inhibitors of monoamine oxidase-A (RIMA) they are claimed not to have the side 
effects of the old MAOI, an example is moclobemide.
3. "Atypical". These fall into neither of the above categories but are nevertheless 
clinically effective; their mechanisms of action are generally unknown (with the 
exception of mianserin, which is a 5 -HT2  antagonist), e.g. iprindole. The fact that 
"atypical" antidepressants are clinically effective appears to indicate that MAOI or 
blockade of reuptake is not essential for antidepressant action.
Effect of Antidenressant Drugs on the 5-HT system
Figure 4 shows a schematic diagram of 5-HT neurotransmission. Under normal 
conditions the effects of released 5-HT are terminated by re-uptake of 5-HT into the 
nerve terminal. Antidepressant treatment increases the synaptic level of 5-HT, termed 
the biophase concentration, by mechanisms depending on the class of antidepressant, as 
outlined above. Specific serotonin uptake inhibitors block the re-uptake of released 5- 
HT within a few hours of peripheral administration. MAOI block the degradation of
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Presynaptic
Figure 4. Schematic diagram of 5-HT neurotransmission. When 5-HT (blue sphere) is released from the nerve terminal it has several different sites of action. It can cross 
the synaptic cleft and bind to a variety of post-synaptic 5-HT receptors; 5-HT1A (pink sphere), 5-HT2C (orange sphere) or 5-HT2 (green sphere). Alternatively it can bind 
to the presynaptically located 5-HT1B autoreceptor (jade sphere). The interaction of 5-HT with its autoreceptor inhibits further 5-HT release. Transmission is terminated 
when 5-HT is taken back into the neuron by the 5-HT transporter (yellow' pacman) and degraded by MAO (turquoise sphere) to 5-HTAA (purple sphere)
neuron Synaptic cleft
5-HIAA
5-HT intraneuronally and 5-HT therefore spills out of the neuron. The acute effect of 
both types of antidepressant affects 5-HT levels in the terminal region by two actions. 
Firsdy at the cell body level, the increase biophase concentration of 5-HT in the RN 
causes stimulation of cell body 5-HT j^  autoreceptors which decreases neuronal firing 
(Blier and de Montigny 1983; Chaput et al. 1986). In the terminal region the increased 
biophase 5-HT level after antidepressant administration stimulates 5-HT1B 
autoreceptors, activation of which further inhibits 5-HT release. As a consequence of 
this increased biophase 5-HT level and concomitant repeated stimulation of the 
autoreceptors, it might be expected that the autoreceptors of both classes would 
desensitise like other classical neurotransmitter receptors. However this does not 
appear to be the case with 5-HT receptors (Maj and Moryl 1992; Newman et al. 1992). 
If the 5-HT 1B receptor is expressed in opossum kidney cell line, incubation with 5-HT 
produces maximal desensitisation of forskolin-stimulated adenylate cyclase and 
receptor down-regulation after 3 hours' incubation; both these parameters started to 
normalise after 48 hours' incubation (Pleus and Bylund 1992).
Whether autoreceptors down-regulate after chronic antidepressant treatment is 
pivotal in the action of antidepressants. Figures 5 and 6  show flow diagrams of the 
consequences of either down-regulation or no change in autoreceptor function. The 
experimental evidence provides support for both down-regulation and no change in 
autoreceptor function. The differences may be due to the diversity of antidepressants 
used, doses, dosing schedules, dosing methods, animal strains and method of assessing 
receptor function. After administration of 5-HT reuptake inhibitors 5-HTj^ and 5- 
HT1B autoreceptors do desensitise (for 5-H T ^ see for example Blier and de Monitgny 
1983; Chaput et al. 1986; Maj and Moryl 1992; Martin et al. 1993b; and for 5-HTig 
Blier and de Montigny 1983; Chaput et al. 1986; Moret and Briley 1990), although 5- 
H T ia  autoreceptor function has also been found to remain the same (Blier and de 
Montigny 1980). Indeed one behavioural test has even shown 5-HT1B function to be 
enhanced after chronic 5-HT uptake inhibition (Maj and Moryl 1992). Again the 
increase in 5-HT concentration in the synaptic cleft would be expected to desensitise
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post-synaptic 5-HT receptors; this has been demonstrated in some, but not all cases. 5- 
HTia receptor sensitivity has been reported to be unchanged (Blier et al. 1984; Chaput 
et al. 1986) or decreased (Blier et al. 1988) in the hippocampus using the same method 
but different antidepressants. The number of 5-HTjq receptor binding sites, but not 
their affinity, is reduced in whole brain (Johanning et aL 1992), but receptor binding 
sites and affinity in the frontal cortex has also been found to be unchanged (Montero et 
al. 1991). Using behavioural measures, 5 -HT2 C receptors have been shown to be 
desensitised (Maj and Moiyl 1992). The number of 5 -HT2  binding sites in the frontal 
cortex is decreased (Peroutka and Snyder 1980) and behaviourally desensitised 
(Maj and Moryl 1992). Treatment with noradrenaline-selective or mixed function 
uptake inhibitors also affects 5-HT receptors, but again results are contradictory. 
Assessed by behavioural measures, 5-HTja autoreceptors are desensitised (Olpe et aL 
1984; Lund et al. 1992) or supersensitive (Dijcks et al. 1991), whilst the number and 
affinity of post-synaptic 5-HTja receptors is decreased in the frontal cortex but 
unaffected in the hippocampus (Lund et al. 1992). The number, but not the affinity, is 
increased in the cortex (Martin et al. 1993) whereas the number, but not affinity, is 
decreased in the cortex but unchanged in the hippocampus (Pandey et al. 1991). The 
number or 5 -HT2  binding sites in the frontal cortex is decreased (Peroutka and Snyder 
1980).
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Figure 5. Flow diagram to show the effect of chronic antidepressant treatment on somatodendritic 5- 
HT1A autoreceptors and the effect on terminal biophase concentration of 5-HT. Chronic specific 
serotonin reuptake inhibition (SSRI) increases the concentration of 5-HT in the raphe nucleus thus 
stimulation the 5-HT1A autoreceptor. If the autoreceptor dovvn-regulates, then 5-HT neuronal firing 
rate, and therefore release, remains the same. However if the autoreceptor's function remains the same 










Figure 6. Flow diagram to show the effect of chronic antidepressant treatment on terminal 5-HT1B 
autoreceptor function. Again, inhibition of 5-HT reuptake will increase the synaptic concentration of 
5-HT in the terminal region. If the 5-HT1B autoreceptor down-regulates. 5-HT release will be 
increased. However, if the function of the autoreceptor does not change then the biophase 
concentration of 5-HT will not be significantly different after uptake inhibition.
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Effect of Antidepressant Drugs on Circadian Rhvthms
There is evidence that prolonged administration of antidepressant drugs affects, 
some circadian rhythms, although taken together the results are not clear cut
The number of some neurotransmitter receptor populations varies over 24 
hours e.g. a- and (3-adrenoceptors, muscarinic acetylcholine receptors (mAChR), 
GABA-benzodiazepine receptors, a-melanocyte-stimulating hormone (cxMSH) and 
dopamine receptors (Kafka et al. 1981a, b; OT>onahue et al. 1982; Wirz-Justice et al. 
1982; Liebowitz et al. 1984; Jhanwar-Uniyal et al. 1986). Non-selective uptake 
inhibitors and MAOI phase delay the rhythm in a-adrenoceptors, GABA- 
benzodiazepine, aMSH, DA and mAChR receptors (Kafka et al. 1981b; ODonahue et 
al. 1982; Wirz-Justice et al. 1982).
A 5-HT/noradrenaline uptake inhibitor, imipramine, has been reported both to 
accelerate the rate of re-entrainment of locomotor activity rhythms after a reversal of 
the photoperiod (Baltzer and Weiskrantz 1975) and to have no effect on the latency of 
re-entrainment to a 6  hour phase advance of the light-dark cycle in hamsters (Refinetti 
and Menaker 1993). The same antidepressant can significantly reduce the amplitude of 
the rhythm in plasma corticosterone in rats without affecting the acrophase i.e. timing 
of the peak (de Franciscis et al. 1987). However, in the same experiment, imipramine 
had no effect on the urinary levels of 5-HT and NA and their metabolites over 24 
hours, though it must be noted that most of the 5-HT and 5-HIAA probably originated 
from the gut (de Franciscis et al. 1987). Clomipramine, a selective 5-HT uptake 
inhibitor and desipramine, a noradrenaline uptake inhibitor, did not affect the circadian 
rhythm in serum corticosterone and melatonin in the rat (Brown and Seggie 1988). 
Clomipramine hastened the re-entrainment of the temperature acrophase to a 6  hour 
phase advance of the light-dark cycle (Brown and Seggie 1988), whilst desipramine did 
not affect the rate of re-entrainment.
Desipramine has been shown to shorten the circadian period (tau, "day" length) 
of hamsters housed in constant darkness (Klemfuss and Kripke 1993) whilst a MAOI, 
clorgyline, increased tau (Wirz-Justice and Campbell 1982; Duncan et al. 1988).
28
Qorgyline treatment also delayed activity onset and offset in hamsters that were 
entrained (Duncan et al. 1988) or in constant darkness (Tamarkin et al. 1983). 
Moreover, chronic clorgyline treatment delayed hamster's re-entrainment to a four hour 
advance in the onset of its dark phase (Tamarkin et al. 1983). The amplitude of the 
free-running activity of rats kept in constant darkness has been shown to be increased 
by chronic treatment with desipramine, a noradrenaline uptake inhibitor and 
moclobemide, a RIMA. The free-running period was shortened by both these 
antidepressants (Wollnik 1992). These two parameters were unaffected by other 
antidepressants such as 5-HT uptake inhibitors and a MAO B inhibitor (Wollnik 1992). 
Interestingly Wollnik (1992) also demonstrated that desipramine and moclobemide 
change the intrinsic pattern of wheel running activity of Lewis rats. Before treatment, 
the nocturnal activity was divided into distinct short activity bouts about 4-5 hours 
apart Prolonged antidepressant treatment unified the multimodal activity pattern. The 
mechansim and/or site of action for this effect is unknown.
Summary
The central 5-HT system is diffuse, projecting to virtually every brain region. 
The release of 5-HT is controlled by many factors including neuronal firing rate, 
somatodendritic and terminal autoreceptors and a circadian rhythm in all aspects of 5- 
HT function. There is much evidence to suggest an abnormalality in 5-HT function as 
the aetiology of depression. Additionally, there is evidence for a circadian rhythm 
malfunction in some forms of depression. Many clinically effective antidepressant drugs 
target the 5-HT system and can affect circadian rhythms. Taken together the results of 
these studies could indicate that antidepressant drugs may be alleviating depression by 
affecting circadian rhythms and that this effect is mediated through the 5-HT system.
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Project Aims
The hypothesis is proposed that the efficacy of antidepressant drugs stems, in 
part, from their ability to differentially alter the degree of control the terminal 5-HT1B 
autoreceptor exerts on synthesis and release through the light-dark cycle. This 
hypothesis is based on the assumption of a link between a deficiency of serotoninergic 
activity and circadian rhythm malfunction in depression, the fact that many clinically 
effective antidepressant drugs affect the central 5-HT system and can be shown to 
affect circadian rhythms and given that central serotoninergic function is itself subject 
to circadian variation. The function of the terminal autoreceptor is of paramount 
importance because it influences the biophase concentration of 5-HT and therefore the 
amount of 5-HT reaching its post-synaptic targets.
The hypothesis was tested by studying the effect 5-HTjg autoreceptor 
stimulation exerted on release, using in vitro superfusion and in vivo microdialysis, and 
on the rate of 5-HT synthesis, by measuring 5-hydroxytryptophan accumulation. The 
effect of receptor stimulation on these two parameters was examined at four, equally 
spaced times through the light-dark cycle and after chronic antidepressant treatment




In this study the continuous superfusion technique developed by Frankhuyzen 
and Mulder (1982) to measure [3 H]noradrenaline ([3 H]NA) release from cortical slices 
in vitro as adapted by Middlemiss (1984) was used.
The technique of Frankhuyzen and Mulder was designed to produce rapid and 
accurate cumulative dose response curves for drugs affecting [3 H]NA release in the 
CNS; the principle being essentially the same as that used for isolated peripheral organ 
preparations. Frankhuyzen and Mulder compared [3 H]NA release during multiple 
20mM K+ pulses or continuous perfusion of 20mM K+-containing Krebs buffer. They 
found that the amount of [3 H]NA released after repetitive stimulation was similar in 
size to that found in the corresponding collection periods during continuous 
stimulation. In both cases the release consisted of at least 85% unmetabolised [3 H]NA. 
The results using, different stimulation methods, showed no differences in the calcium- 
dependence of the release, or inhibition of [3 H]NA release by autoreceptor stimulation. 
Both techniques showed that NA produced maximal inhibition of [3 H]NA release after 
1 0  minutes and that the magnitude of the inhibitory effect of NA was independent of 
the time of its addition to the superfusing buffer, indicating that the sensitivity of the 
autoreceptor remained unchanged. Moreover the recovery from NA-induced inhibition, 
Le. when NA was removed from the buffer, was the same.
Middlemiss (1984) slightly adapted the technique i.e. by inclusion of pargyline 
(to prevent degradation of the radiolabel by MAO) and paroxetine (to block re-uptake 
of 5-HT and thus displacement of the radiolabel) in the superfusing buffer, and used it 
to measure [3 H]5-HT release from cortical "chips". He found that the [3 H]5-HT efflux 
rate in the absence of exogenous 5-HT had declined by 32% compared with the value 
at the beginning of the experiment Using a range of 5-HT concentrations (30, 100, 
300 and lOOOnM) Middlemiss determined that maximal 5-HT inhibition of [3 H]5-HT 
release occurred at lOOOnM, which decreased [3 H]5-HT output by 6 8 %. The apparent 
IC3 4  of the autoreceptor for exogenous 5-HT (i.e. the concentration of 5-HT added
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that decreased [3 H]5-HT release by half, referred to from here simply as the IC5 0  for 
comparison with published data), calculated using the cumulative dose-response 
technique was 46nM.
The technique described above was used in this thesis to measure [3 H]5-HT 
release from hypothalamic "chips". The technique offers the major advantage of 
reducing the number of animals used to construct dose-response curves and to 
calculate pAj values. As with all in vitro studies, the isolation of the tissue from 
neuronal and humoral factors that might affect the neuron's activity could affect the 
response of the neuron.
In vivo microdialysis
The first dialysis model was produced by Bito and colleagues in the mid 1960s. 
It consisted of a permeable sack 8 -12mm long and filled with 6 % dextran in saline. 
Unfortunately, however, only one sample could be obtained per probe. The technique 
of repeated sampling was developed by Delgado and co-workers in the early 1970s. In 
1972 they published a method for assessing neurotransmitter levels in living, conscious 
Rhesus monkeys for up to 8  months. It was an adaptation of the push-pull cannula 
technique, which they termed a transdermal dialytrode since it could incorporate a 
recording/stimulating electrode. The transdermal dialytrode, see figure 7, was totally 
subcutaneous. The probe was formed from two pieces of teflon tubing cemented 
together, with one tip ending 1 mm shorter than the other, both tips were enclosed in a 
polysulphone bag (3pl). The other ends of the tubing terminated separately in two 
rubber reservoirs. The system was continuously superfused and drugs could be injected 
into one bag and samples collected from the other.
U-shaped and transcerebral probes were developed by Zetterstrom and 
Ungerstedt in the early 1980s. These workers were also one of the first groups to 
couple the technique to the highly sensitive detection ability of high performance liquid 
chromatography (HPLC) linked to either electrochemical or fluorometric detection. It 
was only with the advent of HPLC that the full potential of measuring
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neurotransmitters from small samples of extracellular fluid could be exploited. 
Transcerebral and U-shaped probes are not suitable for use in deep brain structures 
such as the hypothalamus, since their implantation causes too much tissue damage. The 
three basic designs of dialysis probe currently used are shown in figure 7.
Microdialysis offers several advantages over other neurochemical techniques. 
The dialysis probe can reflect rapid changes in the extracellular neurotransmitter levels 
(Auerbach et al. 1989). Probe implantation produces minimal tissue damage, it is a 
closed system producing clean samples which do not require lengthy preparation before 
analysis and it can be used in anaesthetised and freely moving animals to measure 
extracellular neurotransmitter levels not their metabolites. It is debated whether 
measuring the levels of the 5-HT metabolite 5-HIAA actually represents 5-HT release 
(see for example Crespi et aL 1990). The probe is stereotaxically implanted into the 
specified brain region with reference to one of two specific points, Bregma and lambda, 
on the surface of the rat's skull as shown in figure 7.
It is important to realise that the neurotransmitter measured in the dialysate 
does not directly represent synaptic release; rather it measures the amount of 
neurotransmitter that diffuses into the area around the tip of the probe. To establish 
that the neurotransmitter measured is neuronally-derived three criteria should be 
fulfilled. The output should be calcium- and tetrodotoxin-dependent and should be 
increased after high K+ (30-100mM) infusion (di Chiara 1990).
The recovery of the probe, i.e. the amount of neurotransmitter that diffuses into 
the probe, is dependent on several factors. Increasing the perfusion rate significantly 
alters the recovery rate. Rates of 0.2-2pl/min produce small but highly concentrated 
samples and the recovery can be as high as 85% (Benviste 1989); faster perfusion rates 
(2 - 1 0 pl/min) produce larger, more dilute samples with a recovery of only 2 - 1 0 %. 
Higher flow rates may produce positive hydrostatic pressure gradients across the 
membrane which decreases mass transport across the membrane. Filtration forces are 
also minimal if the flow rate is kept low. Temperature significantly affects recovery 
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Figure 7. Cross-section through different types of microdialysis probe. A. Top view of a rat's skull 
showing the position of the two reference points. Bregma and lambda, used for stereotaxic 
implantation of microdialysis probes, adapted from Paxinos and Watson (1982) . B. Picture of 
Delgado and colleague's original transdermal diahtrode taken from their 1972 paper; for description 
see text. C. Transcerebral and D. left concentric and right U-shaped microdialysis probes, redrawn 
from di Cliiara 1990.
Recovery is also dependent on the membrane area, obviously the larger the area for 
diffusion the greater the recovery. It is therefore important to measure the recovery of 
the probe before each use, see microdialysis methods section on page 1 2 0 .
There are two potential problems with the technique in vivo. The pathway to 
the dialysis probe can be impeded by the cell membrane which would affect the probe 
recovery. Secondly continuous sampling of the neurotransmitter, especially after 
uptake inhibition, may limit the supply of the neurotransmitter with time. It is also 
essential that the blood brain barrier remains intact after probe implantation to avoid 
contamination from the systemic circulation; this is obviously very important when 
measuring 5-HT. Experiments should therefore not be performed less than 10 minutes 
after implantation because the blood brain barrier is not intact and tissues are reacting 
to the trauma of probe implantation.
Not very much is known about application of drugs via the probe. Theoretically 
it would depend on the drug concentration, drug interaction with the membrane, 
temperature, diffusion coefficient of the drug and its uptake into intracellular and 
vascular compartments. If drugs are administered peripherally they may not penetrate 
the blood brain barrier and exact site of action in the brain cannot be defined. The 
changes in neurotransmitter reflected in the dialysate therefore may be due to direct 
effects in that area or by affecting other neurotransmitter systems which project to the 
area under investigation. In addition the concentration of drug at the receptor site can 
never be estimated. By administering drugs via the probe the effect of the drug can be 
localised and the concentration of drug reaching the receptor site estimated; 
additionally peripheral effects of the drugs can be avoided.
Microdialysis takes advantage of the sensitivity of HPLC, in this study reverse 
phase HPLC linked to electrochemical detection was used. The principles of 
electrochemical detection are outlined below.
Reverse-phase refers to the fact that the stationary phase is non-polar and the 
mobile phase is polar. The stationaiy phase is composed of fine silica particles with 
bonded hydrocarbon alkyl chains, in this case octadecyl. An ion-pairing agent was
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included in the buffer to increase the hydrophobicity of molecules and therefore 
decrease their rate of passage along the HPLC column. The constituents of the 
supernatants are separated along the column according to their molecular size and 
structure. As the eluant from the column is passed over a glassy carbon electrode set at 
an optimum potential for 5-HT oxidation, each molecule of 5-HT is oxidised to 5- 
ketotryptamine and two electrons are released, as shown below. The current generated 
by the released electrons is detected by a reference electrode that deflects the pen of 
the chart recorder to give a characteristically-timed peak. The greater the concentration 




Inhibitors of aromatic-L-amino acid decarboxylase (AAAD) are a useful tool in 
neurochemical research. By inhibiting the conversion of 5-HTP to 5-HT, see page 4, 
these chemicals allow the accumulation of 5-HTP. The extent of this accumulation can 
be used to measure the rate of tryptophan hydroxylation with time. It has previously 
been reported that some AAADs inhibitors also inhibit TrOH (Johansen et al. 1991). 
However these workers found that m-hydroxybenzyhydrazine (NSD1015), the AAAD 
inhibitor used in this study, did not affect TrOH activity in vitro up to a concentration 
of ImM.
Carlsson and colleagues (1972) developed the technique of AAAD inhibition as 
a direct measure of synthesis rate as an alternative to isotopic methods. These workers 
examined several aspects of NSD1015 inhibition of AAAD. They established that the 
accumulation of 5-HTP after NSD1015, at a dose of lOOmg/kg i.p., was linear with
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time up to 30 minutes after administration in the cerebral hemispheres and striatum. 
From 30 to 60 minutes the rate of accumulation seemed to decline slightly. Varying the 
dose of NSD1015 between 50, 100 and 200 mg/kg i.p. had no significant effect on 5- 
HTP accumulation, indicating that the enzyme was fully inhibited at a dose of 
lOOmg/kg i.p.. If NSD1015 (lOOmg/kg Lp.) was administered and the levels of try and 
5-HT measured for 40 minutes after administration then try levels remained level 
throughout that period but 5-HT were observed to drop slightly by 40 minutes after 
AAAD inhibition. The same results have been obtained from studies performed in our 
laboratory and therefore a dose of lOOmg/kg i.p. NSD1015 and a post administration 
interval of 30 minutes were chosen as standard parameters. Bedard and colleagues 
(1971) have shown that the 5-HTP measured is in serotoninergic neurons.
The 5-HTP accumulation technique has the advantage of being able to measure 
the activity of the rate limiting enzyme in serotonin biosynthesis. However it is not so 
successful if used to measure tyrosine hydroxylase activity. The AAAD is a non­
specific enzyme located in noradrenergic and dopaminergic neurons (as well as 
serotoninergic neurons). Therefore it cannot be determined if accumulated 
dihydroxyphenylalanine (DOPA), the common precursor of noradrenaline and 
dopamine, is derived from noradrenergic or dopaminergic neurons. Bearing this in 
mind, there is one other major drawback to the technique. Accumulated DOPA 
undergoes substantial efflux from neurons (Nissbrandt et al. 1988) and could enter 5- 
HT neurons and inhibit TrOH; although this inhibition has been shown to be weak after 
total AAAD inhibition (Johansen et al. 1991). Nissbrandt and colleagues (1988) have 
shown that DOPA levels can rise as high as 16pM after AAAD inhibition by 
NSD1015, but Johansen and co-workers (1991) demonstrated that TrOH activity in 
vitro is only significantly inhibited by DOPA concentrations in excess of 30pM. 
However NSD1015 is commonly used in 5-HT research since it has lesser effects on 
DOPA accumulation that other AAAD inhibitors (Nissbrandt et al. 1988).
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Chapter 2 Superfusion of Hypothalamic Tissue
Hypothesis
In vitro superfusion studies were employed to investigate the hypotheses that in 
rats entrained to a light-dark cycle;
a) The function of the terminal 5-HT1B autoreceptor varies over 24 hours.
b) Chronic antidepressant treatment would alter the function of 5-HT1B receptors 
controlling [3 H]5-HT release.
c) The effect of chronic antidepressant treatment on autoreceptor function would be 
phase-dependent, i.e. differently over the light-dark cycle.
Method
Housing of Animals
Specially designed sound attenuated and light proof boxes were used to phase 
shift animals for circadian rhythm studies as previously described (Hillier et al. 1973). 
The walls of the boxes were insulated with polystyrene (2.4 cm thick) and draught 
excluder strips (1.3cm thick) were stuck to the edge of the cabinet door to exclude 
light. One extractor fan (Phillips, type HR 3408) provided ventilation for 4 boxes 
through a series of pipes. Each box contained its own, independently controllable 
fluorescent strip light (1 0 cm, 1 0 0  lux at the top of the cage) with the choke removed 
and refitted outside the box to keep the boxes cooler. Lighting schedules inside each 
box were manipulated externally using timer switches (Smiths, TS 100 C).
Six male Wistar rats (bred at the University of Bath), initially weighing 150g, 
were placed in a standard animal cage inside each box for 14 days prior to use, to 
entrain their rhythms to their new light-dark cycle. This time is considered to be 
adequate for the re-entrainment of circadian rhythms to new lighting cycles (Hillegaart 
and Ahlenius 1994). In fact, locomotor activity was entrained to a new light-dark cycle 
within 5 days. Inside the box the rats had free access to food and tap water and could 
be left undisturbed between cleanings. They were cleaned out every 2-3 days and the
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time of cleaning was randomised to avoid disturbance acting as a zeitgeber. The 
overhead lights in the animal room were never turned on when the animals were 
cleaned out. If cleaning was carried out whilst rats were in the dark part of their 
lighting cycle the room was illuminated by low intensity red light (4-6 lux) since this 
wavelength of light has been shown to have least effect on rat circadian rhythms 
(McGuire et al. 1973). The rats were handled individually for a few minutes to 
familiarise them to human contact at the same time as cage cleaning. The temperature 
inside the boxes ranged from 20-25°C.
Superfusion apparatus
Jacketed glass buffer reservoirs were connected to the well of the superfusion 
block by three-way taps to make the interchange between buffer solutions easier. 
Buffer was delivered to the ten wells of the superfusion block by a Watson-Marlow 
pump (model 502S). The superfusion block and buffer reservoirs were kept at 37°C by 
a water circulator (Grant) and the buffer was continuously gassed with 95%:5% 
0 2 :CC>2 . The tissues were superfused against gravity and effluent collected into 
scintillation vials using a fraction collector (Gilson, model 203, Anachem).
Tissue preparation
Male Wistar rats (University of Bath) weighing 240-260g were killed by 
cervical dislocation and the basal hypothalamus, including the SCN, rapidly dissected 
onto a cooled cutting disc. Bidirectional 250pm thick slices were cut on a McDwain 
tissue chopper (Gomshall). The slices were incubated for 30 mins at 37°C in 5ml Krebs 
buffer (composition in mM; NaCl 118, KQ 4.75, NaHCC>3 25, MgSC>4 .7 H2 0  1.19, 
KH2 PO4  1.18, CaCl2 .6 H2 0  1.30, glucose 2mg/ml) containing 0.1 pM [3 H]5-HT 
(specific activity 10-20 Ci/mM, Amersham), lOpM pargyline, to prevent the 
breakdown of [3 H]5-HT, and 0.2mM ascorbic acid as an anti-oxidant. The slices were 
washed three times with 5ml Krebs buffer containing, in addition to the above, 3.2pM 
paroxetine, the specific 5-HT uptake inhibitor. Aliquots of tissue (usually 50pl) were
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transferred to the wells of the superfusion apparatus and superfused against gravity 
with Krebs buffer. The tissue was left for 30 mins to equilibrate before the start of any 
experiment At the end of the experiment the tissue from each well was collected and 
sonicated in scintillation fluid for 15 mins to dissolve the tissue and release the [3 H]5- 
HT taken up.
jUptake.Slutites
Two sets of uptake experiment were performed. The first was to determine the 
degree of non-specific uptake of [3 H]5-HT in the hypothalamus and the second to 
investigate the degree of uptake at the four time points chosen.
For the first experiment, two rats were killed and their hypothalami removed as 
described above. Both sets of brain tissue were incubated in 5ml Krebs buffer as above 
but without the [3 H]5-HT, one incubation medium also included 3.2pM paroxetine for 
15 mins. After 15 mins O.lpM [3 H]5-HT and ascorbic acid were added to both sets of 
tissue and the tissue incubated for a further 15 mins.
For the second experiment the hypothalamic tissue from animals killed in the 
appropriate phase of their light-dark cycle, in either normal lighting conditions or dim 
red light (4-6 lux) as necessary, was incubated in 5ml O.lpM [3 H]5-HT for 30 mins.
In both experiments aliquots (lOOpl) of tissue, were transferred to each well of 
the superfusion system; each well contained a pre-weighed nylon gauze at the bottom. 
The tissue was superfused with Krebs buffer for 30 mins, the tissue and gauze from 
each chamber was removed and weighed, then added to a scintillation vial containing 
10ml scintillation fluid. The vials were sonicated for 15 mins to solubilise the tissue, 
and left to stabilise for 3 hours prior to counting.
24 Hour rhvthm studies
Rats which had been phase-shifted as described above were used for these 
experiments. In general rats were taken from each lighting schedule randomly to ensure 
that on one day no two rats taken from the same lighting schedule were used. There
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was one exception however, two rats from the same lighting schedule were used on the 
same day if it would have entailed leaving one rat alone in a cage overnight
Rats were killed at the appropriate phase of their light-dark cycle. The tissues 
were prepared as described above and left to stabilise in the superfusion chambers for 
30 mins. In the 10 chambered superfusion block, two chambers served as controls 
(5mM K+Krebs) throughout the experiment, whilst the other eight chambers received 
25mM K+ Krebs (achieved by isomolar substitution of NaCl for KC1). After two 
control fractions had been collected, four out of the eight chambers receiving 25mM 
K+ were exposed to increasing concentrations of 5-HT (30, 100, 300 and lOOOnM) 
delivered in 25mM K+ Krebs buffer, therefore each manipulation was carried out in 
quadruplicate. Each concentration of 5-HT was exposed to the tissue for four fractions 
(16 min). Using this method 5-HT has previously been shown to have its maximal 
effect after 12 mins (Middlemiss 1984; Singh and Redfem 1994a).
Calcium Studies
Rat hypothalamic slices were incubated in 5ml of Krebs buffer containing 
O.lpM [3 H]5-HT and 0.2mM ascorbic acid and treated as described above. Of the ten 
chambers, two were used as controls receiving normal (5mM K+) Krebs throughout 
the experiment, the other chambers were superfused with Krebs buffer containing 
25mM K+ and two fractions were collected. For the rest of the experiment four 
chambers out of the eight received 25mM K+ Krebs and four chambers 25mM K+ 
Krebs buffer without Ca++ (isomolar replacement of CaCl2  with MgC^). Ten 
consecutive fractions were collected and their radioactive content determined by liquid 
scintillation counting.
Drugs
5-HT creatinine sulphate (30-lOOOnM) was made up in the normal superfusion 
buffer containing pargyline and paroxetine, gassed with 95:5 0 2 :CC>2 and kept at 37° 
C. 5-HT was administered by switching the three way tap to the buffer reservoir
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containing 5-HT, having drained part of the 5-HT-containing buffer which had become 
cold in the tube and being careful not to introduce air bubbles into the tube since they 
would disrupt the release of [3 H]5-HT. The timing of the buffer switch over was 
calculated to allow for the lag between the buffer reservoir and the superfusion 
chamber.
P rug  su p p in g
5-Hydroxy[G-3 H]tryptamine creatinine sulphate was purchased from Amersham 
International pic. All other supplies were purchased from Sigma Chemical Co. with the 
exception of paroxetine which was a gift from SmithKline Beecham.
Calculations and statistics
The total number of counts per chamber was summed. The percentage 
fractional release was calculated by dividing the counts per fraction by the total 
chamber counts, this process was repeated for each fraction.
Unpaired Student's t-test was used to determine significance in the non-specific 
uptake experiments. One-way ANOVA followed by Studentised range test was used in 




U p t a k e  s t u d i e s
Pre-incubation with paroxetine significantly reduced [3H]5-HT uptake into 
hypothalamic slices; control 77.9±14.2 nmoles [3H]5-HT/mg tissue wet weight, 
paroxetine 23.75±4.5nmoles [3H]5-HT/mg tissue wet weight (unpaired Student's t- 
test, PcO.OOl n=4), see figure 8.
The differences in uptake of [3H]5-HT at the four time points studied is shown 
in figure 9; mid light 58.3±8.4nmoles/mg tissue wet weight/30 mins, end light 
101±5.2nmoles/mg tissue wet weight/30 mins, mid dark 49.9±3.4nmoles/mg tissue wet 
weight/30 mins and end dark 60.4±1.7nmoles/mg tissue wet weight/30 mins. There 
was a significant difference between uptake at end light and mid dark (One-way 
ANOVA, P<0.001 and n=4-6).
Circadian rhvthm  studies
Application of 5-HT (lpM ) had no effect on the basal release i.e. 5mM K+ 
stimulus, of [3H]5-HT, see table 2 and figure 10.
Treatment % Fractional Release '
Basal release 1.4±0.07
Basal Release + lpM 5-HT 1.1±0.1
Table 2. Effect of 5-HT on the basal release of tritiated 5-HT. Values in % fractional release, are 
expressed as mean±s.e.m. and n=l experiment performed in quadruplicate. The data quoted were 
obtained 16 min after application of exogenous 5-HT.
There was no difference in the fractional release of tritiated 5-HT at the four 
time points because exogenously applied 5-HT did not decrease [3H]5-HT release, see 
table 3 and figures 11 to 14.
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%  Fractional Release
Treatment Mid Light End Light Mid Dark End Dark
Basal Release 1.2±0.1 1.710.1 2.010.1 2.010.1
25mM K+ 11.0±0.7 11.410.2 12.210.6 11.310.6
25 mM K+ + 5-HT 16.6±0.9 11.210.4 12.510.2 11.510.6
Table 3. Release of [3H]5-HT from hypothalamic slices at four time points. Values, in % fractional 
release, are expressed as mean±s.e.m, n=l-4 experiments performed in quadruplicate. The data quoted 
were obtained 16 min after application of the first concentration of exogenous 5-HT (30nM).
When the concentration of the K+ stimulus was lowered to 15mM, and the 
experiment repeated, there was still no inhibition of [3H]5-HT release by exogenous 5- 






15mM K+ + 5-HT 1.8510.075
Table 4. Effect of lOnM and 30nM 5-HT the 15mM K+-stimulated [3H]5-HT release. Values, in % 
fractional release, are expressed as mean±s.e.m., n=l experiment performed in quadruplicate. The 
data quoted were obtained 16 min after application of the first concentration of exogenous 5-HT.
A higher single concentration of 5-HT (lpM ) was added in case previous 
concentrations had been too low to induce a decrease in tritiated 5-HT release in the 
hypothalamus, the doses having been based on those effective in the cortex. The 
challenge failed to inhibit [3H]5-HT release, see table 5 and figure 16.
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Treatment !. ......  Fractional Release
Basal release 1.45±0.1
25mM K+ 11.510.8
25mM K+ + l]iM 5-HT 11.810.4
Table 5. Tissue response, to lpM 5-HT. Values, in % fractional release, are expressed as mean±s.e.m., 
n=l experiment performed in quadruplicate. The data quoted were obtained 16 min after application 
of exogenous 5-HT.
Finally the incubation time was decreased to 15 min, the tissues were stimulated 
with 20mM K+ and one concentration of 5-HT (lOpM) added; there was no 
suppression of 5-HT release, see table 6 and figure 17.
Treatment
~ ~  .. .............................................................................
1 P R  H R R  M  1 M M 1% Fractional Release
Basal Release 1.710.07
20mM K+ 6.710.4
20mM K+ + 5-HT 7.110.02
Table 6. Effect of a reduction in incubation time on [3H]5-HT release. Values, in % fractional release, 
are expressed as mean±s.e.m., n=l performed in quadruplicate. The data quoted were obtained 16 min 
after application of exogenous 5-HT.
C a l c i u m  s t u d i e s
Removal of Ca++ from the perfusing medium did not inhibit the 25mM K+- 
stimulated release of [3H]5-HT. When the K+ stimulus was reduced to 20mM K+, and 
the experiment repeated, there was still no decrease in tritiated 5-HT output, see table 
7 and figures 18 and 19 respectively.
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Treatment ' ~ % Fractional Release
Basal Release 1.5±0.01
25mMK+ 2.7±0.25
25mM K+ without Ca++ 4.0±0.2
Basal Release 0.7±0.01
20mM K+ 5.2±0.07
20mM K+ without Ca++ 3.0±0.2
Table 7. Effect of calcium ion removal on the 25mM K+- or 20mM K+-stimulated release of [^H]5- 
HT. Values, in % fractional release, are expressed as mean±s.e.m., n=2-3 experiments performed in 
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Figure 8. H\pothalamic slices were incubated with paroxetine to determine the non-specific uptake of 
[3H]5-HT. Values, in nmoles [3H]5-HT/mg tissue wet weight/15 mins. are expressed as mean±s.e.m., 
**P<0.001 vs control, n=4 for each treatment group. Control □ and in the presence of paroxetine 0.
47
Figure 9. The uptake of [3H]5-HT into h>pothalamic slices was determined at mid light, end light, 
mid dark and end dark. Values, in nmoles [3H]5-HT/mg tissue wet weight/30 min, are expressed as 
mean±s.e.m., *P<0.05 end light vs mid dark. n=4-6 depending on time point and treatment. Mid light 
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Figure 10. Effect of l|iM  5-HT on basal (5mM K+) [3H]5-HT release from hypothalamic slices. 
Exogenous 5-HT was present in the buffer as shown by the open bar. Values, in percentage fractional 
release, are expressed as mean±s.e.m., n=l experiment performed in quadruplicate, 5mM K+ ( • )  and 
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Figure 11. Effect of the addition of 5-HT (30-1000nM) on the 25mM KMnduced [3H]5-HT overflow 
from hypothalamic slices at mid light. Increasing concentrations of 5-HT were added as indicated by 
the bar fill; 30nM open bar, lOOnM left-sloping hatched bar, 300nM right-sloping hatched bar, 
lOOOnM solid bar. Values, in percentage fractional release, are expressed as mean±s.e.m., n=l 
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Figure 12. Effect of the addition of 5-HT (30-1000nM) on the 25mM K+-induced [3H]5-HT overflow 
from hypothalamic slices at end light. Increasing concentrations of 5-HT were added as indicated by 
the bar fill; 30nM open bar, lOOnM left-sloping hatched bar, 300nM right-sloping hatched bar, 
lOOOnM solid bar. Values, in percentage fractional release, are expressed as mean±s.e.m., n=3 
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Figure 13. Effect of the addition of increasing concentrations of 5-HT (30-lOOOnM) on the 25mM K+- 
induced [3H]5-HT overflow from hypothalamic slices at mid dark. Increasing concentrations of 5-HT 
were added as indicated by the bar fill; 30nM open bar, lOOnM left-sloping hatched bar, 300nM right- 
sloping hatched bar, lOOOnM solid bar. Values, in percentage fractional release, are expressed as 
mean±s.e.m., n=4 experiments performed in quadruplicate, 5mM K+ ( • ) ,  25mM K+ (▼) and 25mM 
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Figure 14. Effect of the addition of 5-HT (30-1000nM) on the 25mM K+-induced [3H]5-HT overflow 
from hypothalamic slices at end dark. Increasing concentrations of 5-HT were added as indicated by 
the bar fill; 30nM open bar, lOOnM left-sloping hatched bar, 3()0nM right-sloping hatched bar, 
lOOOnM solid bar. Values, in percentage fractional release, are expressed as mean±s.e.m., n=4 
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Figure 15. Effect of lOnM and 30nM 5-HT on the 15mM K+-induced release of [3H]5-HT. 5-HT was 
applied as indicated by the bar fill; lOnM open bar. 30nM hatched bar. Values, in percentage 
fractional release, are expressed as mean±s.e.m.. n=l experiment performed in quadruplicate, 5mM 
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Figure 16. Effect of adding one high concentration of 5-HT (ljiM), shown by the open bar, on the 
25mM K +-stimulated overflow of [3H]5-HT. Values, in percentage fractional release, are expressed as 
mean±s.e.m., n=l experiment performed in quadruplicate. 5mM K+ ( • ) ,  25mM K+ (T) and 25mM 
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Figure 17. The incubation time was reduced to 15 minutes and the effect of IOjiM 5-HT, open bar, on 
the 20mM K-stimulated release, hatched bar, assessed. Values, in percentage fractional release, are 
expressed as mean±s.e.m., n=l experiment performed in quadruplicate, 5mM K+ ( • ) ,  20mM K+ (T) 
and 20mM K+ + lOpM 5-HT (■).
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Figure 18. Calcium ions were removed from the 20mM K+ superfusing medium, as indicated by the 
open bar. Values, in percentage fractional release, are expressed as mean±s.e.m., n=2-3 experiments 
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Figure 19. Calcium ions were removed from the 25mM K+ superfusing medium, as indicated b\ the 
open bar. Values, in percentage fractional release, are expressed as mean±s.e.m., n=2-3 experiments 
performed in quadruplicate. 5mM K+ ( • ) ,  25mM K+ (▼) and 25mM K+ without Ca2+ (■).
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Discussion
The superfusion technique developed by Frankhuyzen and Mulder (1982), 
adapted to measure 5-HT release by Middlemiss (1984; 1985) and employed in our 
laboratory by Singh and Redfem (1994a,b) to study autoreceptor function in the 
hippocampus and cortex in vitro was applied directly to the hypothalamus.
Uptake experiments
Initial uptake experiments indicated that there was almost twice as much non­
specific uptake in the hypothalamus (29.5%) as in the cortex (cortex 16%; Singh and 
Redfem 1994a). The uptake of tritiated 5-HT into hypothalamic slices at four time 
points showed a significant variation, with the peak occurring in animals sacrificed at 
end light, and no significant difference between the amount of [3 H]5-HT taken up at 
the other three times. However the degree of non-specific uptake was not measured at 
each of the time points. All these experiments were carried out within 4 days of the 
arrival of the same batch of [3 H]5-HT using randomly assigned animals. The 
degradation of [3 H]5-HT is considered to be 2% per month when stored at +2°C. In 
the laboratory [3 H]5-HT was aliquoted in 0.2mM ascorbic acid and stored at -20 °C 
until use. It is unlikely, therefore, that the differences seen are due to degradation of the 
radiolabel. The results of the [3 H]5-HT uptake experiments are partially in agreement 
with Meyer and Quay (1976). These workers showed that the uptake of [3 H]5-HT into 
hypothalamic homogenates or SCN slices displayed a marked variation, with peak 
uptake occurring towards the end of the light phase (Meyer and Quay 1976). However 
the trough in uptake appeared during the earlier hours of the light cycle in both 
hypothalamic homogenates and SCN slices, whereas in this study the uptake into 
hypothalamic chips was equal at mid dark, end dark and mid light. The difference could 
be due to the use of basal hypothalamus; all the hypothalamic nuclei dissected could 
display rhythms in uptake with varying, and perhaps opposed, acrophases and 
barthyphases. It might have been advisable to use only one hypothalamic nucleus, but 
this would have entailed an increased number of rats.
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24 Hour Rhythm Studies- What went wrong?
This set of experiments attempted to measure the IC5 0  value for the inhibition 
of [3 H]5-HT release by exogenous 5-HT at mid light, end light, mid dark and end dark. 
Thus the actual decrease in 5-HT with time was overlooked until it was found that the 
IC5 0  at each time point was the same. In order to check whether this was a valid 
observation, the time course of the experiment was plotted and showed that in fact 
exogenously applied 5-HT was failing to inhibit [3 H]5-HT release. This could not be 
because the exogenous 5-HT was being degraded since pargyline was present in the 
perfusing buffer throughout the experiment Neither could the exogenous 5-HT be 
taken up into 5-HT terminals since the selective 5-HT uptake inhibitor paroxetine was 
present throughout the experiment at a concentration known to effective (Middlemiss 
1984; 1985).
One possibility was that the 5-HT might not be reaching receptor sites because 
of the buffer flow round the tissues. However, since Singh and Redfem (1994a) had 
used the same apparatus, tissue volume and size successfully this seems unlikely. To 
examine the possibility that, in the hypothalamus, the initial 5-HT challenge might be 
too low, a high concentration of 5-HT was applied; this too failed to inhibit tritiated 
[3 H]5-HT release. It is unlikely that the 5-HT receptor was already occupied since the 
tissue had a 30 minute stabilisation period to allow for dissociation of ligands from 
receptors. A further possibility was that the concentration of radiolabel used was 
insufficient to label intraneuronal 5-HT stores effectively in 5-HT neurons. This is 
improbable since it has been shown that the uptake of O.lpM [3 H]5-HT into 
hypothalamic slices reaches a plateau at a tissue concentration of lOmg/ml wet weight 
(Shaskan and Snyder 1970); the tissue concentration used in the experiments described 
here was about 15mg/ml. On the other hand the concentration of radiolabel may have 
been too high so that it entered other neurons and/or glial cells. Again this is unlikely. 
At a concentration of O.lpM [3 H]5-HT has been shown to be preferentially taken up 
by serotoninergic neurons (Shaskan and Snyder 1970). The uptake of [3 H]5-HT into 
hypothalamic slices was found to have two components; a high affinity uptake
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component with a Km for 5-HT of 0.17pM and a low affinity component with a Km for 
5-HT of 80pM. At low concentrations of 5-HT the high affinity uptake system 
accounts for 4 times the uptake by the low affinity system (Shaskan and Snyder 1970). 
The incubation time may have been insufficient or too long. The uptake of [3 H]5-HT 
into hypothalamic slices reaches a plateau at an incubation time of 24 minutes (Shaskan 
and Snyder 1970) and reaches equilibrium in synaptosomes after 30 minutes (Wolf and 
Kuhn 1986). Thus the conditions used should have ensured preferential uptake into 5- 
HT neurons. It is possible that [3 H]5-HT may have been taken up into 5-HT neurons 
but not entered part of the functional cytoplasmic pool.
The results of the Ca++-removal experiments suggest that the [3 H]5-HT was 
being taken up into glial cells since [3 H]5-HT release from neurons in the cortex and 
hippocampus has been shown to be calcium-dependent (Gothert 1980; Singh and 
Redfem 1994a).
There are two other possibilities for the lack of effect of 5-HT. Firstly the 
concentration of 5-HT used could have been too low to preferentially activate 5-HT 1B 
autoreceptors. However the IC50 for 5-HT inhibition of [3 H]5-HT using this 
technique, but using cortical tissue, is 46nM (Middlemiss 1984) and lpM 5-HT had no 
effect in this study. 5 -HT3  receptors have been demonstrated to affect 5-HT release in 
the ventral hippocampus (Martin et al. 1992). Stimulation of these receptors increases 
5-HT release since the 5 -HT3  receptor is a cation channel. The relative Kj values of 5- 
HT for 5-HTjg and 5 -HT3 , receptors derived from binding studies, are 7.6nM 
(Peroutka 1986) and 270nM (Maricq et al. 1991) respectively. Thus the 5-HT1B 
receptor would have been preferentially stimulated at the concentrations of 5-HT 
(30nM-lpM) used in this study. Additionally there are few 5 -HT3  receptors in the 
hypothalamus (Palacios et al. 1990). An alternative explanation is that the K+ stimulus 
might stimulate the release of other neurotransmitters which might enhance 5-HT 
release e.g. nicotinic acetylcholine receptors (Hery et al. 1977a). However, since 
[3 H]5-HT release was not calcium-dependent it would argue against this factor. An 
uptake inhibitor was included in the superfusing buffer so exogenous 5-HT could not
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enter 5-HT neurons (and perhaps glia) and displace [3 H]5-HT intracellularly. It is also 
unlikely that 5-HT displaced [3 H]5-HT from, for example dopamine neurons, since no 
increase in [3 H]5-HT was seen even after the maximal concentration of 5-HT.
The hypothalamus is rich in glial cells which are known to possess two amine 
uptake systems. The first is a low affinity system which is temperature and sodium ion 
independent, with a Km for 5-HT of 1.5mM. The second system has a high affinity for 
5-HT, comparable to that of neurons, and is temperature and sodium ion dependent, it 
has a Km of 0.4pM for 5-HT (Katz and Kimberger 1985). This second system is also 
susceptible to inhibition by uptake inhibitors such as clomipramine (Suddith et al. 
1978). Thus the results showing 29.5% non-specific uptake would probably not have 
included this high affinity uptake site, indeed the degree of non-specific uptake could 
even be higher.
In order to determine whether the results obtained arose because the technique 
was inappropriate for hypothalamic tissue, additional experiments were performed. The 
stimulation was changed to two pulses of 25mM K+, each 4 minutes long, the first (Si) 
8  minutes after the end of the stabilisation period and the second (S2 ) 40 minutes later. 
Drugs to be tested were added 20min before S2  and the ratio of S1/S2  calculated. 
Stimulation produced a good increase in [3 H]5-HT output over basal fractional release, 
however exogenously applied 5-HT (lpM) failed to inhibit 25mM K+-induced [3 H]5- 
HT output and had no effect on basal [3 H]5-HT fractional release. Electrical 
stimulation of the tissues was attempted using two different commercially available 
superfusion systems, one from Linton Instrumentation, see figure 20, and a Brandel 
superfusion system. In the first system no current flow was detected at low voltages. 
At high voltages (150V) the platinum electrodes oxidised but there was still no current 
flow. In the second system current flowed between the electrodes but there was never 
a reproducible release of [3 H]5-HT. Two stimulation parameters were tried. The first is 
designed to prevent build up of [3 H]5-HT around the tissue on stimulation which might 
inhibit further [3 H]5-HT output (Fischer et al. 1990; O'Connor and Kruk 1991). Pulses 








Figure 20. Cross section through the Linton Instrumentation superfusion apparatus used. Tissue is 
placed on a nylon mesh and inserted into the well of the chamber, which lies in one half of the block. 
The two halves of the superfusion block are then screwed together and the whole inserted into a water 
bath maintained at 37°C. Buffer flows in at a side inlet, over the tissue chips and out the top of the 
superfusion block. Air bubbles can be removed by a siphon device which opens into the chamber. A 
platinum electrode is built into each half of the superfusion block to stimulate the tissue.
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sec). The second was a more physiological approach using the same frequency as 5-HT 
neuronal firing during quiet waking (3-5Hz) (Jacobs and Azmitia 1992), but for a long 
duration (4 min). Neither stimulation parameter produced a reproducible release of 
[3 H]5-HT.
Binding sites for 5-HT have been demonstrated on horse striatal astroglia 
(Murphy and Pearce 1987). There is debate whether these sort of receptors are 
functionally linked; some reports have shown that the receptors are positively linked to 
adenylate cyclase. It might be thought that glial cells cannot be depolarised by K+, but 
one study demonstrated the K+-induced release of GABA from glia (Murphy and 
Pearce 1987). 5-HT stimulation of glia can also lead to the release of taurine, a highly 
active neuropeptide, which increases chloride conductance and would therefore 
hypeipolarise neurons. Thus [3 H]5-HT taken up into glia might be released 
uncontrollably by perfusion of a medium containing elevated K+.
The data here are in agreement with the findings of Passarelli and colleagues 
(1987) which suggest that the hypothalamus is different from other brain regions. 
These workers compared electrically- and 20mM K+ pulse-stimulated release of [3 H]5- 
HT in hypothalamic slices and found significant differences. When calcium ions were 
removed from the superfusing buffer 2 0  min prior to electrical stimulation the release 
of [3 H]5-HT was almost entirely prevented; this was not true of K+-stimulation. If 
slices were superfused for 40 min in the presence of the calcium ion chelator EGTA 
(ImM), [3 H]5-HT release was only inhibited by 40-50%. The effects of tetrodotoxin 
varied with stimulus. Electrically-evoked [3 H]5-HT output was inhibited by 
tetrodotoxin, but if elevated K+ was used as the stimulus the output was unaffected by 
tetrodotoxin. In addition the paper compared the effects of lysergic acid diethylamine 
(LSD), 5-methoxytryptamine (both autoreceptor agonists) and methiothepin on 
electrically and K+-evoked tritiated 5-HT release. The [3 H]5-HT-inhibiting effects of 
the agonists were markedly attenuated when elevated K+ was used as the depolarising 
stimulus. These workers concluded that the [3 H]5-HT output observed in the 




Using the technique of in vitro superfusion, an attempt was made to measure 
the sensitivity of the terminal 5-HT autoreceptor in hypothalamic slices at four, equally 
spaced time points through the light-dark cycle. The hypothalamus appears to behave 
differently from the hippocampus and cortex in vitro. The results indicate that 
radiolabelled 5-HT is actively taken up into hypothalamic glial cells where its release 
can not be controlled. One way to overcome the problem could be to measure [^H]5- 
HT release from purified hypothalamic synaptosomes. The technique could have been 
verified by trying to repeat experiments in the cortex or by using a 5-HTib receptor 
agonist, such as 5-methoxy-3-(l,2,3,6-tetrahydro-4-pyridyl)-lH-indole (RU24969) 
instead of 5-HT. However, using the same technique, Middlemiss (1985) found that 
the IC5 0  for RU24969 was 35nM in cortical slices which is not different from the IC5 0  
for 5-HT (46nM). Since the technique proved to be unviable, no conclusions can be 
drawn with regard to the hypothesis of this section.
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Chapter 3 5-Hydroxytryptophan Accumulation
Hypothesis
Synthesis was the second parameter of 5-HT function to be studied. The 
experiments in this chapter investigated the hypotheses that, in entrained rats;
a) The degree of 5-HT1B-mediated inhibition of 5-HT synthesis varies significantly 
over 24 hours.
b) Chronic antidepressant treatment would down-regulate this 5-HTjg-mediated 
control.
c) The scale of down-regulation would be significantly different over the light-dark 
cycle.
The experiments were divided into three sections; the first section aimed to confirm 
previous demonstrations of a rhythm in basal 5-HT synthesis, the second section to 
verify whether 5-HT synthesis could be affected by RU24969, a 5-HT1B agonist, and 
thus pharmacologically define the receptor mediating the effect; the final section 
investigated the effect of chronic antidepressant treatment on RU24969-mediated 
control of 5-HT synthesis.
Four time points spaced equally through the light-dark cycle were chosen; these 
were mid light (Circadian Time 6 ), end light (CT11.45), mid dark (CT 18) and end 
dark (CT23.45). Circadian time refers to the time in hours after lights on in the relavent 
animal colony. These time points were chosen because, from previous work, they 
should coincide with maxima and minima in enzyme activity so that comparisons could 
be made with the literature.
Method
Animals
Groups of 6  phase-shifted male Wistar rats, as described on page 39, weighing 
230-270g were used throughout the experiments. In each group, 2 rats served as 
controls, receiving the drug vehicle; control rats received the same injection volume,
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and the same number of injections at corresponding time intervals as experimental rats. 
The remaining rats were drug treated. Treatments were not randomised, i.e. the rats in 
the group that were to receive treatment were all injected with the same dose of the 
same drug e.g. RU24969. Similar treatments were performed within a week so that, for 
example, groups of rats used for RU24969 (3 or 9mg/kg i.p.) studies were treated, 
killed and the tissue samples processed/frozen within 5 days of each other. This 
protocol was adopted for several reasons. First there was a limit both to the total 
number of rats available at any one time and to the number of rats that could be phase- 
shifted together. Secondly, randomisation of drug treatments might not take into 
account circannual rhythms in 5-HT receptors which have been demonstrated (Weiner 
et al. 1992). Third it ensured that control rats and treated rats had been subjected to the 
same environmental conditions and finally it reduced the risk of differences in breeding. 
Control rats were included in every set of drug treatments at every time point to cross­
check 5-HTP levels with other controls and basal levels. If the manipulations were 
performed during the rats' light phase the animals were injected under normal room 
lighting, however rats injected during their dark phase were treated in dim red light (4- 
6  lux). Rats were subjected to either of the two protocols below. Each stage of the 
protocol was separated by 30 minutes.
©Agonist —» NSD 1015 —» cervical dislocation at appropriate phase of light-dark 
cycle.
©Antagonist —> agonist —» NSD 1015 -» cervical dislocation at appropriate phase of 
the light-dark cycle.
After each stage of the treatment animals were returned to their cages and the cage 
placed back inside the appropriate box of the environmental cabinet. Doses of drugs 
and the timing between injections were assessed from published work.
Tissue preparation
Rats were killed by cervical dislocation and the whole brain removed from 
which the frontal cortex, hippocampus, hypothalamus and striatum were dissected onto
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ice. These particular brain regions were chosen since their innervation from the RN 
differs; the hypothalamus and hippocampus receive afferents both the MRN and DRN 
whilst the input to the frontal cortex is solely from the MRN and that to the striatum 
from the DRN. The brain regions were weighed and the frontal cortex and 
hippocampus wrapped in foil and frozen at -75°C until assay. Hypothalamic and striatal 
tissue was homogenised in 10% w/v 0.1M perchloric acid (Tri-R Stir-R) at 4°C. The 
homogenates were ultracentrifuged at 15,000 x g for 15 min at 4°C (Beckman 
preparative ultracentrifuge, model LM-8 ). Supernatants were filtered through 0.45pm 
nylon acrodiscs (Gelman Sciences, Fisons), aliquoted into amber light-proof 
microcentrifuge tubes (Eppendorf, BDH) and the supernatants frozen at -20°C until 
they were assayed for their 5-HTP content by reverse phase high performance liquid 
chromatography coupled to electrochemical detection (HPLC-ECD). The pellets were 
re-suspended in Tris-HEPES buffer (composition in mM: NaCl 118; KQ 4.8; MgSC>4 
1.2; CaCl2  2.5; HEPES 20; Tris HC1 200; containing 0.1% Triton X-100) and assayed 
for their protein content. Microprotein assays were performed using BioRad protein 
dye reagent with bovine serum albumin serving as the standard.
Measurement of 5-HTP in the supernatant
An HPLC system to measure 5-HTP levels had been set up and optimised 
previously in the laboratory. However the system has been dissembled and it was 
therefore necessary to establish and optimise a new system. Separation of 5-HTP, 5- 
HT and 5-HIAA had been achieved in 30 minutes in the former system with the 
following parameters; electrode potential 0.6V, flow rate lml/min, octane sulphonic 
acid 0.3mM, EDTA O.lmM, NaHjPO^ 0.07M, 8 % methanol v/v adjusted to pH 2.75, 
with the column kept at 30°C by a water bath.
The parameters for resolution of 1-DOPA, DA, 5-HTP, 5-HT, 5-HIAA for the 
HPLC system described in this section were based on the previous optimisation, but 
slightly modified to produce a shorter run time (15 min). Samples (200pl) were 
automatically injected (Gilson sample injector, model 231 attached to a Gilson dilutor,
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model 401, Anachem) via a Rheodyne sample injector (model 7125) fitted with a lOOpl 
loop, onto a reverse phase HPLC column packed with 5pm Hypersil ODS (20cm x 
5cm o.d.). The constituents of the sample were separated along the column and 
detected by an amperometric detector set at +0.6V (BAS LC3A amperometric 
detector, Anachem). The chromatogram was plotted onto a chart recorder (JJ. Lloyd 
Instruments). Mobile phase (composition in mM: octane sulphonic acid 0.3; EDTA
0.1; NaH2 PC>4 70; 12% v/v methanol to pH 2.75 with 6 M sulphuric acid) was pumped 
through the system at a rate of lml/min by a Constametric LDC model HI pump. The 
flow rate was lowered to 0. lml/min when the HPLC was not in use. Fresh buffer was 
made up every 2-3 days as required using double-distilled, filtered water (Milli Q). The 
buffer was filtered under vacuum through 0 .2 pm nitrocellulose membrane filters 
(Whatman, Fisons) and bubbled with helium for 10 min to purge any dissolved oxygen 
from the buffer. Each month the system was flushed through with 90:10 methanol:Milli 
Q at a rate of 8 ml/min. In addition the pump was flushed through with 0.1% warm 
Decon solution at 8 ml/min for 10 min, then Milli Q water and finally with the 
methanol:Milli Q solution. A signal to noise ratio of 2:1 was considered acceptable.
Perchloric acid (0.1M) was injected onto the HPLC column to check whether it 
produced a peak that might interfere with the interpretation of the chromatogram. The 
concentration of 5-HTP in the supernatant was determined by comparing the ratio of 
the peak height of the internal standard (5,7-dihydroxytryptamine) to the peak height of 
a known concentration of 5-HTP. A standard curve was constructed from these values 
and the concentration of 5-HTP in the sample read from this standard curve.
The recovery of 5-HTP through the preparation stages was also checked. A 
known concentration of 5-HTP was prepared and stored as for brain samples. A 
sample of 5-HTP (200pl) prepared this way was injected onto the HPLC column, the 
peak height measured, and the concentration calculated as above. The recovery of 5- 
HTP through these stages was 94±3%.
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Chronic antidepressant treatment
Rats, housed as described previously, were treated for 21 days with a once 
daily injection of either paroxetine hydrochloride (1 0 mg/kg i.p.), desipramine 
hydrochloride (10mg/kg i.p.) or an equivalent volume of saline. In each group at least 
two rats served as saline-treated controls. Injections were performed once a day within 
an 8  hour window, to prevent the rats taking the injections as a time cue. If the rats 
were in their dark cycle at the time of injection then dim red light was used, as for cage 
cleaning. All experiments were performed after a 24 hour washout period. 
Antidepressant drug doses were chosen following literature review as being typical 
doses used. In order to assess any antidepressant-induced alterations in 5-HT1B 
receptor function, the potency of RU24969 (9mg/kg i.p) was re-evaluated after chronic 
antidepressant treatment. It is known that monoamine levels and neurons decrease with 
age (Tatton et al. 1991), therefore rats were treated with antidepressant drugs and 
phase-shifted at the same time, to ensure that the rats' final weight were comparable to 
those of earlier studies.
Drugs
RU24969, desipramine hydrochloride and paroxetine hydrochloride were all 
made up in 0.9% saline. (±)Cyanopindolol and (-)n-tert-butyl-3-(4-(2- 
methoxyphenyl)piperazin- 1  -yl)-2 -phenylpropionamide dihydrochloride
((+)WAY100,135) were first dissolved in a few drops of glacial acetic acid and then 
made up in 0.9% saline and brought to pH 7.4 with 6 M sodium hydroxide, m- 
Hydroxybenzylhydrazine (NSD 1015) was made up in 0.9% saline and adjusted to the 
correct pH with 6 M sodium hydroxide. In all experiments control animals received the 
drug vehicle.
Drug Suppliers
Drugs were purchased from the suppliers as follows; m- 
hydroxybenzylhydrazine (NSD 1015), desipramine hydrochloride, Triton X-100,
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HEPES, Tris hydrochloride, bovine serum albumin (Sigma Chemical Company), 
octanesulphonic acid, NaCl, KC1, MgSC^, CaCl2 , NaKyPC^ and EDTA all HPLC 
grade (Sigma Chemical Company); perchloric acid (BDH) and HPLC grade methanol 
(Fisons).
The following drugs were donated by the companies indicated in brackets, 
RU24969 (Roussel-Uclaf), (±)cyanopindolol (Sandoz), paroxetine hydrochloride 
(SmithKline Beecham) and (+)WAY100135 (Wyeth).
Statistics
Data for variations in 5-HTP concentration over 24 hours and vehicle controls 
vs basal levels was analysed by one-way analysis of variance (ANOVA) followed by 
Studentised range test. All other results were analysed using two-way ANOVA with 
post hoc Studentised range test. Values of P<0.05 or less were considered statistically 
significant
Since the measurement of 5-HTP after studies using WAY100135 was not 
performed on the same HPLC system and the samples were prepared slightly 
differently, homogenisation in 5%w/v perchloric acid and inclusion of sodium 
metabisulphite in the homogenising buffer, the data have been normalised. Thus, the 5- 
HTP levels from treated animals were calculated as a percentage of the average 5-HTP 
levels of the WAY100135 vehicle control animals. The data from WAY100135 vehicle 
control animals was then assumed to be the average of the 5-HTP values obtained from 
previous vehicle control animals (statistical analysis had indicated there was no 
difference between basal levels and vehicle control levels of 5-HTP from rats used in 
RU24969 and (±)cyanopindolol studies, see later) and the 5-HTP level after 
WAY100135 recalculated using these new WAY100135 vehicle control 5-HTP levels. 
Percentages of control value were used for statistical analysis involving data derived 
from WAY 100135 studies. Statistical methods and outcomes are set out in appendix 1.
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Results
Variation in 5-HTP levels over 24 hours
Basal levels of 5-HTP, i.e. without decarboxylase inhibition, measured at mid 
light only were below the detection limit of the HPLC system. Following decarboxylase 
inhibition measurable amounts of 5-HTP were present in samples from each time point 
and brain region.
An example of a chromatogram obtained from a hypothalamic sample is shown 
in figure 21. Quantitative data from all the following studies are presented in appendix
1. The levels of 5-HTP, after decarboxylase inhibition, in the hypothalamus, 
hippocampus, frontal cortex and striatum are shown together in figure 2 2  and table A1 
of appendix 1. There were significant differences between the 5-HTPacc with time in 
each brain region. There was a significant variation in the levels of 5-HTP measured in 
the hypothalamus at the four time points. In the hypothalamus the peak accumulation 
of 5-HTP was at mid dark (1.15±0.06ng 5-HTP/pg protein/30 mins), whilst the trough 
was at end dark (0.75±0.03ng 5-HTP/pg protein/30 mins), the levels at the other two 
time points were 1.08±0.06ng 5-HTP/pg protein/30 mins at mid light and 0.94±0.04ng 
5-HTP/pg protein/30 mins at end light The hippocampus showed a significant 
variation in 5-HTP levels over 24 hours. Peak 5-HTPacc occurred at mid light 
(6.7±0.3ng 5-HTP/pgprotein/30 mins) whereas lowest levels were determined at end 
dark (3.8±0.2ng 5-HTP/pg protein/30 mins); other levels were 4.65±0.2ng 5-HTP/pg 
protein/30 mins at end light and 5.9±0.4ng 5-HTP/pg protein/30 mins at mid dark. In 
the frontal cortex levels varied significantly over 24 hours, the zenith occurring at mid 
light (7.0±0.3ng 5-HTP/pg protein/30 mins) whilst the nadir was at end dark 
(3.6±0.2ng 5-HTP/pg protein/30 mins); other levels were 6.8±0.45ng 5-HTP/pg 
protein/30 mins at end light and 6.3±0.4ng 5-HTP/pg protein/30 mins at mid dark. The 
striatum showed peaks and troughs in 5-HTPacc that were directly opposite to those of 
the frontal cortex and hippocampus. Striatal 5-HTP levels varied significantly over the 
four time points. Peak 5-HTPacc was measured at end dark (7.4±0.2ng 5-HTP/pg 
protein/30 mins) whilst the trough was at mid light (1.7±0.09ng 5-HTP/pg protein/30
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mins); other levels were 4.7±0.4ng 5-HTP/pg protein/30 mins at end light and 
2.8±0.2ng 5-HTP/pg protein/30 mins at mid dark.
Vehicle controls
In no brain region and at no time point did 5-HTPacc in vehicle treated animals 
differ significandy from basal 5-HTPacc. Data from vehicle controls from WAY100135 
studies has not been included. Statistical analysis was performed by one-way ANOVA 
with post hoc Studentised range test, with corresponding treatment vehicle controls, 
but, in graphs vehicle control data was pooled for simplicity. All data and statistical 
analysis is presented in appendix 1 .
Agonist and Antagonist Studies over 24 hours
Adminstration of RU24969 (9mg/kg i.p.) caused the appearance of a marked 5- 
HT syndrome, but the syndrome did not appear to be more pronounced at one time 
point relative to another. The syndrome was not present when (±)cyanopindolol was 
administered before RU24969 (9mg/kg i.p.), but persisted after (+)WAY100135 pre- 
treatment 
Hypothalamus
RU24969 (3mg/kg i.p.) did not significantly affect 5-HTPacc at any time point. 
However at the higher dose of 9mg/kg i.p. RU24969 significantly decreased 5-HTPacc 
at all times, -27±0.9% at mid light -27±3.6% at end light -24±5.6% at mid dark and 
-35±9% at end dark. The degree of inhibition did not vary significantly over the time 
points though. Pre-treatment with (±)cyanopindolol (CP, 3mg/kg i.p.) blocked the 
RU24969-mediated decrease in 5-HTPacc, whilst having no effect on 5-HTPacc when 
administered alone. Interestingly, treatment with CP and RU24969 at mid light 
significantly increased 5-HTPacc. (+)WAY100135 (WAY, 5mg/kg i.p.) pre- 
administration did not block the effects of RU24969 (9mg/kg i.p.) and had no effect on 
5-HTPacc when administered alone, see figure 23 and 24 and table A2 of appendix 1.
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Hippocampus
At mid dark RU24969 (3mg/kg i.p.) significantly decreased 5-HTPacc by 
26±0.3%. The effect at this time point was significantly different from the effects of 
RU24969 (3mg/kg i.p.) at the other three times. RU24969 (9mg/kg i.p.) significantly 
decreased 5-HTPacc at all times but the degree of inhibition varied significantly with 
time. CP pre-treatment blocked the 5-HTPacc-suppressing effects of RU24969 
(9mg/kg i.p.). By itself CP had no effect on 5-HTPacc at mid light and mid dark but 
significantly increased 5-HTPacc at end light and end dark, this effect being 
significantly different with time. This may indicated a degree of autoinhibitory tone in 
the hippocampus at these time points. WAY (5mg/kg i.p.) pre-administration had no 
effect on the RU24969-induced suppression of 5-HTPacc and had no effect on 5- 
HTPacc when administered alone, see figure 25 and 26 and table A3 of appendix 1. 
Frontal Cortex
RU24969 (3mg/kg i.p.) significantly decreased 5-HTPacc at end light by 
15±1%. The effect of RU24969 at this time point was significantly different from its 
effects at the other three time points. RU24969 (9mg/kg i.p.) decreased 5-HTPacc 
significantly at all times, and RU24969's effects varied significantly with time. CP pre- 
treatment blocked the effects of RU24969, whilst having no effect when administered 
alone. Pre-administration of WAY did not affect the RU24969-induced decrease in 5- 
HTPacc and had no effect on 5-HTPacc when administered by itself, see figure 27 and 
28 and table A4 of appendix 1.
Striatum
At mid light RU24969 (3mg/kg i.p.) significantly decreased 5-HTPacc by 
13±3%, the effect at mid light was significantly different from the effect of RU24969 
(3 mg/kg i.p.) at other time points. RU24969 (9 mg/kg i.p.) decreased 5-HTPacc 
significantly at all times, and the effect differed significandy with time. Pre­
administration of CP blocked the RU24969-mediated decrease in 5-HTPacc, having no 
effect when administered alone. WAY pre-treatment did not affect the suppression of 
5-HTPacc caused by RU24969, and had no effect when administered by itself, see
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figure 29 and 30 and table A5 of appendix 1.
75
L
Figure 21. Example of a hypothalamic chromatogram. The arrow indicates the solvent front, 1-DOPA 
(1) Rt 2.5 min, DA (2) R, 4 min, 5-HTP (3) Rl 6.5 min, 5,7-DHT (4) Rl 8 min, 5-HIAA (5) Rl 10.5 
min and 5-HT (5) Rt 11 mins. The detector potential was set at +0.6V and the sensitivity was 
0.5nAmp full scale deflection, the bar denotes 5 mins. Details of the mobile phase and other 
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Figure 22. Variation over 24 hours of 5-HTP accumulated after decarboxylase inhibition in the four 
brain regions studied. Values expressed as ng 5-HTP/pg protein, mean±s.e.m„ n=6 for each rime point 
in each brain region, mid light <p), end light (0), mid dark (H) and end dark (■). Statisucal 
probabilities of differences in 5-HTP level with time for each brain region are given in table A1 in 
appendix 1.
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Figure 23. Effect of various pharmacological manipulations on the rate of accumulation of 5-HTP in 
the hypothalamus. Values are expressed in ng 5-HTP/pg protein, as meanis.e.m., *P<0.05, **P<0.01 
vs corresponding vehicle control, n=4-8 depending on time point and treatment, pooled vehicle 
control (D), 3mg/kg i.p. RU24969 (0), 9mg/kg i.p. RU24969 (0), 3mg/kg i.p. (±)cyanopindolol + 
9mg/kg i.p. RU24969 (®), 3mg/kg i.p. (±)cyanopindolol (■), 5mg/kg s.c. WAY100135 + 9mg/kg i.p. 
RU24969 dm), 5mg/kg s.c. WAY 100135 (£3).
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Figure 24. Compound graph of the effects of RU24969 at the four time points in the hypothalamus. 
Values are expressed in % change from corresponding vehicle control value, as meanis.e.m., 
*P<0.05, **P<0.01 vs vehicle control, n=4 for each time point and treatment, vehicle control (a ), 
3mg/kg i.p. RU24969 (S3) and 9mg/kg i.p. RU24969 (*). ML denotes mid light, EL end light, MD 
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Figure 25. Effect of various pharmacological manipulations on the rate of accumulation of 5-HTP in 
the hippocampus. Values are expressed in ng 5-HTP/pg protein, as mean±s.e.m., *P<0.05, **P<0.01 
vs corresponding vehicle control, n=4-8 depending on time point and treatment, pooled vehicle 
control (□), 3mg/kg i.p. RU24969 (0), 9mg/kg i.p. RU24969 (E33), 3mg/kg i.p. (±)cyanopindolol + 
9mg/kg i.p. RU24969, (J550, 3mg/kg i.p. (±)cyanopindolol 0 ),  5mg/kg s.c. WAY100135 + 9mg/kg i.p. 
RU24969 (jm), 5mg/kg s.c. WAY100135 (g).
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Figure 26. Compound graph of the effects of RU24969 in the hippocampus. Values are expressed in 
% change from corresponding vehicle control value, as mean±s.e.m., *P<0.05, **P<0.01 vs vehicle 
control, n=4 for each time point and treatment, vehicle control (□ ), 3mg/kg i.p. RU24969 (tes) and 









































































Figure 27. Effect of various pharmacological manipulations on the rate of accumulation of 5-HTP in 
the frontal cortex. Values are expressed in ng 5-HTP/pg protein/30 min, as meanls.e.m., *P<0.05, 
**P<0.01 vs corresponding vehicle control, n=4-8 depending on time point and treatment, pooled 
vehicle control (jZ3), 3mg/kg i.p. RU24969 (E3), 9mg/kg i.p. RU24969 0 . 3mg/kg i.p. (±)cyanopindolol 
+ 9mg/kg i.p. RU24969, (83), 3mg/kg i.p. (±)cyanopindolol (M), 5mg/kg s.c. WAY100135 + 9mg/kg 
i.p. RU24969 &IJ), 5mg/kg s.c. WAY 100135 p ) .
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Figure 28. Compound graph of the effects of RU24969 in the frontal cortex. Values are expressed in 
% change from corresponding vehicle control value, as mean±s.e.m., *P<0.05, **P<0.01 vs vehicle 
control, n=4 for each time point and treatment, vehicle control (jcj), 3mg/kg i.p. RU24969 $3) and 
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Figure 29. Effect of various pharmacological manipulations on the rate of accumulation of 5-HTP in 
the striatum. Values are expressed in ng 5-HTP/pg protein/30 min, as mean±s.e.m., *P<0.05, 
**P<0.01 vs corresponding vehicle control, n=4-8 depending on time point and treatment, pooled 
vehicle control (CJ), 3mg/kg i.p. RU24969 (H), 9mg/kg i.p. RU24969 (S3), 3mg/kg i.p. 
(±)cyanopindolol + 9mg/kg i.p. RU24969 (^), 3mg/kg i.p. (±)cyanopindolol (Hi), 5mg/kg s.c. 
WAY100135 + 9mg/kg i.p. RU24969 (PH>, 5mg/kg s.c. WAY 100135 (g).
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Figure 30. Compound graph of the effects of RU24969 in the striatum . Values are expressed in % 
change from corresponding vehicle control value, as mean±s.e.m.f *P<0.05, **P<0.01 vs vehicle 
control, n=4 for each time point and treatment, vehicle control (□ ), 3mg/kg i.p. RU24969 (S3) and 
9mg/kg i.p. RU24969 (■). ML denotes mid light, EL end light, MD mid dark and ED end dark.
85
Chronic antidepressant treatment
Quantitative data tables and details of statistical analysis are presented in 
Appendix 1.
Basal TrOH activity
Rats were treated chronically with either saline, paroxetine or desipramine to 
gauge the effect that chronic antidepressant treatment might have on basal TrOH 
activity. Time and resources only permitted this to be carried out at one time point 
End light was chosen because RU24969 (9mg/kg i.p.) was generally most effective in 
rat brain regions at this time point. Chronic paroxetine or desipramine treatment had no 
effect on 5-HTPacc compared to saline-treated animals at end light in any of the four 
brain regions.
Effect of RU24969 in antidepressant-treated animals 
Hypothalamus
Chronic paroxetine treatment significantly attenuated the decrease in 5-HTPacc 
after RU24969 at end light compared with saline-treated animals. Chronic desipramine 
treatment attenuated the RU24969-induced 5-HTPacc suppression at mid light and end 
dark compared to saline-treated animals. At the other time points chronic treatment 
with either antidepressant did not significantly affect RU24969-mediated decrease in 5- 
HTPacc compared to saline-treated rats, see figure 31 and table A6  of appendix 1. 
Hippocampus
Chronic paroxetine treatment significantly enhanced the decrease in 5-HTPacc 
by RU24969 administration at mid light compared to saline-treated animals. At the 
other two times chronic paroxetine treatment did not affect the ability of RU24969 to 
suppress 5-HTPacc. Desipramine did not have any significant affect on 5-HTPacc after 
RU249696 at any of the four times, compared to saline-treated animals, see figure 32 
and table A7 of appendix 1.
86
Frontal Cortex
The RU24969-mediated decrease in 5-HTPacc was attenuated in paroxetine- 
treated rats at mid light and mid dark compared to saline-treated rats. At end light, 
however, prolonged paroxetine treatment enhanced the effect of RU24969. Whilst the 
RU24969-induced decrease in 5-HTPacc in desipramine-treated animals was enhanced 
at mid light but attenuated at end light and mid dark compared to saline-treated rats. At 
the other time points, chronic antidepressant treatment did not significantly affect the 
RU24969-mediated decrease in 5-HTPacc compared with saline-treated rats, see figure 
33 and table A8  of appendix 1 .
Striatum
After chronic paroxetine treatment 5-HTPacc following RU24969 
administration was enhanced at mid light and attenuated at end light compared to 
saline-treated animals. Chronic desipramine treatment enhanced the RU24969-induced 
suppression of 5-HTPacc at end dark but attenuated it at end dark compared to saline- 
treated rats. Chronic antidepressant treatment had no effect on the RU24969-induced 
suppression of 5-HTPacc measured at the other time points, see figure 34 and table A9 
of appendix 1 .
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Figure 31. Effect of chronic antidepressant treatment on the pattern of RU24969-induced decrease in 
the accumulation of 5-HTP in the hypothalamus over 24 hours. Values are expressed in ng 5-HTP/pg 
protein/30 min, as mean±s.e.m., *P<0.05, **P<0.01 vs saline-treated control, n=4 for each time point 
and treatment, mid light (□), end light (0), mid dark (E2) and end dark (H). The effect of RU24969 on 
































Figure 32. Effect of chronic antidepressant treatment on the RU24969-induced decrease in the 
accumulation of 5-HTP in the hippocampus. Values are expressed in ng 5-HTP/pg protein/30 min, as 
meanls.e.m., *P<0.05 vs saline-treated control, n=4 for each time point and treatment, mid light (Cl), 
end light 03), mid dark (E3) and end dark (■). The effect of RU24969 on 5-HTP accumulation in 
untreated animals, data repeated from figure 25, is included for reference.
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Figure 33. Effect of chronic antidepressant treatment on the RU24969-induced decrease in the 
accumulation of 5-HTP in the frontal cortex. Values are expressed in ng 5-HTP/pg protein/30 min, as 
mean±s.e.m., *P<0.05, **P<0.01 vs saline-treated control, n=4 for each time point and treatment, mid 
light (Of), end light (^ ), mid dark (JES) and end dark (■). The effect of RU24969 on 5-HTP 
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Figure 34. Effect of chronic antidepressant treatment on the RU24969-induced decrease in the 
accumulation of 5-HTP in the striatum. Values are expressed in ng 5-HTP/pg protein/30 min, as 
mean±s.e.m., *P<0.05, **P<0.01 vs saline-treated control, n=4 for each time point and treatment, mid 
light (a ) , end light (®), mid dark (6a) and end dark (W). The effect of RU24969 on 5-HTP 
accumulation in untreated animals, data repeated from figure 29, is given for reference.
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Discussion
The activity of TrOH was gauged over 24 hours by measuring the accumulation 
of 5-HTP (5-HTPacc) in four brain regions that receive major 5-HT innervation. The 
regions, hypothalamus, hippocampus, frontal cortex and striatum, were chosen because 
of this innervation and because 5-HT synthesis has previously been shown to vary 
significantly over 24 hours in these brain regions (Hery et al. 1972; Kan et al. 1977; 
Poncet et al. 1993). The results of these experiments demonstrate a variation in both 
basal synthesis through the light-dark cycle and a 5-HT 1B-mediated influence on 5-HT 
synthesis. Chronic antidepressant treatment affected this 5-HTiB-mediated control of 
5-HT synthesis in a phase-dependent manner, as predicted by the hypothesis.
Basal 5-HTP levels
Each of the four brain regions studied here showed a significant variation in 
basal synthesis rate. There is only one other comparable study measuring 5-HT 
synthesis rate in vivo by the same technique. Poncet and colleagues (1993) 
demonstrated significant circadian variation in 5-HTPacc in tissue samples obtained by 
"micropunch" from many brain regions of male OFA rats of comparable weight to the 
animals used in my experiments. However the brain regions studied do not directly 
correspond. Poncet and co-workers (1993) found that cortical 5-HTPacc peaked, with 
a value of 140% of the daily mean, at mid dark having reached a low point, of about 
70% of the daily mean, about 3 hours after the end of the light phase. After the peak, 
5-HTPacc tailed off from this level to reach a steady level of 100% of the daily mean 
by the end of the dark phase; this level continuing throughout the light phase. 
However, the data presented here for the frontal cortex show a different pattern of 5- 
HTPacc; equally high levels were measured throughout the light phase (106-118% of 
the daily mean) with a trough at the end of the light phase, 61% of the daily mean. 
Poncet and colleagues measured 5-HTPacc in two hypothalamic nuclei; the 
suprachiasmatic (SCN) and the ventromedial (VMN). In both regions, 5-HTPacc 
peaked at mid dark, with a value of 140% of the daily mean, and reached a trough at
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mid light (70% and 80% of the daily mean for the SCN and VMN respectively). In the 
basal hypothalamus, however, a different pattern was observed; peak accumulation 
occurred at mid dark (117% of the daily mean) while the lowest 5-HTPacc was 
measured at end dark (76% of the daily mean). The differences may be accounted for 
by the differences in brain region, e.g. cortex vs frontal cortex, or by differences in 
sampling frequency (Poncet and colleagues sampled every 4 hours whilst I sampled 
every 6  hours) or by the method of obtaining samples, dissection vs micropunches.
The only other published studies of 5-HT synthesis used homogenates or 
sonicates derived from rats killed at the appropriate phase of their light-dark cycle. 
However the photoperiod, strain and methodologies used vary significantly.
Significantly higher 5-HT synthetic rates in the light phase have been reported 
in the hypothalamus and cortex in vivo and in slices in vitro (Hery et ah 1972). 
However it would appear that the observed rhythm was probably a result of their 
methodology which measured [3 H]5-HT and [3 H]5-HIAA levels after administration 
of [3 H]tryptophan, the uptake of which has itself been shown to vary over 24 hours 
(Hery et al. 1972; Liozou and Redfem 1986). The conversion index of 5-HT was the 
same during the light phase and dark phase (Hery et al. 1972).
Using striatal sonicates from OFA rats of comparable weight, Kan and co- 
workers (1977) demonstrated a significant circadian variation in TrOH activity in vitro. 
The pattern observed was dissimilar from the data presented in this thesis; peak activity 
was measured at mid light (150% of daily mean) and was lowest at mid dark (50% of 
the daily mean). McLennan and Lees (1978), however, were unable to detect a rhythm 
in TrOH activity in striatal homogenates from male Sprague-Dawley rats using a 
different method from Kan and colleagues (1977).
The regional differences in 5-HT synthesis rate through the light-dark cycle 
may reflect the role of 5-HT in those brain regions. However there is not very much 
research in this area of 5-HT.
The firing rate of 5-HT neurons in the RN has been considered to be correlated 
to the behavioural state of that animal (Trulson and Jacobs 1979). In rats (Imeri et al.
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1994) and cats (Trulson and Jacobs 1979; Wilkinson et al. 1991) neuronal firing rate 
. increases with increasing levels of consciousness. However the terminal release of 5- 
HT has been found to be both related to (Imeri et al. 1994) and independent of (Kalen 
et al. 1989) the activity state. There is some evidence that 5-HT synthesis might be 
related to neuronal activity. This theory stems from two observations; firstly electrical 
stimulation of the DR or MR increases TrOH activity in vivo (Petersen et al. 1989) and 
secondly administration of 5 -H T agon is t s ,  which decrease neuronal firing, also 
decrease 5-HT synthesis (Invemizzi et al. 1991). Interestingly the increase in 5-HT 
synthesis induced by 1-try administration, as outlined on page 1 2  of the introduction, 
was blocked by concurrent administration of 8 -OH-DPAT (Femstrom et al. 1990), also 
implying that neuronal activity is required for synthesis, and a mechanism involving 
cAMP cannot be ruled out, see later.
The results presented here are not in agreement with the theory that 5-HT 
synthesis parallels neuronal activity. Generally synthesis rates were found to be higher 
during the light phase a time when RN firing rates are low, but each region showed its 
own characteristic pattern of 5-HTPacc. The synthesis rate could be affected by three 
differing factors.
First, handling and injection of the rats and the stress invoked may affect 5-HT 
release/synthesis. Rats were handled every 2-3 days whilst they were phase-shifted in 
order to habituate them and to reduce stress on human contact However, rats handled 
during their light phase would be expected to be stimulated more than rats handled 
during their dark phase. The resultant stimulation might increase neuronal firing rate. 
However it has been shown in cats that restraint and introducing a dog into their 
vicinity has no effect on dorsal raphe neuronal firing (Jacobs and Azmitia 1992), even 
though there is a normal behavioural response. On the other hand handling rats has 
been shown both to increase 5-HT release in the hippocampus (Kalen et al. 1989) and 
to have no effect on extracellular 5-HT levels in the frontal cortex and DRN (Clement 
et al. 1993). Any stress-induced 5-HT release might in turn cause feedback to inhibit 5- 
HT synthesis; the effect of this feedback could vary in different brain regions.
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The brain regions studied here receive innervation from both RN, with the 
exception of the striatum which receives only a DRN input. It is well known that the 
fibres from the DR and MR are neuroanatomically distinct, see page 3 of the 
introduction. Additionally the RN possess a high degree of topographical organisation 
(Jacobs et al. 1978; van Bockstaele et al. 1993). For example the DR input to the 
amygdala and hippocampus stems from the caudal wings of the DRN (Imai et al. 
1986). The behavioural state/neuronal firing relationship, as outlined earlier, has been 
demonstrated in both MR and DR, however not all 5-HT neurons display this 
relationship. There are subsets of DR and MR neurons that are not clocklike i.e. do not 
show the relationship between state of arousal and firing rate, which are scattered 
throughout the nuclei (Shima et al. 1986). It is therefore conceivable that the regional 
pattern of 5-HTPacc reflects preferential innervation from one RN rather than another 
and therefore the type of 5-HT fibre and the number of non-clocklike neurons 
projecting to that area might contribute to the effect of topographical innervation.
The RN receive many afferents which can influence the neuronal firing rate, for 
example noradrenaline (NA) is thought to have a tonic excitatory effect on 5-HT 
neuronal firing rate mediated by a j-adrenoceptors. Interestingly, in the DR some of 
these afferents only exert an effect during certain behavioural states. The GABA input 
mediates suppression of neuronal activity only during slow wave sleep, the NA input is 
maximal during wakefulness whilst the EAA input only affects firing rate in response to 
auditory stimulus (Levine and Jacobs 1992). It is conceivable that these inputs might 
affect neuronal firing differently over the sleep-wake cycle and thus affect 5-HT 
synthesis. In addition some afferent-mediated control may be evoked during handling 
and injection.
It is unlikely that tryptophan availability accounts for changes in basal 5- 
HTPacc in the four brain regions studied. It has previously been shown that if food is 
restricted to a few hours during the light phase then the circadian rhythm in brain 5-HT 
content is not significantly different from animals allowed free access to food (Morgan 
and Yndo 1973). In addition, although plasma 1-try varies over 24 hours, the kinetics of
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the neuronal 1-try transporter also vary and in effect buffer the entry of 1-try into the 
neuron (Loizou and Redfem 1986).
Ayonist and Antagonist Studies 
Pharmacology
There is a paucity of selective 5-HT1B ligands; RU24969 was chosen since it 
was the agonist with least affinity for other receptors (see van Wijngaarten et a l 1990).
At a dose of 3mg/kg RU24969 significantly reduced 5-HTPacc in some brain 
regions at some time points, whilst RU24969 (9mg/kg i.p.) significantly reduced the 
rate of formation of 5-HTP in all brain regions at all time points. Although the latter 
dose is high (Euvrard and Boissier 1980) it was used because 3mg/kg i.p. RU24969 
had little effect in the hypothalamus. Animals that received the higher dose showed 
marked 5-HT syndrome with flat body posture, hyperlocomotion, Straub tail and 
sweating. RU24969 (l-10mg/kg) has previously been shown to cause a dose- 
dependent decrease in 5-HTPacc after decarboxylase inhibition (Euvrard and Boissier 
1980). At the maximal dose, accumulation was decreased by 34% and 35% in the 
brainstem and forebrain respectively. In the experiments performed in this thesis 
maximal inhibition of 5-HTPacc by RU24969 (9mg/kg) was 44% in the hypothalamus, 
51% in the hippocampus, 30% in the frontal cortex and 33% in the striatum.
RU24969 has only slightly greater affinity for the 5 -HTj3  receptor than the 5- 
HTia autoreceptor (pKj 5 -H T ^ 8.06nM and pKj 5-HTjb 8.23nM van Winjgaarten et 
al. 1990). Pre-administration of (±)cyanopindolol, a 5-HTj^jg antagonist (Schlicker 
et al. 1985 pA2  8.3 at the terminal autoreceptor; Neill and Cooper 1989), blocked the 
effects of RU24969, but the RU24969-induced suppression of 5-HTPacc may still have 
been due to effects on both the 5-HT1A and 5-HTjb receptors. Therefore further 
receptor characterisation was performed using (+)WAY100135, a novel silent 5-HTja 
antagonist (Fletcher et al. 1993; Routledge et al. 1993; Lanfumey et al. 1993). 
(+)WAY100135 was given either alone or in conjunction with RU24969 to gauge what 
proportion of the decrease in 5-HTPacc after administration of RU249696 might be
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attributable to stimulation of 5-HT1A receptors. (+)WAY100135 did not block the 5- 
HTPacc-suppressing effects of RU24949 (9mg/kg i.p.) and (+)WAY100135 alone had 
no effect on 5-HTPacc, as previously reported (Fletcher et aL 1991). This indicates 
that stimulation of a 5-HT1A receptor had very little contribution to the effect of 
RU24959 and that its function did not apparently vary with time of day. Therefore it 
can be concluded that the RU24969-induced decrease in 5-HTPacc is mediated by a 5- 
HTjb receptor.
To summarise, the 5-HT receptor affecting 5-HTPacc was pharmacologically 
characterised as being a 5-HT1B receptor since the effects of RU24969, a 5 -H T ^ 1B 
agonist, were blocked by the 5- H T ^ jb antagonist (±)cyanopindolol but not the 
selective 5-HT1A anatgonist WAY100135.
One factor that must not be overlooked is the effect of 5-HTjb ligands on 
dopamine or noradrenaline synthesis and release, since the decarboxylase inhibitor used 
blocks the conversion of DOPA to dopamine. Accumulated DOPA might leave 
dopaminergic and noradrenergic neurons and interfere with TrOH activity, although 
this effect is known to be minimal (Nissbrandt et al. 1988). Experimental evidence 
indicates that 5-HTjg ligands have no significant effect on the firing rate of 
nigrostriatal dopaminergic neurons (Kelland et al. 1990) and 5-HTj^ ligands do not 
affect the firing rate of substantia nigra neurons (Nissbrandt et al. 1988). However 
RU24969 decreases noradrenergic neuronal firing (Clement et al. 1992a) which might 
affect the tonic excitation of aj-heteroreceptors. There is one report of a 5-HT1B 
agonist increasing DOPA accumulation after AAAD inhibition (Hjorth 1993). However 
the 5-HTjb agonist used shows less discrimination between 5-HTj^ and 5-HTjg 
receptors than does RU24969 (van Winjgaarten et al. 1990).
5-HT heteroreceptors have been demonstrated to affect ACh (Maura and 
Raiteri 1986), DA (Ennis et al. 1981) and NA terminals (Feuerstein and Hertting 
1986). 5-HTjg receptors decrease ACh release whilst a 5 -HT3  receptor mediates the 
effects of 5-HT on DA and NA release in vitro (Blandina et al. 1989). One in vivo 
microdialysis study has reported that RU24969, infused via the probe, increases
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dialysate DA levels (Benloucif and Galloway 1991). However at the concentration of 
RU24969 used (50pM), RU24969 would affect all subtypes of the 5-HTj receptor, 5- 
HT2  and 5 -HT3  receptors, as well as a- and p-adrenoceptors, and D2  receptors.
The location of the 5-HT 1 3  receptor responsible for the suppression of 5-HT 
synthesis was not direcdy determined. There are two possible locations, either 
presynaptically or post-synaptically on a neuron which in turn impinges on and 
influences the 5-HT neuron. The two possibilities are shown in figure 35; the putative 
mechanism for presynaptic inhibition of inhibition of TrOH is described later. In the 
indirect mechanism 5-HT^g stimulation inhibits the release of a neurotransmitter that 
tonically activates serotoninergic neurons. The inhibition of this tonic excitatory effect 
could in turn causes a decrease in the activity of TrOH. One candidate could be an ion 
channel. Nicotinic acetylcholine receptors are found presynaptically on 5-HT terminals; 
however nicotinic antagonists have no effect on [^H]5-HT release (Heiy et al. 1977a). 
A GAB A a  receptor is also ruled out since GABA^ agonists and antagonists do not 
affect pH]5-HT release (Schlicker et al. 1984). Other possible candidates are receptors 
linked to the stimulation of cAMP, e.g. p-adrenoceptors or Dj dopamine receptors. 
There is no evidence of presynaptic p-adrenergic or dopaminergic heteroreceptors on 
affecting 5-HT terminal release (Frankhuyzen and Mulder 1980; Gross et al. 1987). A 
further alternative would involve a post-synaptic 5-HTig receptor located on the cell 
body of a neuron which synapses on a second neuron that itself impinged onto the 5- 
HT neuron. The neurotransmitter of this second neuron could be either excitatory or 
inhibitory depending on the nature of the intemeuron. On balance the presynaptic 
autoreceptor model is more likely since autoreceptors modulating release have been 
demonstrated on synaptosomes from the hypothalamus (Martin and Sanders-Bush 
1982). To define the location of the receptors, 5-HTPacc in synaptosomes could be 
measured to indicate whether the receptor responsible was located presynaptically. 
Alternatively antisense deoxyoligonucleotides for the 5-HT1B receptor could be 




Figure 35. Two models to explain how the RU24969-mediated decrease in 5-HTP accumulation might 
be achieved. A. The effect of RU24969 is mediated by a presynaptic 5-HT1B autoreceptor, negatively 
linked to cAMP B. The 5-HT1B receptor is located post-synaptically on a another nerve terminal that 
impinges on the 5-HT terminal. The neurotransmitter released from this post synaptic neuron would 
normally exert a tonic excitatory effect on 5-HT neurons. Stimulation of the inhibitory 5-HT1B 
heteroreceptor decreases the release of the excitatory neurotransmitter thus removing the tonic 
stimulation. Alternatively the 5-HT]B heteroreceptor might be located on the cell body of an 
intemeuron which in turn affects the release of second interneuron which then affects the 5-HT 
neuron.
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Proposed mechanism of the 5-HTig-induced decrease in TrOH
Hamon and colleagues (1973) produced the first evidence that 5-HT might be 
controlling its own synthesis. Measuring the rate of pH]5 -HT synthesis from pH]l-try 
in striatal slices, they found that exogenously applied 5-HT could reduce the 
production of pH]5-HT. The effect was not inhibited if a selective 5-HT uptake 
inhibitor was included in the buffer, indicating that the effect was mediated 
extracellularly. It has recently been demonstrated that this effect is mediated by a 5- 
HT1B (auto)receptor (Hjorth 1993) and was resistant to hemitransection and reserpine 
pre-treatment. These results demonstrate that the effect was not dependent on nerve 
impulses and was directly mediated by a receptor.
The mechanisms controlling TrOH activity have not been investigated in any 
detail and are poorly understood. TrOH is phosphorylated by cAMP-dependent protein 
kinase (PKA) and calcium/calmodulin-dependent protein kinase (Ca+'VCaM PKII) in 
the presence of an activator protein, protein 14-3-3 (Yamauchi et al. 1981; Makita et 
a1. 1990). Protein 14-3-3 alone has no effect on PKA or Ca^/CaM PKII-dependent 
phosphorylation of TrOH; but protein 14-3-3 binding appears to be responsible for 
protein kinase-dependent activation (Furukawa et al. 1993). If it is accepted that the 
effect of RU24969 is mediated by a 5-HT1B autoreceptor, the results suggest that the 
control is exerted at the level of TrOH since the decarboxylation step was inhibited. A 
possible mechanism is shown in figure 36. The activity of at least one type of adenylate 
cyclase (AC; see later) is known to be tonically stimulated by calcium/calmodulin. The 
activity of this enzyme would be inhibited by the released oq, and perhaps fty subunits 
of the Gj-protein which dissociate when the 5-HTjg receptor is stimulated, as 
described on page 10 of the introduction. A decrease in the activity of adenylate 
cyclase would decrease the intracellular concentration of cAMP and therefore PKA 
activity. It has also been proposed that the 5-HTjg autoreceptor decreases the 
intracellular influx of Ca++ through voltage-dependent calcium channels
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Figure 36 Putative mechanismoFthe inhibition of tryptophan hydroxylase after 5-HT1B autoreceptor
stimulation. When 5-HT binds to its G protein-linked autoreceptor (yellow trilobed structure), it 
causes the dissociation of the Gj into its a, p and y subunits which inhibit adenylate cyclase (AC, 
orange oval) activity . The inhibition of this basally active enzyme decreases the intracellular level of 
cAMP and therefore PKA stimulation. Under normal conditions, therefore, there is a basal stimulation 
of tryptophan hydroxylase (TrOH, turquoise shape) by PKA which is prevented after 5-HT1B 
autoreceptor stimulation. Additionally 5-HT1B mediated closure of calcium channels (red oblong) 
might prevent the basal activation of TrOH by calcium/calmodulin-dependent protein kinase II 
(Ca++/CaM PKII). Activation of TrOH requires the presence of an activator protein (pink sphere). 
PKA is also thought to regulate the rate of transcription of certain genes, perhaps including the 5- 
HT1B receptor, via a cAMP response element-binding protein (CREB) at the cAMP response element 




There are several possible explanations for the regional differences in the effect 
of RU24969.
The simplest explanation is that the concentration of RU24969 in some brain 
regions was higher than in others because of differential blood supply and cell density. 
This could be ascertained by measuring RU24969 levels in the specific brain areas after 
peripheral administration using either microdialysis or homogenates and HPLC.
The differences may be attributable to a regional variation in the distribution 
and density of terminal 5-HTjg autoreceptors. There are no reports on the regional 
distribution of presynaptic 5-HT 1B receptors, which makes interpretation of the results 
more speculative. However the total number of 5-HTjg binding sites has been 
measured and, in decreasing Bmax, the rank order of distribution is 
hypothalamus>caudate-putamen>frontal cortex>hippocampus (Bruinvels et al. 1993). 
These findings do not correlate well with the regional effects of RU24969 in my 
experiments. For example the hypothalamus an area rich in 5-HTig receptors showed 
less sensitivity to RU24969 than the frontal cortex, whereas the hippocampus, with the 
lowest total 5 -HT1B binding, proved to be the area most affected by RU24969. 
Alternatively the of 5-HT autoreceptors might vary between regions, opening up 
the possibility that 5-HT synthesis is more tightly controlled in some regions than 
others. The results indicate that over the light-dark cycle the hippocampus shows the 
greatest degree of control, closely followed by the frontal cortex, whilst the 
hypothalamus shows the least. Superfusion studies employed by Middlemiss (1984) in 
frontal cortex, striatum and hippocampus showed that the degree of inhibition of 
pH]5-HT release after addition of lpM 5-HT varied between region. Exogenous 5-HT 
added to frontal cortical slices inhibited release by 63%, in the hippocampus by 58% 
and in the striatum by 46%. If my results at mid light are compared to those of 
Middlemiss (1984) then the striatum shows least inhibition and the hippocampus most, 
although the frontal cortex value was close (hippocampus 28%, hypothalamus 27%, 
frontal cortex 21% and striatum 17%). The number and affinity of binding sites
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throughout the brain could be measured by binding studies using 5-HT, RU24969 or 
cyanopindolol as ligands, or quantitative in situ hybridisation.
Secondly the differential regional response to RU24969 may be due to effects 
on the somatodendritic 5-HTja and 5-HT1B receptors in the DRN and MRN. 5-HT1B 
receptors are found in the raphe nuclei (Neumaier et al. 1993) so peripherally 
administered RU24969 is free to act at these sites. As explained earlier RU24969 is not 
selective for 5-HT1B receptors. Since RU24969 was administered peripherally the 
effects of RU24969 may in part be due to stimulation of the raphe somatodendritic 5- 
HT1A and 5-HT1B autoreceptors. However the results from the study using 
(+)WAY100135 indicate that most of the RU24969-induced decrease in 5-HTPacc is 
due to stimulation of 5-HT1B receptors.
Somatodendritic 5-H T^ autoreceptors can affect synthesis and terminal 
release of 5-HT (Invemizzi et al. 1991). Some experiments have suggested that the 
sensitivity of the somatodendritic 5-HTj^ receptor differs in the DRN and MRN 
(Sinton and Fallon 1988; Invemizzi et al. 1991). In areas that receive innervation from 
both the DRN and MRN, such as the hippocampus and hypothalamus, stimulation of 
the 5-HTja receptors in the DRN had no effect on 5-HTPacc, whereas stimulation of 
the MRN decreased 5-HTPacc (Invemizzi et aL 1991). There are some early 
indications that the 5-HT1A receptor subdivision might comprise two receptors (Radja 
et al. 1992; Blier et al. 1993a, b). Radja and colleagues propose that the two types of 
5-HT1A receptor occur both presynaptically and post-synaptically. Perhaps one type of 
5-HT1A receptor is more prevalent in one area of the RN than the other, and, given the 
topographical organisation of the RN, provides more autoreceptor control for one 
brain area than the other type of 5-HT1A receptor. Interestingly, peripheral 
administration of 5-HT1B agonists can also influence the firing rate of DRN and MRN 
neurons differentially (Sinton and Fallon 1988). In the DRN the agonists decreased the 
firing rate, but in the MRN the agonists had biphasic effects, low concentrations caused 
excitation, whilst higher concentrations had either inhibitory effects or returned firing 
rates back to baseline. Measurement of the effect of microinjection of RU24969 in the
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DR or MR on 5-HTPacc in various brain region could be used to determine the 
contribution of somatodendritically located 5-HTjg receptors in the RU24969-induced 
decrease in 5-HTPacc.
Since RU24969 was administered peripherally, it would have to compete with 
endogenous 5-HT for binding to 5-HT1B receptors. Therefore the contribution of 
endogenous 5-HT to the observed effect would depend on its biophase concentration. 
More 5-HT might be released in some brain regions than others, although it might be 
expected that autoreceptor number or sensitivity might also vaiy, in effect cancelling 
out this effect The level of 5-HT in each brain region and the sensitivity of the 
autoreceptor in that region could be determined by in vivo microdialysis.
Regional differences could be due to differences in the adenylate cyclase type 
coupled to the 5-HT1B receptor. To date, there are at least 6  distinct types of adenylate 
cyclase (AC) which show distinct regional localisations and sensitivities to Ca++, CaM 
and G-protein coupled receptors (Choi et al. 1993; Pieroni et al. 1993).
Type I AC (AC I) is located in the hippocampus CA2 region and to a lesser 
extent in the neocortex. AC I is the best studied and characterised AC isozyme. It is 
basally stimulated by Ca++/CaM and inhibited by free p7  G protein subunits. Type II 
AC (AC II) is found in the hippocampus regions CA1-4 and the hypothalamus and is 
the most unusual type. It is inhibited by G^a and this inhibition can be overcome by 
protein kinase C-induced stimulation; additionally free p7  subunits released after Gj 
dissociation stimulate AC II. Type III AC is found in low levels throughout the 
hippocampus; it is basally stimulated by CaM and is insensitive to bg subunits. Type V 
AC (AC V) is only found in the striatum and is inhibited by low intracellular Ca++ 
levels and Gja, it is insensitive to free p7  subunits. It has been postulated that AC V is 
inhibited by PKA (Choi et al. 1993; Pieroni et al. 1993). The presence and relative 
amounts of the different types of AC would therefore determine what effect 5-HT1B 
receptor stimulation would have on cAMP levels intracellularly. If the amount of each 
type of AC could be measured after selective destruction of the 5-HT system by 5,7- 




The effect of RU24969 showed a significant circadian variation in the 
hippocampus, frontal cortex and striatum but not in the hypothalamus. It appears 
strange that the hypothalamus, the seat of the SCN, displayed no circadian rhythm in 
sensitivity to autoreceptor stimulation. This might be because whole hypothalamus was 
used and the different nuclei in the preparation displayed differing rhythms that 
effectively cancelled each other out
The variation in the response to RU24969 found in the 3 other brain regions 
could be due to four factors.
There may be a circadian rhythm in the sensitivity or number of 5-HT1B 
autoreceptors in the hippocampus, frontal cortex and striatum. A significant increase in 
total 5 -HTbinding during the dark phase has been reported in the SCN (Prosser et 
al. 1993) although these authors only compared total 5-HTjb binding at one time point 
in the light phase and one time point in the dark phase. In my study the hypothalamic 
response was the same over the light-dark cycle although there was a trend towards 
more inhibition of 5-HTPacc at the end of the dark phase. In a more comprehensive 
study, 5-HTjb binding was measured over 24 hours in the cerebral cortex of male 
Wistar rats (Akiyoshi et al. 1989). The number of 5-HT1B binding sites was low 
throughout the dark period and rose after the lights were switched on to peak 3 hours 
after lights on, falling steadily through the light phase and reaching a minimum 6  hours 
into the dark phase. The results presented here show that the receptor appears more 
responsive during the light phase in the frontal cortex which would agree with the 
findings of Akiyoshi and colleagues i.e. maximal inhibition when the receptor number is 
maximal. There is also behavioural evidence to suggest a rhythm in 5-HTjB function 
(Martin et al. 1987) although the behavioural model used is a measure of post-synaptic 
5-HT1B receptors. The authors found that 5-HTjB function was greater during the 
light phase than the dark phase in mice. However Singh and Redfem (1994a) found no
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difference in cortical autoreceptor function over 24 hours when measured in vitro. 
Binding studies performed over 24 hours could help to elucidate this point
A circadian rhythm in the receptor-effector coupling mechanism could underlie 
the differences. A circadian rhythm in the basal concentration of cAMP has been 
demonstrated (Prosser and Gillette 1991). The variation is due to a circadian rhythm in 
the activity of the phosphodiesterase (PDE) not adenylate cyclase. Thus the inhibitory 
effect of stimulating the 5-HT autoreceptor could lead to a greater decrease in cAMP 
levels at some time points than others. However the results of experiments conducted 
by Lemmer and colleagues (1991) suggest that there is no rhythm in the induction of 
cAMP by (3-adrenoceptor agonists. However, as the authors discuss, it is possible that 
there is a seasonal rhythms in adenylate cyclase activity with a circadian rhythm in 
activity only at distinct times of the year. This has been shown for p-adrenoceptors in 
rat heart ventricles which display a circadian rhythm in binding only during the autumn 
and winter. Equally PKA or Ca++/CaM PKII activity or levels, or protein 14-3-3 might 
vary over 24 hours, although to date there are no studies measuring these parameters. 
Measurement of the inhibition of forskolin-stimulated AC by 5 -HTjb ligands, PKA or 
Ca+'tyCaM PKII levels and activity over 24 hours would decide which one, or 
combination, of these factors could be responsible for the variation.
It is well established that 5-HT release is higher in the dark phase in the 
hippocampus (Kalen et al. 1989) and the hypothalamus (Martin and Marsden 1985; 
Imeri et al. 1994). However the levels do vary considerably within each phase of the 
light-dark cycle (Kalen et al. 1989). The same volume of RU24969 was administered at 
all four time points but if the biophase concentration of 5-HT was greater at some time 
points, then the effect of RU24969 might be additive. For example if more 5-HT was 
released at mid dark than mid light, then after RU24969 administration more 5-HT1B 
agonist would be present in the synaptic cleft at mid dark to induce a response. Indeed 
the results support this theory to a certain extent; in the striatum and hippocampus 5 - 
HT receptor function appeared greater during the light phase. Measurement of the 5- 
HT levels in each brain region over 24 hours by microdialysis would define this point
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Chronic Antidepressant Treatment 
Basal TrOH activity in treated animals
Rats were treated chronically with two antidepressant drugs with differing 
effects. Desipramine is a selective noradrenaline uptake inhibitor (Kj NA 0.61nM, 5- 
HT 180nM and DA llOOOnM; Bolden-Watson and Richelson 1993) and paroxetine a 
selective 5-HT uptake inhibitor (Kj NA 33nM, 5-HT 0.73nM and DA 1700nM; 
Bolden-Watson and Richelson 1993). Rats were treated with the antidepressant whilst 
they were being phase-shifted. This was necessary to ensure the rats were the same 
final weight as rats used for the initial RU24969 experiments for comparability. 
Another factor to be taken into consideration is age, since monoamine levels and 5-HT 
receptor numbers are known to decrease with age. Treatment with 5-HT and NA re­
uptake inhibitors has been shown either to have no effect (Brown and Seggie 1988; 
Refinetti and Menaker 1993) or to increase (Baltzer and Weiskrantz 1975; Brown and 
Seggie 1988) the rate of re-entrainment to a shift in the light-daik cycle. There was one 
obvious drawback to the experimental protocol used. The time when drugs were 
administered could not be standardised because the rats might take the injection as a 
cue and entrain to it. Neither could the antidepressants be administered by drinking 
water or by osmotic minipumps since paroxetine will only dissolve (and stay dissolved) 
in warm water. Additionally osmotic minipumps could not be used since they would 
have to be replaced during the study and subjecting rats to anaesthesia could have 
interfered with the results. Consequently, rats were injected in a random fashion and 
some rats received injections solely during their active phase, others during their 
inactive phase and a third group during both phases. Thus some of the results might be 
related to specific timing of antidepressant administration, although to date there is 
very little in the literature about this aspect of pharmacology. A great advance could be 
made if programmable time release drug formulations could be made and a relationship 
between time of administration and clinical efficacy measured.
Chronic treatment with either antidepressant had no effect on basal TrOH 
activity when measured at end light End light was chosen as a representative time
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point because the RU24969-induced decreased in 5-HTPacc was greatest throughout 
the brain at this time. It might be argued that the attenuation of RU24969's effects on 
5-HTPacc after chronic antidepressant treatment might not represent a "down- 
regulation" of the 5-HT1B receptor, rather that chronic antidepressant treatment had 
increased TrOH activity as demonstrated by Moret and Briley (1992) or Redfem and 
Sinei (1986). Thus RU24969 would decrease 5-HTPacc less in antidepressant-treated 
rats than saline-treated control animals because there was more TrOH present. Both 
antidepressants, administered chronically, attenuated the effects of RU24969 in the 
hypothalamus and striatum at end light However in the hippocampus only chronic 
desipramine caused "down-regulation", and in the frontal cortex neither antidepressant 
affected the decrease in 5-HTPacc mediated by RU24969. These facts, taken together 
with the finding that at end light there was no significant change in basal 5-HTPacc 
after chronic antidepressant treatment and "up-regulation" at some time points, argue 
against an induction of TrOH. In addition there are experimental differences between 
this study and those of Moret and Briley (1992) and Redfem and Sinei (1986). Moret 
and Briley treated Sprague-Dawley rats orally, twice daily with either 20mg/kg/day 
citalopram (a selective 5-HT uptake inhibitor) or milnacipram (a MAOI) and measured 
5-HTPacc after AAAD inhibition by NSD1015 (lOOmg/kg i.p. 30 minutes before 
death). However their study was not a circadian one. Redfem and Sinei (1986) treated 
Wistar rats twice daily with either 20mg/kg i.p. mianserin (an atypical antidepressant 
which is thought to be an antagonist at 5 -HT2  receptors) or 7.5mg/kg clomipramine (a 
selective 5-HT uptake inhibitor) and measured 5-HT synthesis by the CO2  trapping 
method at mid light and mid dark. Svensson (1978) found no change in basal 5-HT 
synthesis rate after chronic imipramine (a 5-HT/NA uptake inhibitor). Measurement of 
TrOH activity in vivo and the level of mRNA for TrOH after chronic antidepressant 
treatment over 24 hours would decide whether TrOH activity was increased or TrOH 
was induced or not after antidepressant treatment.
Chronic antidepressant treatment is complicated by our ignorance of its effects 
on all receptor populations. As outlined on page 24 of the introduction, the biophase
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concentration of 5-HT is determined by whether somatodendritic and terminal 
autoreceptors down-regulate or not and the experimental evidence is contradictory. In 
addition the DR and locus coeruleus (LC) receive mutual innervation, and the two 
systems can affect the firing rate and release of the other (Clement et al. 1992b). The 
role of ct2 -autoreceptors on NA terminals in the DR after chronic desipramine 
treatment, is therefore crucial since they control the biophase concentration of 
noradrenaline in the DR and thereby the tonic stimulatory effect of the <Xp 
adrenoheteroreceptor on the firing rate of DR neurons. After chronic desipramine 
treatment o^-adrenoceptors normally down-regulate in a classical manner. Therefore 
the response of aj-adrenoheteroreceptors to the increased biophase level of NA will 
also determine the rate of 5-HT neuronal firing. There is no experimental evidence of 
the effect of chronic antidepressant treatment on these ai-adrenoheteroreceptors. 
However if these a  i-adrenoheteroreceptors do down-regulate it might not necessarily 
affect the firing rate of DR neurons because if they did down-regulate in response to 
increased NA levels, the decrease in 5-HT neuronal firing rate would decrease 5-HT 
release from dendrites and lessen 5-H T ^ autoreceptor stimulation. Thus the effect of 
down-regulation of cxi-adrenoheteroreceptors would be negated by decreased 
stimulation of inhibitory 5-HT1A autoreceptors.
Regional Differences
Significant regional differences in the 5-HTPacc after RU24969 were detected 
after chronic treatment with both paroxetine and desipramine. Regional differences in 
receptor down-regulation after chronic antidepressant treatment have been noted 
before (Martin et al. 1992b).
These regional differences might represent differing regional "susceptibilities", 
i.e. 5-HT1B receptors in some brain regions might be less sensitive to increases in the 
biophase concentration of 5-HT than other areas. Regional differences in 5-HT 
receptor populations after chronic antidepressant treatment are well documented (for 
example Martin et al. 1992b). This theory could be tested by implanting in vivo
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microdialysis probes in the various brain region.
Alternatively the differences could be due to a mixture of preferential 
innervation from different RN nuclei and the heteroreceptors located 
somatodendritically. Earlier the proposal that there are two types of 5-H T^ receptor 
was put forward. There is evidence that two different types of 5-HT1A receptor are 
affected differently by repeated treatment with 8-OH-DPAT (Larsson et al. 1990), one 
type of receptor down-regulating after repeated treatment, the other remaining the 
same. The same might be true after chronic antidepressant treatment. The relative 
proportions of the two types of 5-H T^ receptor on the cell body could affect the 
terminal release of 5-HT and thus the degree of feedback inhibition.
There are no experimental data on the effect that chronic antidepressant 
treatment has on cell body heteroreceptors. Each of the array of heteroreceptors might 
be phase-dependently down- or up-regulated thus affecting terminal 5-HT release.
An added dimension to the effect of chronic antidepressant treatment on 
autoreceptors and heteroreceptors is their topographical organisation. The proportion 
of these receptors on cell bodies and whether they down-regulate in subregions of the 
DR or MR may affect terminal 5-HT biophase differently depending on the brain 
region.
At the nerve terminal the only heteroreceptor to have been investigated after 
chronic antidepressant treatment is the a 2 -heteroreceptor. It has been shown to be 
down-regulated (Gonzalez et al. 1992) or unchanged in the cortex and hippocampus 
(Schoeffelmeer et al. 1982), after chronic treatment with the same antidepressant, but 
for differing treatment times; Gonzalez and colleagues treated for 14 days whilst 
Schoefflmeer and co-workers treated for 28 days.
All of these parameters could be tested using in vivo microdialysis to assess 
somatodendritic and terminal autoreceptor and heteroreceptor function after chronic 
antidepressant treatment. The effect of microinfusion of ligands within subregions of 
the RN on terminal release might be used to assess topographical influence.
This is the first demonstration of down-regulation of 5-HT1B autoreceptor
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control of 5-HT synthesis in vivo following prolonged antidepressant treatment. The 
results indicate that control of synthesis is compromised following antidepressant 
treatment and that the compromise is regional.
Circadian Aspects
As shown in figure 31 to 34, the "rhythm" in RU24969-induced inhibition of 5- 
HTPacc was significantly altered in some brain regions by chronic antidepressant 
treatment. There are several possible explanations for how chronic antidepressant 
treatment changed the parameters of RU24969-mediated inhibition of 5-HTPacc with 
time. There are no published comparable studies to my knowledge.
Antidepressant treatment could be altering circadian parameters of serotonin 
function. Desipramine and paroxetine, like all other antidepressants, inhibit liver 
tryptophan pyrrolase (Badawy and Evans 1982; Badawy and Morgan 1991) and 
therefore increase circulating levels of 1-try. This could interfere with the circadian 
rhythm in plasma 1-try and thus 1-try entry into the brain ultimately affecting 5-HT 
synthesis. Indeed Redfem and Martin (1985) have shown that chronic antidepressant 
treatment alters the acrophase of plasma 1-try. In general antidepressant treatment 
phase delayed the peak in plasma 1-try levels. Antidepressant treatment also modifies 
circadian parameters of 5-HT synthesis in the hypothalamus (Greco et aL 1988). 
Before chronic antidepressant treatment the levels of 1-try, 5-HTP and 5-HT in 
hypothalamic homogenates were well correlated, all being higher at the transition from 
light to dark. Antidepressant treatment phase-delayed the position of the 1-try, 5-HTP 
and 5-HLAA peaks, but phase-advanced the 5-HT peak. The mechanism by which 
antidepressant drugs achieve these effects is unclear. However it is unlikely that shifting 
the peak plasma 1-try concentration could affect the circadian rhythm in brain 5-HT 
(see Morgan and Yndo 1973 and Liozou and Redfem 1986, as cited earlier in this 
discussion).
Prolonged antidepressant treatment could alter a circadian rhythm in 
presynaptic 5-HT1B receptor number or affinity. Although, to date, the binding of
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presynaptic 5-HT1B has not been investigated, total 5-HT1B binding in the cortex is 
increased during the light phase and lower throughout the dark phase (Akiyoshi et al.
1989). As outlined on page 28 of the introduction, a phase delay in the peak binding of 
a- and p-adrenoceptors, GABA-benzodiazepine and opiate receptors has been 
reported after chronic antidepressant treatment (Wirz-Justice et al. 1982). The rhythm 
of muscarinic acetylcholine receptors is also altered after antidepressant treatment 
(Kafka et al. 1981b; Wirz-Justice et al. 1982). Thus chronic antidepressant treatment 
can alter receptor numbers in a phase-dependent manner. How chronic antidepressant 
treatment might affect the expression of neurotransmitter receptors has not been 
investigated. It is possible that 5-HT1B receptors might be able to control their own 
expression by regulating their transcription as has been proposed for p2 -adrenoceptors, 
which are also G protein linked receptors. A proposed mechanism is detailed on the left 
hand side of figure 36. Cyclic AMP response element-binding protein (CREB) is 
known to mediate the effects of cAMP on gene expression (Nestler and Greengard 
1994), it binds to a specific sequence of DNA termed a cAMP response element (CRE) 
in the regulatory region of the gene and can influence the rate of transcription. It is 
thought that an increase in intracellular cAMP causes PKA to phosphorylate CREB, 
thus activating it and enhancing transcription. The CREB is also phosphoiylated by 
Ca++/CaM PKII. In the scenario outlined in an earlier section, stimulation of the 5- 
HT1b receptor decreases the intracellular level of cAMP and Ca++ and thus PKA and 
Ca++/CaM PKII activity thus decreasing the rate of transcription of e.g. 5-HT1B 
receptors, given that there is a basal activity of adenylate cyclase. Regulation of 
transcription is a slower mechanism than receptor desensitisation and this could explain 
the delay in clinical efficacy witnessed.
Therefore repetitive stimulation of the autoreceptor might affect the normal 5- 
HT1B control of the expression of 5-HT1B receptors; this might explain why "up- 
regulation" was seen in this study as well as "down-regulation". The level of mRNA 
encoding 5-HT1A, 5-HT1B and 5-HT2 receptors in whole brain (Spurlock et al. 1994), 
and 5 -HT2  receptors in the forebrain (Roth and Ciaranello 1991) has been found to be
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the same after chronic treatment with either mianserin, imipramine, fluvoxamine or 
citalopram. However since these workers did not separate brain structures the overall 
changes in mRNA could have been cancelled out. Interestingly, incubating cultured 
raphe cells with cAMP for 48 hours decreases the mRNA for 5-HTj^ receptors but did 
not affect mRNA for 5-HT2 receptors (Foguet et al. 1993), indicating a cAMP- 
dependent mechanism for modulating a receptor negatively coupled to adenylate 
cyclase. The mRNA for 5-HT1B receptors and its regulation by PKA could be 
measured after chronic antidepressant treatment over 24 hours to assess this factor.
The phase-dependent up- and down-regulation of 5-HT 1B autoreceptor 
function seen after chronic desipramine and paroxetine may also be due to effects on 
other intracellular mechanisms or possibly the 5-HTjg receptor-effector mechanism 
becomes uncoupled. Interestingly, the time course of intracellular modification again 
more closely parallels the delay seen in clinical efficacy of antidepressant drugs. 
Prolonged treatment with desipramine has been shown to modify the cAMP-dependent 
phosphorylation of microtubule-associated protein, which is involved in microtubule 
function e.g. transport of receptors and/or synthesising proteins to the nerve terminal 
(Perez et al. 1989). This may mean that chronic antidepressant treatment interferes 
with the transport of 5-HT 1B receptors to the nerve terminal, affecting the number of 
receptors in the terminal region.
It is feasible that 5-HT1B receptor coupling to adenylate cyclase via its Gj 
protein is disrupted after chronic antidepressant treatment. Treatment with desipramine 
has been shown to decrease the accumulation of cAMP-induced by noradrenaline in 
vitro (Okada et al. 1988; Sapena et al. 1992); the effect has been linked to a decrease in 
coupling between the P-adrenoceptor and its Gs protein (Okada et al. 1988). Long­
term treatment with imipramine, desipramine and clorgyline decreases the 
immunoreactivity and mRNA for Gj (Lesch et al. 1991b), although the effect was 
antidepressarit and region specific. The activity of PKA is also altered after chronic 
antidepressant treatment (Nestler et al. 1989). The enzyme activity in the particulate 
fraction was decreased after antidepressant treatment, whilst activity was increased in
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the crude nuclear fraction. The authors postulate that antidepressant treatment induces 
translocation of the catalytic subunits of PKA from the cytosol to the nucleus. As 
hypothesised earlier, the expression of 5-HTjg receptors may be controlled by a 
mechanism involving PKA. Antidepressant-induced changes in PKA activity could 
therefore alter the rate of transcription of the 5-HT1B receptor gene by an action at the 
CRE in the regulatory domain. Changes in various G proteins have been detected 
following chronic antidepressant treatment (Lesch et al. 1992). However, these results 
are very complicated. Both increases and decreases in Gs, Gj and G0 were found and 
the change was both antidepressant and regionally specific. For example, desipramine 
treatment decreased the a  subunit of Gs in the striatum and LC and Gj in tjhe frontal 
cortex, whilst it increased the a  subunit of G0 in the frontal cortex and LC. Therefore 
the only conclusion that can be drawn is that there are changes, but what actually 
happens to G proteins in different neurotransmitter systems is unclear.
Like the fo-adrenoceptor, there are two PKA target sites on the 5-HTjb 
receptor (Voigt et al. 1991), as outlined on page 10 of the introduction. If 5-HTjb 
regulation of intracellular cAMP levels is lost PKA levels/activity might rise and 
phosphorylate these sites. Phosphorylation of the two PKA binding sites on the P2 " 
adrenoceptor is thought to be responsible for the decreased sensitivity of the receptor 
after chronic exposure to agonists (Hausdorff et al. 1989). Both PKA binding sites 
adjoin the region where the p2‘a^renocePtor interacts with its Gs protein. If the same 
were true of the 5-HT1B receptor then chronic antidepressant treatment could affect 5- 
HTjB function through PKA. This effect could be phase-dependent perhaps because of 
the circadian rhythm in intracellular cAMP levels.
Thus the intracellular mechanisms by which antidepressant treatment affects 
receptors could be linked to cAMP and PKA regulation of receptor expression or 
receptor transport or alternatively, changes in G proteins and coulping of the receptor 
to its G protein, by whayever mechanism.
The results of this section clearly demonstrate that chronic antidepressant 
treatment can affect 5-HTjb receptor control of 5-HT synthesis in a time of day
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dependent manner. Therefore the normal pattern of control of synthesis over 24 hours 
will be altered, perhaps leading to changes in the amount of 5-HT released per nerve 
impluse. This would in turn affect the 24 hour differences in stimulation of post- 
synaptic targets, altering 5-HT modulation of converging signals in that neuron. This 
effect of antidepressants on 5-HT1B receptor-mediated control of synthesis might be 
part of the antidepressant's clinical efficacy.
Summary
5-HT synthesis through the light-dark cycle displayed a marked variation in the 
hypothalamus, hippocampus, frontal cortex and striatum. Administration of RU24969 
decreased the production of 5-HTP and the receptor responsible was 
pharmacologically defined as a 5-HT1B receptor. In the hippocampus, frontal cortex 
and striatum, inhibition of 5-HT synthesis varied significantly over 24 hours. However, 
each brain region displayed a characteristic pattern but, interestingly, the hypothalamus 
showed no variation. Chronic antidepressant treatment with either paroxetine or 
desipramine altered the effects of RU24969 on synthesis; both receptor down- 
regulation and up-regulation were observed. In effect prolonged antidepressant 
administration altered the 24 hour pattern of 5-HTig inhibition of 5-HT synthesis. The 
results are in agreement with the hypothesis.
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Chapter 4 In vivo microdialysis
Hypothesis
In vivo microdialysis experiments tested the hypothesis that in entrained rats;
a) The function of the terminal autoreceptor differs at two time points in the light-dark 
cycle.
b) Chronic antidepressant treatment would significantly down-regulate autoreceptor 
function.
c) The degree of down-regulation at the two time points would be different.
The studies were performed in vivo in order to assess the 5-HT system when it was 
interacting with other neurotransmitter systems and while humoral factors were intact; 
thus the parameter measured was physiologically relevant
Method
The principle of microdialysis is simple. A microdialysis probe is stereotaxically 
implanted into a specified brain region. Low molecular weight compounds will diffuse 
across a semipermeable membrane driven by a concentration gradient from the 
extracellular fluid to the perfusing artificial cerebrospinal fluid. The dialysate can then 
be analysed for specific compounds. Page 33 of the techniques appraisal gives details 
of the principles of microdialysis.
The experiments described in this chapter were performed at Boots 
Pharmaceuticals Research Department, therefore some of the experimental details, 
including the HPLC apparatus, were different from those described earlier for the 
experiments performed at the University of Bath.
Implantation of the dialysis probe
Male Wistar rats (Olac, Bicester) weighing 240-260g were housed in pairs 
under a 12:12 light-dark cycle (lights on 0600), at an ambient temperature of 21°C and 
had free access to food and tap water.
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Rats were anaesthetised with chloral hydrate (600mg/kg i.p.) and 
supplementary doses of anaesthetic (30mg i.p.) were given as needed. A rectal probe, 
attached to an homeothermic blanket (Model 50-7016, Harvard Instruments), was 
inserted to monitor core body temperature and maintain it at 36.8°C. Ear bars were 
inserted and the head of the anaesthetised rat placed in a stereotaxic frame with the 
incisor bar set at -3.3mm, to ensure a flat skull (David Kopf Instruments). A vertical 
scalpel cut the length of the skull was made and the loose skin kept clear of the skull by 
artery clips. The skull surface was scraped clean of any tissue and the skull cauterised 
with hydrogen peroxide to expose Bregma more clearly. The dialysis probe (CMA/12 
microdialysis probe, 2mm long membrane and 0.5mm o.d., Carnegie Medicin, Biotech 
Instruments) was positioned directly above Bregma and then lowered slowly so the tip 
just touched the skull surface, the position of the probe was checked under microscope 
(Nikon SMZ-1) and the co-ordinates for Bregma noted. The co-ordinates for the 
anterior hypothalamus were calculated with reference to Bregma and the skull surface 
(anterior-posterior (AP) -1.3, mediolateral (ML) -0.6 and depth -9.3) according to the 
adas of Paxinos and Watson (1982). The position was marked and a circular burr hole 
made with an electric drill (RS Instruments) around the mark almost through the skull 
surface. The passage of the probe lies adjacent to the sagittal sinus, so the bone was 
gendy removed from the opposite side from the sinus to avoid piercing the sinus and 
promoting gross bleeding. If the sinus was nicked, any bleeding was stopped using 
saline-soaked cotton wool and gende pressure. The dura was pierced with a 22 gauge 
needle and the microdialysis probe was slowly lowered to the required depth. The 
exposed brain was covered with cotton wool soaked with saline to prevent drying and 
the skin pulled back across the skull. Figure 37 is taken from the adas of Paxinos and 
Watson (1982) to show the final position and relative size of the microdialysis probe in 
the rat brain.
The probe was continuously perfused at a rate of lpl/min (model 22 
Microinjection pump, Harvard Apparatus or CMA/100 Microinjection pump, Carnegie 




Interaural 7 .70  mm Bregma - 1 .3 0  mm
Figure 37. Coronal section through the rat brain, at the -1.3mm from Bregma level, to show where the 
final position of the microdialysis probe would be. Each major tick horizontally and vertically 
represents 1mm, the probe was implanted -0.6mm from 0 mediolaterally and -9.3mm deep. The probe 
is 0.5mm wide and had a dialysis membrane 2mm long. It can therefore be seen that 5-HT in the 
dialysate originated from the anterior hypothalamus, suprachiasmatic nucleus and medial preoptic 
area. The cross-section is taken from the atlas of Paxinos and Watson (1982). D3V dorsal third 
ventricle; LV lateral ventricle, CPu caudate putamen; GP globus pallidus, AH anterior hypothalamus; 
LA lateral anterior hypothalamus, LH lateral hypothalamus; SCh suprachiasmatic nucleus, ox optic 
tract and SO supraoptic nucleus .
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in mM: NaCl 147; KC1 4; CaCl2  4) containing the selective 5-HT uptake inhibitor 
citalopram (lpM), and the effluent collected onto ice. At the end of the experiment the 
brain was removed and the position of the probe was visually confirmed.
Experimental Protocol
At the beginning of each day the recovery of 5-HT from the probe in the 
dialysis solution was checked in vitro at the flow rate used. Probes were dialysed in 
aCSF containing lOOnM 5-HT for 30 mins and the peak height compared to the 
standard of the same concentration. Probes with recoveries of below 15% were 
discarded. New probes were flushed through with aCSF, at a rate of 30pl/mins, before 
use. The dialysis bag at the tip of the probe was checked for air bubbles, which were 
removed by gently tapping the steel cannula of the probe.
No dialysate samples were collected from rats during the 90 mins after probe 
implantation. This was to allow the efflux of 5-HT to stabilise following the damage 
caused by implantation of the probe. Experiments performed previously in the 
laboratory have shown that this time is adequate. Two 15 mins aliquots were taken to 
serve as pre-intervention controls and successive 15 mins fractions collected 
throughout the experiment For agonist studies the drug was infused via the probe for 
15 mins, immediately after the control samples, and 6 subsequent samples were 
collected. For antagonist studies, the antagonist alone was infused via the probe for 15 
mins, after the control samples, then the agonist and the antagonist were infused 
together via the probe for a further 15 mins. Dialysate samples were assayed for their 
5-HT content using reverse phase high performance liquid chromatography coupled to 
electrochemical detection (HPLC-ECD), the principles of which are set out on page 36 
of the techniques appraisal.
At the end of the experiment the dialysis probe was flushed through with 
distilled water for 30 mins, at a rate of 30pl/min, to prevent any buffer crystallising and 
subsequently blocking the tubing.
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Measurement of 5-HT in the dialvsate
The HPLC-ECD system consisted of a Hypersil ODS2 column (10 cm x 2 mm 
o.d.) with 3pm packing (HPLC Technology) linked to a Coulochem electrochemical 
detector with dual electrodes, electrode 1 set at +0.1V and electrode 2 at +0.28V 
(model 5011 analytical cell, ESA Inc.). Buffer (composition: NaH2 P0 4  0.1M; sodium 
octane sulphonic acid 0.93M; 0.07% v/v dibutylamine and 12% v/v methanol, adjusted 
to pH 3.0 with orthophosphoric acid) was supplied to the system by a Severn 
Analytical solvent delivery system (SA6410B Severn Analytical) at a flow rate of 
0.45ml/min. Samples were injected, using a 20pl Hamilton syringe, into a Rheodyne 
(model 7125) injection port attached to a 20pl loop, the loop was flushed through with 
distilled water before each injection. The chromatogram was plotted on a Shimadzu C- 
R6A chromatopac integrator (Dyson Instruments Ltd.). The pump flow rate was 
decreased to lOpl/min overnight.
Chronic antidepressant treatment
Rats were treated for 21 days with a once daily injection of either desipramine 
hydrochloride (lOmg/kg i.p.) or paroxetine hydrochloride (lOmg/kg i.p.) or an 
equivalent volume of saline. Both rats in the cage received the same treatment, but all 
rats used in this study were housed in the same room and therefore under the same 
environmental conditions. The precise time of injection was varied each day to avoid 
the animals taking the injection as a time cue, but injection was always performed in the 
afternoon during the rat's light phase. All experiments were performed after a 24 hour 
washout period. One saline-treated animal and one antidepressant-treated animal were 
dialysed at the same time at each time point.
Drugs
All drugs infused via the probe were made up in aCSF including lpM 
citalopram on the day of use. Chloral hydrate was made up in 0.9% sterile saline every 
2 days as required.
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Drug Suppliers
Drugs were purchased from suppliers as follows: NaCl, KC1, orthophosphoric 
acid and NaH2 P0 4  all Aristar quality (BDH Chemicals), octane sulphonic acid (Kodak 
Clinical Drugs Ltd.), HPLC grade methanol (Rathbum Chemicals), dibutlyamine 
(Aldrich), chloral hydrate, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and 
desipramine (Sigma Chemical Co.).
The following drugs were donated by the companies indicated; RU24969 
(Roussel-Uclaf), citalopram (Lundbeck), methiothepin (Hoffmann-LaRoche) and 
paroxetine (SmithKline Beecham).
Statistics
Values are expressed as a percentage of the control value i.e. average 
concentration of 5-HT in the two dialysate samples taken immediately prior to any 
drug infusion. Data was analysed by two-way analysis of variance (ANOVA) to detect 
differences between treatments, followed by Studentised range test to determine where 
differences lay between treatments; P<0.05 was considered significant. Statistical 
methods and outcomes are presented in appendix 1.
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Results
All experiments were performed during the early to middle stages of the light 
period unless otherwise stated. Absolute values for 5-HT levels in the dialysate are 
given as a guide and are therefore not corrected for individual probe recoveries.
5-HT levels in control animals
The output of 5-HT into the dialysate was stable over the collection period. 
The mean 5-HT level in the first 30 mins of collection was 2.5±0.2fmoles/15pl sample. 
In general a control animal and a treated animal were dialysed at the same time, but for 
convenience all control values were pooled.
Calcium-dependence
The average 5-HT level in the first 30 mins of collection was 
23±5.7fmoles/15pl sample. Calcium ions were removed from the perfusing aCSF for 
60 mins, within the first 15 mins of this infusion there was a rapid decrease in 5-HT 
output, reaching a maximum decrease of 98% (2%±0.6%, P<0.01, n=4) at t=45 mins. 
When calcium ions were re-introduced, 5-HT levels increased rapidly back to baseline, 
increasing to a maximum of 121 ±6.6% at t=150 mins, figure 38.
Independence
Modified aCSF containing lOOmM K+ was infused via the probe for 15 mins. 
Pre-intervention 5-HT levels were 23±0.3fmoles/15pl sample. Infusion of 100mMK+ 
led to an immediate and significant increase in 5-HT output of 456±11.5% (P<0.01, 
n=7) in the first fraction and 345±8.0% (P<0.01, n=6) in the second fraction, data not 
shown.
Infusion of 8-OH-PPAT fluM)
8-OH-DPAT is a selective agonist at the 5-H T^ receptor. It was used because 
subsequent experiments used RU24969 which is not completely selective for the 5-
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HT1B receptor, having an almost equal affinity for the 5-H T ^ receptor. 8-OH-DPAT 
was infused into the anterior hypothalamus to ensure that any effect of RU24969 
produced was due to its activity as a 5-HT1B agonist. Pre-intervention 5-HT levels 
were 34±4.5fmoles/15pl sample. A 15 mins infusion of lpM 8-OH-DPAT had no 
significant effect on 5-HT release compared to the control animals, see figure 39.
Infusion of RU24969 (O.l-lOuM)
Increasing concentrations of RU24969 were infused for 15 mins via the probe 
leading to a dose-dependent decrease in 5-HT output. Basal, pre-intervention 5-HT 
concentrations in the dialysis were 2.3±0.26fmoles/15pl sample in animals treated with 
lOpM RU24969, 3±0.4fmoles/15pl sample in rats infused with lpM RU24969 and 
1.6±0.18fmoles/15pl sample in animals receiving 0.1 pM RU24969. At a concentration 
of lOpM, there was a maximum inhibition of 65% (35±2% at t=30 mins, P<0.01, n=6), 
lpM 56% (44±1.7% at t=45 mins, P<0.01, n=4) and O.lpM had a maximum inhibition 
of 49% (51±6.2% at t=45 mins, P<0.05, n=4), see figure 40.
Effect of Methiothenin on the response to RU24969
Methiothepin (metitepin) is a 5-HTj receptor antagonist; there are no selective 
5-HT1B antagonists. Methiothepin (lpM) was infused for 15 mins alone and then with 
lpM RU24969 for 15 mins. Pre-intervention 5-HT levels were 17±1.6fmoles/15pl 
sample. Methiothepin reversed the RU24969-induced decrease in 5-HT output In the 
presence of lpM methiothepin, lpM RU24969 caused a maximum inhibition of 5-HT 
output of 27% (73±7% at t=30 mins, n=4), which was not significantly different from 
the control animals. Methiothepin (lOpM) also antagonised the effect of 5pM 
RU24969; pre-intervention 5-HT concentrations were 40±6fmoles/15pl sample, so that 
the maximal maximum inhibition of 5-HT output was 17% (83±3.8% at t=30 mins, 
n=4), which was not significantly different from controls.
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Infusion of Methiothepin (1 and lOulVO
Basal 5-HT levels were 14±0.37fmoles/15pl sample. Infusion of methiothepin 
(lpM) alone for 30 mins significantly increased 5-HT output, with a maximum increase 
of 115 ±5.8% at t=45 mins (P<0.05, n=4). Pre-intervention 5-HT levels were 
48±7.8fmoles/15pl sample. Infusion of methiothepin (lOpM) alone also significantly 
increased dialysate 5-HT levels by a maximum of 242±7.1% at t=60 mins (P<0.01, 
n=5), see figures 41 and 42.
Basal 5-HT levels at mid light and end light
Basal 5-HT levels at mid light were 38.7±0.3fmoles/15pl sample (n=4). Basal 
levels of 5-HT at end light were 28.4±0.1 fmoles/15pl sample (n=6) and there was no 
significant change in 5-HT release after lights off. The level of 5-HT in dialysate was 
significantly higher at mid light than end light (p<0.05 unpaired Student's t-test).
Infusion of RU24969 at mid light
There was a stable release of 5-HT from control animals over the course of the 
experiment and pre-intervention 5-HT levels were 41±4.6fmoles/15pl sample. When 
5pM RU24969 was infused at mid light, i.e. 1200hr, it produced a maximal decrease in 
5-HT release of 65% (35±3.3% at t=45 mins, P<0.01, n=4), with levels returning to 
basal by t=90 mins, see figure 43.
Infusion of RU24969 at end light
Basal 5-HT concentrations in the first 30 mins of collection were 
35±2.2fmoles/15pl sample. Infusion of RU24969 at 1800hr, the time lights went off in 
the animal colony, significantly reduced 5-HT output by a maximum of 100 ±0% from 
t=60 mins (P<0.01, n=5), but, in contrast to mid light, 5-HT levels did not return to 
basal values over the course of the experiment, see figure 44.
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Basal 5-HT levels in dialysate at mid light and end light in treated animals
Chronic antidepressant treatment did not affect basal levels of 5-HT (saline- 
treated 39±8.2fmoles/15pl sample, paroxetine 30.7±4.1 fmoles/15pl sample, 
desipramine 34.4±2.2fmoles/15pl sample) measured at mid light When measured at 
end light prolonged paroxetine treatment did not affect basal 5-HT levels but 
desipramine treatment increased basal levels compared to saline-treated animals (saline- 
treated 35±9fmoles/15pl sample, paroxetine 34.2±4.5fmoles/15jil sample, desipramine 
41.3±5.6fmoles/15pl sample; one-way ANOVA with post hoc Studentised range test, 
P<0.05, n=4-5).
Effect of RU24969 at mid light in antidepressant-treated animals
RU24969 (5pM) infused in rats treated chronically with saline produced 
maximal inhibition of 51% (49±1.7% at t=60 mins, n=4). However when rats were 
treated with either of the two antidepressant drugs (paroxetine or desipramine), the 
effects of RU24969 were significantly attenuated from t=75 mins. Thus although the 
rate of onset and magnitude of the effect of RU24969 were not altered, the rate at 
which 5-HT levels returned to baseline was increased. At this time there was a rapid 
reversal of the effects of RU24969 in rats treated chronically with paroxetine or 
desipramine. Infusion of RU24969 via the dialysis probe in desipramine treated animals 
lead to a maximal inhibition of 47% (53±1.7% at t=45 mins, n=5). Paroxetine treated 
animals gave a similar result; with a maximal inhibition of 46% (54±2.9% at t=60 mins, 
n=4), see figure 45.
Effect of RU24969 at end light in antidepressant-treated animals
Infusion of RU24969 (5pM) via the probe decreased 5-HT output significantly 
in saline-treated rats, with a maximal inhibition of 98.8% (1.2±1.8%, n=4). Chronic 
antidepressant treatment significantly attenuated the effects of a 5pM probe infusion of 
RU24969. The maximal inhibition of 5-HT output in desipramine-treated rats was 35% 
(65±2.0% at t=15 mins, p<0.01, n=4), whereas paroxetine treatment led to a maximum
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decrease in 5-HT release of 66.5% (43.5±1.9% at t=45 mins, p<0.01, n=5), see figure 
46. Thus, at end light the rate of onset and the magnitude of the response to RU24969 
were significantly decreased after chronic antidepressant treatment
The degree and extent of inhibition of 5-HT output by RU24969 at the two 
time points after chronic antidepressant treatment were significantly different (one-way 
ANOVA with post hoc Studentised range test, P<0.05 n=4-5). However the statistical 
difference was found to stem from the rebound in dialysate 5-HT level in 
antidepressant treated rats at mid light from t=75mins. Thus chronic antidepressant 
treatment made the curves at mid light and end light after chronic paroxetine or 
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Figure 38. Effect of removing calcium ions from the perfusing medium on the level of 5-HT in the 
dialysate. Open bar indicates infusion of calcium-free buffer, which started at t=15 mins. Values are 
expressed as a percentage of the concentration of 5-HT in the two dialysate samples taken 
immediately prior to any intervention (control value), as mean ±s.e.m.,**P<0.01 vs pooled control, 
n=12 for pooled control and n=4 for treatment, pooled control ( • )  and Ca++ free buffer (▼).
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Figure 39. Effect of infusion of the 5-HT1A agonist, 8-OH-DPAT, indicated by the open bar, on 5-HT 
output. Values are expressed as a percentage of the concentration of 5-HT in the two dialysate samples 
taken immediately prior to any intervention (control value), as mean ±s.e.m., n=12 for pooled control 
and n=4 for treatment, pooled control ( • )  and lpM  8-OH-DPAT (T).
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Figure 40. RU24969 (0.1 pM, lpM  and lOpM) was infused for 15 mins, as indicated by the bar. 
Values are expressed as a percentage of the concentration of 5-HT in the two dialysate samples taken 
immediately prior to any intervention (control value), as mean ±s.e.m.,*P<0.05, **P<0.01 vs pooled 
control value, n=12 for pooled control, n=4 for O.lpM and lpM RU24969 and n=6 for lOpM 
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Figure 41. Effect of methiothepin infusion on the effect of RU24969. Methiothepin was infused for 15 
mins, filled bar, and then either co-infused with RU24969 for a further 15 mins, stripped bar or 
infused alone, filled bar. Values are expressed as a percentage of the concentration of 5-HT in the two 
dialysate samples taken immediately prior to any intervention (control value), as mean ± 
s.e.m.,*P<0.05 vs pooled control value, %><().05, ^P<0.01 vs lpM RU24969, n=12 for pooled 
control, n=4 for lpM methiothepin and 1 pM methiothepin + 1 pM RU24969, pooled control (• ) , 
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Figure 42 Effect of methiothepin infusion on the effect of RU24969. Methiothepin was infused for 15 
mins, filled bar, and then either co-infused with RU24969 for a further 15 mins, stripped bar or 
infused alone, filled bar. Values are expressed as a percentage of the concentration of 5-HT in the two 
dialysate samples taken immediately prior to any intervention (control value), as mean ± 
s.e.m.,**P<0.01 vs pooled control value, ##P<0.01 vs 5pM RU24969, n=12 for pooled control, n=5 
for lOpM methiothepin and n=4 for 10pM methiothepin + 5pM RU24969, pooled control (• ) ,  10pM 
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Figure 43. Infusion of 5pM RU24969, open bar, at mid light. Values are expressed as a percentage of 
the concentration of 5-HT in the two dialysate samples taken immediately prior to any intervention 
(control value), as mean ±s.e.m.,**P<0.01 vs control value for mid light, n=6 for mid light controls 
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Figure 44 Infusion of 5pM RU24969, open bar, at end light. Values are expressed as a percentage of 
the concentration of 5-HT in the two dialysate samples taken immediately prior to any intervention 
(control value), as mean ±s.e.m.,**P<0.01 vs control value for end light, n=5 for end light controls 
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Figure 45. Rats were treated chronically with either paroxetine, desipramine or saline and the effect 
of 5pM RU24969, open bar, re-assessed at mid light. Values are expressed as a percentage of the 
concentration of 5-HT in the two dialysate samples taken immediately prior to any intervention 
(control value), as mean ±s.e.m.,*P<0.05 vs saline-treated rats, n=4 for saline-treated rats, n=4 for 
paroxetine-treated rats and n=5 for desipramine-treated rats, saline-treated + 5pM RU24969 (• ) ,  

















Figure 46. Rats were treated chronically with either paroxetine, desipramine or saline and the effect 
of 5p.M RU24969, open bar, re-assessed at end light. Values are expressed as a percentage of the 
concentration of 5-HT in the two dialysate samples taken immediately prior to any intervention 
(control value), as mean ±s.e.m.,*P<0.05 vs saline-treated rats, n=6 for saline-treated rats, n=4 for 
both paroxetine-treated rats and desipramine-treated rats, saline-treated + 5pM RU24969 ( • ) , 
paroxetine-treated + 5pM RU24969 (■) and desipramine-treated + 5pM RU24969 (▼).
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Discussion
In vivo microdialysis was used to examine terminal 5-HT autoreceptor function in the 
hypothalamus of the anaesthetised rat, at two time points, after chronic antidepressant 
treatment The hypothesis described earlier in this chapter predicted that the effects of 
chronic antidepressant treatment on 5-HT 1 3  autoreceptor function would be different 
at the two time points investigated in this study. The results presented here concur with 
this prediction.
The microdialysis probe was implanted into the anterior hypothalamus because 
this region is adjacent to the suprachiasmatic nucleus (SCN) and, like the SCN, it 
receives innervation from both RN. In fact, the microdialysis probe was implanted so 
that the medial side of the probe was located on the lateral border of the SCN. Thus at 
least a part of the dialysate 5-HT was likely to be derived from neurons in the SCN. It 
was not possible to implant the dialysis probe used here directly into the SCN because 
the SCN is too small; being 0.95mm long, 0.42mm wide and 0.40mm in depth, whilst 
the outer diameter of the probe is 0.5mm. However, other workers have implanted 
carbon fibre voltammetry electrodes combined with differential pulse voltammetry 
(8 pm o.d.; Faradji et al. 1983; Martin and Marsden 1985) or specially constructed 
dialysis probes (o.d. 230pm; Glass et al. 1992) into the SCN and successfully measured 
5-HT and 5-HIAA directly.
In order to remove the possible influence of environmental factors on 5-HT 
neuronal firing, it was decided to perform these experiments on anaesthetised animals. 
Sound and light have been shown to increase DR firing rate in freely moving cats 
(Heym et al. 1984). However, this increase is abolished if the animals were 
anaesthetised with chloral hydrate. On the other hand, chloral hydrate anaesthesia has 
been shown to decrease the activity of TrOH in rats (Tappaz and Pujol 1980) and to 
decrease the rate of DR neuronal firing in cats (Heym et al. 1984). In addition, since 
the 5-HT level was to be measured at end light, anaesthesia would avoid the influence 
of altered 5-HT release due to the rats starting to explore and groom during the dark 
phase. Although 5-HT release in the hippocampus does not reflect behavioural activity
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state (Kalen et al. 1989), in the hypothalamus Imeri and colleagues (1994) have 
reported a close relationship between 5-HT release and arousal.
Origin of 5-HT Measured in the Pialvsate
Sharp and colleagues (1989) have characterised 5-HT output in the 
hippocampus of anaesthetised rats, using a similar experimental protocol. These 
workers found that pre-treatment with the selective 5-HT neurotoxin, 5,7- 
dihydroxytryptamine (5,7-DHT) given intraventricularly, decreased the 5-HT level in 
the dialystae by 57%. This indicates that at least half the 5-HT measured in the 
dialysate was derived from 5-HT neurons projecting from the DR, given that 5,7-DHT 
lesion only destroys DR neurons. Local infusion of tetrodotoxin into the hippocampus 
via the dialysis probe also decreased 5-HT levels by 75% testifying that most of the 5- 
HT measured was neuronally derived. Electrical stimulation of the the DR at 
frequencies of 2-20Hz i.e. encompassing the normal physiological firing rates, 
increased 5-HT output by a maximum of 400% at the highest frequency. There was no 
increase in 5-HT output when the stimulating electrode was implanted dorsal or ventral 
to the DR. These two results demonstrate that the 5-HT detected in dialystae is derived 
from 5-HT neurons.
The basal level of dialysate 5-HT measured in this study ranged from 
1.6fmoles/15pl sample to 48fmoles/pl sample. These levels are lower than those 
reported by Sharp and colleagues (1989) of 100fmoles/20pl sample and by Kalen and 
co-workers (1988) of 20pmoles/60pl sample in the hippocampus but are close to those 
of Auerbach and workers (1989) of 5-8fmoles/60pl sample in the hypothalamus. Thus 
despite small differences, probably due to a number of factors: brain regions, longer 
interval between sample collection and different probe types (outer diameters and 
dialysis membrane length), as discussed in the techniques appraisal, the dialsyate 5-HT 
levels measured here are not dissimilar from'those previously reorted (Kalen et al. 
1988; Sharp et al. 1988; Auerbach et al. 1989).
Two methods were employed to verify that the overflow of 5-HT in the
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dialysate was neuronally derived. First, since exocytotic release of neurotransmitters is
9
considered to be calcium dependent, calcium ions were removed from the perfusate. 
Following this intervention, there was an almost immediate drop (98% decrease 
compared to pre-intervention values) in the levels of 5-HT, figure 38. When calcium 
ions were re-introduced into the aCSF, the concentration of 5-HT increased rapidly 
towards control values, with an increase in 5-HT levels above baseline by about 20% at 
the end of the experiment Secondly, infusion of aCSF containing lOOmM K+ for 15 
min caused an immediate statistically significant increase (465% compared to pre- 
intervention levels) in the overflow of 5-HT into the perfusing medium. Increasing the 
extracellular concentration of K+ leads to depolarisation of the nerve membrane and 
concomitant release of neurotransmitter, similar to that seen when an action potential 
travels down the nerve and invades the nerve terminal. This K+-dependence was 
further evidence that the 5-HT output measured in dialysate effluent was neuronally 
derived. Both these findings are in agreement with those of Auerbach and colleagues 
(1989) who have characterised dialysate 5-HT output in the hypothalamus of freely 
moving rats and found that the extracellular levels measured reflect neuronal release. In 
their hands a 2 hour infusion of 120mM K+ increased 5-HT output by 410%, and 
omission of Ca++ from the aCSF for 2 hours decreased 5-HT levels in dialysate by 
58%. Therefore based on the present and previously published findings it is reasonable 
to assume that the 5-HT measured in dialysate was neuronally derived and subsequent 
studies could be initiated to look at neuronal function.
Pharmacological Characterisation of the Receptor
The terminal 5-HT autoreceptor has been extensively examined and found to be 
of the 5-HTjb subtype in the SCN (Martin and Marsden 1986; O'Connor and Kruk
1992) and other brain regions (Martin and Sanders Bush 1982; Engel et al. 1986; 
Hjorth and Tao 1991). The hypothalamus, but not the SCN (Roca et al. 1993), is well 
endowed with 5-HT1A and 5 -HT2 C receptors (Pazos and Palacios 1985), but these are 
considered to be post-synaptic receptors.
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Infusion of increasing concentrations of RU24969 (0.1-10pM) led to a dose- 
dependent decrease in dialysate 5-HT levels. This dose-dependent effect has not 
previously been reported. RU24969 (l-5pM), when infused via the dialysis probe, has 
been shown to increase 5-HT output (Auerbach et al. 1991; Hjorth and Tao 1991) in 
the absence of an uptake inhibitor. However, when lpM citalopram, an uptake 
inhibitor, was included RU24969 (lpM) decreased 5-HT output. This indicates that 
RU24969 itself can act as an uptake inhibitor, but in the data presented here an uptake 
inhibitor was already present in the aCSF, and drug solutions, throughout the 
experiments it can be assumed that RU24969 acted solely as a 5 -HT1B agonist. The 
IC5 0  of RU24969 on [3 H]5-HT release in vitro is 35nM (Middlemiss 1985), therefore 
the concentrations of RU24969 used in this study would be sufficient to decrease 5-HT 
output The concetrations of RU24969 in the dialysate were 0.1-10pM. Previous, 
unpublished in vitro studies in the Boots laboratory have shown that approximately 
10% of drug leaves the probe. Thus during a 15 min application the amount of 
RU24969 adminsitered to the anterior hypothalamus can be estimated as being 0.01- 
lpM. This clearly indicates that the effects of RU246969 are at pharmacologically 
relevant concentrations.
The inhibitory effects of RU24969 on 5-HT output in the frontal cortex and 
ventral hippocampus have been demonstrated before in vivo (Sleight et aL 1989; 
Hjorth and Tao 1991; Martin et al. 1992), although Martin and colleagues were the 
only other workers to show a dose-response relationship in the ventral hippocampus; 
0.1 pM RU24969 did not significantly decrease 5-HT output whereas lpM RU24969 
decreased 5-HT levels by 47%. This compares with my values of a 49% decrease after 
O.lpM RU24969, 56% after lpM RU24969 and 65% after lOpM RU24969.
To confirm that the output of 5-HT measured in the dialysate was controlled by 
a 5-HT1B receptor, the selective 5-HT1A agonist 8 -OH-DPAT (lpM) was infused. 8 - 
OH-DPAT was infused also because RU24969 has only slightly greater affinity for the 
5-HT1B receptor than the 5-HT1A autoreceptor (pKj5-HTiA 8.06nM and pKj 5-HTiB 
8.23nM van Wijngaarten et al. 1990). Since 8 -OH-DPAT infusion was without effect
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on the levels of 5-HT in the dialysate it can be concluded that 5-H T ^ receptors do not 
affect the output of 5-HT measured in this system and that any effect of RU24969 must 
therefore be due to an action at a 5-HT 1B receptor.
Pre-infusion of methiothepin (lOpM) blocked the effects of RU24969 (5pM) as 
described previously (O'Connor and Kruk 1991; Martin et al. 1992). The pre-infusion 
method was chosen because it gives the antagonist a chance to diffuse throughout the 
area and bind to 5-HT1B receptors. Infusion of methiothepin alone (lOpM and lpM) 
increased the overflow of 5-HT. It has been reported previously that methiothepin (1- 
lOpM) elicited a concentration-dependent enhancement of both basal and K+- 
stimulated endogenous 5-HT and [3 H]5-HT release in hypothalamic slices in vitro 
(Pettibone and Pflueger 1984). O'Connor and Kruk (1991) have also reported an 
increase in 5-HT levels of 83% after administration of methiothepin (0.1-lpM) in slices 
containing the SCN. Methiothepin (lOmg/kg i.p.) has been shown to increase 5-HT 
output in vivo by up to 57% (Baumann and Waldmeier 1984, Martin and Marsden
1986). Methiothepin is a 5-HT receptor antagonist which shows some selectivity for 5- 
HTj receptors (Hibert and Middlemiss 1986), however it is not entirely selective for 5- 
HT receptors. Methiothepin is also an antagonist at (^-adrenoceptors which are known 
to be present on 5-HT terminals and to have an inhibitory effect on 5-HT release in 
vivo (Hjorth and Tao 1992; Tao and Hjorth 1992) which is tonic (Mongeau et al.
1993). The increased 5-HT output after methiothepin was concentration dependent; 
the increase after lpM was 15% and after lOpM 142%. Thus the increased output of 
5-HT seen may be attributable partly to inhibition of the autoinhibitory tone of both the 
5-HT1B autoreceptor and the 0 C2  heteroreceptor. However, since methiothepin blocked 
the effects of RU24969, it is reasonable to conclude that in view of the data discussed 
above, RU24969 exerts its effects on 5-HT release in the rat via the 5-HT 
autoreceptor.
Thus the receptor controlling 5-HT release in the anterior hypothalamus can be 
pharmacologically characterised as a 5-HT1B receptor.
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Basal 5-HT Levels at mid light and end light
The dialysate concentrations of 5-HT at mid light was significantly higher than 
those measured at end light Experiments in vivo using voltammetry or microdialysis 
probes implanted into the SCN or ventromedial hypothalamus of rats and hamsters 
have shown that 5-HT and 5-HIAA levels begin to rise at the end of the light phase and 
peak during the dark phase (Faradji et al.1982; Martin and Marsden 1985; Glass et al. 
1992). In the hippocampus, however, 5-HT levels were slightly higher during mid light 
(20pmoles/60pl) than at end light (15pmoles/60pl) (Kalen et aL 1989). In my 
experiments significantly more 5-HT was detected at mid light (38fmoles/15pl) than 
end light (28fmoles/15pl). There are two possible explanations for the differences 
between my results and those of other workers. Firstly in the experiments of Martin 
and Marsden (1985), and Glass and colleagues (1992), hamsters and rats were freely 
moving, so that behaviour, arousal and other external factors might affect the 
endogenous pattern of 5-HT release, as discussed previously. Whilst outside the scope 
of the present discussion, these observations question whether the 24 hour rhythm in 5- 
HT release is indeed an endogenous circadian rhythm. However, very recently 
Cagampang and Inouye (1994) have presented evidence showing that in the SCN, 
tissue 5-HT levels exhibit an endogenous 24 hour rhythm. In my experiments rats were 
anaesthetised and therefore 5-HT levels were not influenced by movement and arousal. 
Secondly, most of the authors, with the exception of Martin and Marsden (1985) used 
5-HIAA as a measure of 5-HT release and there is currently debate as to whether 5- 
HIAA levels are a true reflection of 5-HT release (Auerbach et al. 1989; Crespi et al.
1990).
Since these experiments were performed in anaesthetised rats, they indicate that 
the difference in 5-HT release measured at mid light and end light are an inate 
phenomenon not related to activity or behavioiural state.
Effect of RU24969 at mid light and end light
The effects of a 15 min infusion of RU24969 were significantly different at the
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two time points investigated. RU24969 administration caused a quantitatively greater 
inhibiton of 5-HT output at end light compared to mid light
The greater effect of infusion of 5pM RU24969 at end light compared to mid 
light could be due either to a difference in the amount of 5-HT released and therefore 
receptor occupation, or the sensitivity/number of autoreceptors at the two time points, 
or to a variation in the second messenger level/activity. A significant variation in 5- 
HTjb binding has been demonstrated over 24 hours, but only in the cortex (Akiyoshi et 
aL 1989). The number of sites varied significantly whilst the affinity did not change. 
The number of binding sites at mid light was significantly higher than at end light which 
does not correlate with my findings. The differences could be because the technique 
measured both presynaptic and post-synaptic receptors or the cortical rhythm is 
different from that in the hypothalamus. mRNA levels for the 5-HTjq receptor in the 
SCN have been found not to vary over 24 hours (Roca et al. 1993), when measured at 
four equally spaced time points in the light-dark cycle. However since this is a measure 
of post-synaptic receptors it does not preclude a rhythm in presynaptic receptors. In 
the anterior hypothalamus more receptors could be present at end light or the affinity 
of these receptors could be gready increased compared to mid light Another 
explanation, as extensively discussed in chapter 3, is that there could also be circadian 
rhythms in receptor-effector coupling, adenylate cyclase activity or the intracellular 
level of cAMP due to a circadian rhythm in phosphodiesterase as described by Prosser 
and Gillette (1991) and Perez and colleagues (1991).
Chronic Antidepressant Treatment
Basal 5-HT levels at mid light and end light in treated animals
Rats were treated chronically with two different types of antidepressant; 
desipramine is a selective noradrenaline uptake inhibitor (Kj NA 0.6 InM, 5-HT 180nM 
and DA 1 lOOOnM; Bolden-Watson and Richelson 1993) and paroxetine a selective 5- 
HT uptake inhibitor (Kj NA 33nM, 5-HT 0.73nM and DA 1700nM; Bolden-Watson 
and Richelson 1993). Rats were treated for 21 days since the clinical effects of
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antidepressant drugs are usually not seen until about 2-3 weeks after initial 
administration.
Significantly more basal 5-HT was detected in dialysate samples taken from rats 
treated with desipramine when measured at end light At mid light no differences in 
basal dialysate 5-HT level were detected between saline- and drug-treated rats. This 
was also the case at end light in those animals treated with paroxetine.
The increase in basal 5-HT levels seen after chronic desipramine treatment at 
end light may by caused by two, not mutually exclusive, factors. The increase could 
represent a phase-dependent down-regulation of the terminal ot2 -heteroreceptor (Tao 
and Hjorth 1992) or the cell body ai-heteroreceptor (Baraban and Aghajanian 1980; 
Clement et al. 1992a) located on 5-HT neurons. The down-regulation of <Xp 
heteroreceptors after chronic desipramine treatment may be due to a down-regulation 
of (X2 -autoreceptors, located on NA terminals projecting to the DR from the LC. 
Frontal cortical (X1 3  binding is decreased after chronic treatment with imipramine, 
although a 1A binding in the frontal cortex and a 1A and a 1B binding in the 
hippocampus were unaffected (Hayakawa et al. 1992). However there is as much 
evidence for an up-regulation (Maj et al. 1985) or no change in a  1-adrenoceptors (Li 
et al. 1988). The subtype of the 0 4 -heteroreceptor in the RN has not been determined, 
nor has its function been assessed after chronic antidepressant treatment. A change in 
the function of these adrenoheteroreceptors may affect the cell body biophase 
concentration of 5-HT and thereby in turn down-regulate 5-HTjA autoreceptors. This 
may then in turn affect firing rate and thus the terminal release of 5-HT, as outlined in 
the introduction. However, since a  1 -heteroreceptors exert a tonic excitatory effect on 
DR neuronal firing, their down-regulation would decrease neuronal firing, decreasing 
dendritic 5-HT release and stimualtion of 5-HT1A autoreceptors. Down-regulation of 
presynaptic (X2 -heteroreceptors after chronic desipramine treatment has also been 
reported (Gonzalez et al. 1992), although although others claim that there is no change 
in function (Campbell et al. 1992). The effect of prolonged treatment with 5-HT uptake 
inhibitors on a 2 -heteroreceptor function has not been assessed. Singh and Redfem
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(1994b) have shown that there is no difference in cortical c^-heteroreceptor sensitivity 
through the light-dark cycle in in vitro, but the basic agonsit and antagonist studies 
here were performed during the earlier parts of the light phase. It is unknown whether 
the o^-heteroreceptors display a circadian rhythm in the anterior hypothalamus and 
therfore, no firm conclusions about the cause of the effect of desipramine on basal 5- 
HT can be drawn.
Effect of RU24969 at mid light and end light in antidepressant-treated animals
The results at mid light will be considered first because it is at this time point 
that most other assessing neurotransmitter receptor binding and function are canried 
out.
When the effect of RU24969 (5pM) was re-assessed after chronic 
antidepressant treatment at mid light, there was no significant difference in effect 
between antidepressant- or saline-treated animals. In general neither desipramine nor 
paroxetine significantly altered the maximal response of the autoreceptor to RU24969 
but there was a significant increase in 5-HT output at the end of the experiment These 
results are in agreement with the only comparable published study, Sleight and co- 
workers (1989), if it is assumed that these workers carried out their experiments during 
the middle of the light phase. These workers found that chronic treatment with either 
amitriptyline or MDL72394 (a putative MAOI) had no effect on the response to 
RU24969 (lOmg/kg i.p.) in the frontal cortex of the anaesthetised rat. Other studies in 
vivo studies using a different technique have indirectly demonstrated autoreceptor 
down-regulation in the hippocampus after chronic fluoxetine or citalopram but not 
clorgyline treatment (Chaput et al. 1986; Blier et al. 1988). In alll these studies rats 
were chloral hydrate anaesthetised.
Other studies looking at the function of the 5-HT autoreceptor after chronic 
antidepressant treatment were carried out in vitro. However the results were equivocal, 
reporting both a decrease in sensitivity after treatment with MAOI or 5-HT and 5- 
HT/NA uptake inhibitors (Maura and Raiteri 1984; Moret and Briley 1990) and a
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decrease (Johanning et al. 1992) or no change in the number of 5-HTig binding sites 
(Montero et al. 1991) after treatment with a 5-HT uptake inhibitor. It is difficult to 
reconcile these disparate in vitro findings with the more physiologically relevant in vivo 
data presented here and by Sleight and co-workers (1988). However the wide variation 
in both methodology and drug adminsitration may play a significant role.
By contrast, at end light prolonged antidepressant treatment significantly 
attenuated the effects of RU24969, desipramine having a greater effect than 
paroxetine. The down-regulation of 5-HT autoreceptors following chronic desipramine 
treatment might reflect a desensitisation of terminal <X2 -heteroreceptors. This 
desensitisation could be achieved by an increase in NA around the 5-HT nerve terminal 
following blockade of NA reuptake. Down-regulation of the c^-heteroreceptor would 
decrease the feedback inhibiton of this receptor on 5-HT release. The biophase level of 
5-HT could then rise and down-regulate the 5-HT autoreceptor. Treatment with 
paroxetine would have a more direct affect. Blockade of 5-HT reuptake would directly 
increase 5-HT levels in the synaptic cleft thus allowing desesitisation of the 
autoreceptor. Since this is the first observation that antidepressant drugs decrease 5- 
HTjb function in vivo it is pertinent to consider the posssible mechanisms that may be 
involved. As discussed in chapter 3, it may be due to changes in autoreceptor and 0 2 - 
heteroreceptor expression, expression of their G protein, uncoupling of the receptor- 
effector coupling or changes in intracellular signal transduction pathways.
The reason for the greater effect of desipramine is unclear. Clearly, it could be 
connected to the finding of increased basal levels of 5-HT at end light only after 
desipramine treatment. As explained earlier in this section, the down-regulation in the 
(X2 -heteroreceptor would increase the terminal biophase concentration of 5-HT and 
perhaps expose the terminal autoreceptor to a greater level of 5-HT at end light 
compared to mid light, thus leading to greater down-regulation at this time point
An antidepressant-induced change in the circadian rhythm in receptor numbers 
and tissue 5-HT concnetration has been demonstrated before. As mentioned in the 
Introduction (chapter 1), the peak binding in the daily rhythm of a-adrenoceptors,
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GABA-benzodiazepine, a-MSH, DA and mAChR receptors (Kafka et aL 1981b; 
ODonahue et al. 1982; Wirz-Justice et al. 1982). receptors is delayed following 
chronic antidepressant treatment. Additionally, Ozaki and colleagues (1994) have 
shown that the circadian rhythm of tissue 5-HT concentration from different brain 
regions is changed following chronic clorgyline administration. Furthermore the 
changes in rhythm varied according to the region studied. Thus in the SCN and DRN 
the peak level was delayed, whilst in the paraventricular nucleus of the hypothalamus, 
medial preoptic area, vLGN and MRN the rhythm was abolished. Therefore, 
extrapolation of the findings presented here across the 24 hour period suggest either a 
flattening of rhythms or an alteration of the time of peak effect Neither of these 
possibilities is in disagreement with the results described above.
In conclusion, therefore, my results demonstrate that chronic antidepressant 
drug adminsitration down-regulates 5-HT1B receptor function in a time of day 
dependent manner. The exact mechanism whereby the alteration in function is achieved 
is unclear but it is tempting to speculate that it involves one or more of the processes 
extensively discussed in chapter 3. Nevertheless, the present data stress the need to 
examine receptor function throughout the 24 hour cycle to determine whether chronic 
treatments induce adaptational changes.
Summary
In summary, 5-HT output in the anterior hypothalamus is controlled by a 5- 
HTib autoreceptor which appears to display autoinhibitory tone. Terminal 5-HT1B 
receptor function displays a marked diurnal variation when compared at mid light and 
end light Perhaps the most important finding is that chronic treatment with paroxetine 
or desipramine changed the function of the autoreceptor in a phase-dependent manner. 
Chronic antidepressant treatment did not affect the receptor at mid light, but 
significantly down-regulated the 5-HT1B receptor at end light In fact, chronic 
antidepressant treatment made the response to RU24969 at mid light and end light 
equal. This was the case with both antidepressants which target either the 5-HT or NA
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system selectively. Down-regulation only occurred at one time point, which provides 
good evidence for the hypothesis of this thesis that antidepressant treatment would 
affect 5-HT control of 5-HT release only at some time points.
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Chapter 5 General Discussion
The aim of this chapter is to synthesise the results from preceeding 
experimental chapters outlining similarities and differences in results and possible 
reasons for those anomalies. Additionally I shall discuss how the results tally with the 
original hypothesis and how the hypothesis might be expanded, as well as indications of 
future work needed to enlighten "dark comers".
Synthesis of experimental findings
Three different techniques were used to assess autoreceptor control of synthesis 
and release. However since one technique proved unsuccessful this section will mainly 
concentrate on bringing together the results from the 5-HTP accumulation and 
microdialysis studies.
Uptake of [3 H]5-HT into hypothalamic slices varied over 24 hours, being 
considerably higher at end light but not significantly different at the other three time 
points. It is possible that the degree of uptake may have affected the basal synthesis 
rate of 5-HT. As outlined in the discussion in chapter 3, the biophase concentration of 
5-HT could feed back to affect the rate of synthesis. If 5-HT uptake is higher at end 
light then it might be expected, that the synthesis rate would be higher as a result of less 
negative feedback. However the synthesis rate was quantitatively highest at mid dark, 
and significantly higher at mid dark than at end light. Either the rhythm in [3 H]5-HT 
uptake is not a major factor in vivo or alternatively the difference could be due to the 
use of hypothalamic slices and [3 H]5-HT. Experiments using in vivo microdialysis 
indicated that 5-HT levels were higher at mid light than end light Thus in the 
hypothalamus it might be expected that the synthesis rate would be lower at mid light 
than at end light Again these results do not tally with the variation in synthesis rate 
observed which may be due to anterior hypothalamus vs whole hypothalamus.
The higher uptake of [3 H]5-HT at end light could lead to a reduction in the 
biophase level of 5-HT. This would decrease the competition between 5-HT and
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RU24969 for the 5-HT1B binding site. However in the hypothalamus the RU24969- 
induced decrease in 5-HTPacc did not vary over 24 hours. Therefore the uptake might 
be higher at this time point because 5-HT release is greater, although the results of the 
in vivo microdialysis studies argue against this.
In dialysate the 5-HT levels was Ca++- and agonist-dependent which is in direct 
conflict with the results from superfusion studies. The release seen in both studies was, 
however, K+-dependent. This indicates that an increased output of 5-HT after elevating 
the K+concentration does not necessarily reflect an increased neuronal release.
Administration of RU24969 had different effects on synthesis and release over 
24 hours. The results from in vivo microdialysis experiments demonstrated a significant 
difference in the effect of RU24969 at mid light compared to end light In contrast, 
RU24969 had the same effect on 5-HT synthesis rate measured through the light-dark 
cycle. Again this difference might be due to the use of anterior hypothalamus vs whole 
hypothalamus.
Basal TrOH activity was not significantly different after chronic antidepressant 
treatment at end light, however basal 5-HT levels, measured by in vivo microdialysis, 
were higher at end light after chronic desipramine treatment The difference could be 
accounted for because different parameters were being measure, the treatment 
schedules of the rats used were different or perhaps a-adrenoheteroreceptors do not 
have as great an effect on synthesis as they do on release.
The 5-HT -mediated control of synthesis was attenuated by chronic 
desipramine treatment at mid light and chronic paroxetine treatment at end light 
However 5-HTjg-mediated control of release was down-regulated by both 
antidepressant drugs only at end light Again the difference might be attributable to 
variations in the dosing schedule. The timing of administration of the antidepressant 
drugs could be very important in its effect on receptor populations. Animals used in in 
vivo microdialysis experiments were always injected during the latter half of the light 
phase, whilst those used for synthesis experiments were randomly injected. There are 
no studies on the chronopharmacokinetics of desipramine or paroxetine. The fact that
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antidepressant-treated rats were treated whilst being phase-shifted may also account 
for the difference, although published data do not support this contention. The rats 
came from different suppliers; rats used for dialysis experiments were bought from 
Olac, whilst those used for synthesis experiments were bred at the University of Bath. 
Again the differences in down-regulation might be due to the fact that the same 
parameter was not being measured. Possibly the intracellular pathway for release, 
involving synapsin, synaptophysin and other cytoskeletal elements might react 
differently fom intracellular factors affecting synthesis, involving PKA, activator 
proteins and/or TrOH.
Thus the results taken together indicate that chronic antidepressant treatment 
affects 5-HT 1 3 -mediated control of synthesis and release over 24 hours in a differential 
manner.
Hypothesis tested
The initial hyothesis of this thesis was that prolonged treatment with 
antidepresant drugs alters the 24 hour pattern of control the terminal 5-HT1B 
autoreceptor exerts on 5-HT synthesis and release.
This prediction was based on elements from several lines of evidence. On one 
hand, 5-HT has been implicated in the aetiology of depression for many yeras and many 
clinically effective antidepressant drugs target the central serotoninergic system. 
Secondly, in at least a subpopulation of depressives, a malfunction of the circadian 
system has been demonstrated. Additionally, in laboratory animals some 
antidepressants have been shown to alter circadian rhythms in locomotor activity and in 
receptor populations. Finally, several factors are known to affect the activity of 
serotoninergic neurons e.g. autoreceptors and circadian rhythms.
Based on this original hypothesis, a model has been developed to explain how 
antidepressant drugs interact with the 5-HT system, via 5-HT1B receptors, to modualte 
circadian rhythms and therby exert therapeutic effects.
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Model of interaction between 5-HT, antidepressant drugs and ciradian rhvthms
The proposed model suggests that in a certain subset of depressed patients, the 
regulation of 5-HT^ autoreceptor expression or post-translational processing is 
abnormal, leading to an overexpression or increased affinity of these autoreceptor. 
Thus when 5-HT is released and the autoreceptors are stimulated the inhibitory effect 
of these autoreceptors decreases 5-HT synthesis and release and therefore the amount 
of 5-HT released per impulse, further increasing the number or sensitivity of the 
autoreceptors. Such as process clearly leads to a self-reinforcing positive feedback 
loop. Under normal conditions autoreceptor function and release are correlated; when 
the extracellular 5-HT level rises, the autoreceptor stimualtion is greater and feedbak 
inhibition increased. If the autoreceptor function is abnormal, then this relationship 
breaks down; this is shown diagrammatically in figure 47 and explained in the legend. 
The breakdown in the relationship affects the biophase concentration of 5-HT over 24 
hours and therefore stimualtion of post-synaptic targets, some of which may be central 
elements in the circadian system.
The model further proposes that antidepressant drugs exert their therapeutic 
actions in this subset of depressives by altering the function of autoreceptors by up- or 
down-regualtion, depending on the time of day, to "normalise" the activity of the 
autoreceptor. This normalisation of the 5-HT input to the biological clock may reset 
circdian rhythms and thereby help to alleviates depression.
The data presented in this thesis, in conjunction with published work, can be 
used to validate the model. However, since the model is complex it will be broken 
down into its constituent parts.
5-HTxb receptors in depression
There is good evidence for an alteration in the function of the 5-HT system in 
at least a subpopulation of depressives. For example, plasma 1-try levels are 
significantly lower in depressed patients (Cowen et al. 1989; Pietraszek et al. 1991). In 
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Figure 47. Relationship between 5-HT autoreceptor function and extracellular 5-HT level. Under 
normal conditions 5-HT release and autoreceptor function are well correlated. As the extracellular 
concentration of 5-HT increases it feeds back onto the autoreceptor to decrease further 5-HT release. 
However, if the autoreceptor pattern is altered, by changes in receptor expression, then this feedback 
mechanism will break down and affect the pattern in 5-HT release.
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depletion of tryptophan induces a relapse into a depressed state (Delgado et al. 1990). 
Their state improves when a normal diet is given. Neuroendocrine challenge tests also 
provide evidence for a serotonin abnormality in depressives (Lesch et aL 1990; Price et 
al 1991).
The function of the terminal 5-HT autoreceptor is very important since it 
controls release and therefore the biophase concentration of 5-HT, it can respond 
rapidly to changes in extracellular 5-HT levels, adjusting release as necesary.
Although direct evidence of a 5-HTjb malfunction in depression is not found in 
the literature, the results of several experiments indirectly point in this direction. The 
increase in post-synaptic 5-HTjd (Lowther et al. 1991), 5 -HT2  (Stanley and Mann 
1982) and 5-HTj (Cheetham et al. 1990) receptor density demonstrated in depression 
could indicate a functional up-reguation of these receptors in response to the decrease 
in 5-HT release due to a supersensitive terminal autoreceptor. Similar changes in post- 
synaptic receptors are seen after neurochemical lesion of the 5-HT system (Underwood 
et al. 1992).
5-HTib autoreceptor function over 24 hours
The data in this thesis have demonstrated that, in the anterior hypothalamus, 
hippocampus, frontal cortex and striatum, 5-HT1b receptor function varies over 24 
hours. This is in contrast to the findings of Singh and Redfem (1994a) who have shown 
that in vitro 5-HT1B autoreceptors in the frontal cortex do not display any rhythm.
However, several other workers have presented evidence for rhythms in 5- 
HT1B receptors. Martin and colleagues (1987) have demonstratd a circadian rhythm in 
post-synaptic 5-HT1B receptors in the mouse using a behavioural model. These 
workers found that the receptor was more sensitive during the dark phase. Prosser and 
co-workers (1993) have shown that 5-HT1B binding is higher during the middle of the 
dark phase compared to the middle of the light phase in the SCN. In the cerebral cortex 
5-HT1B binding is higher during the light phase than the dark phase (Akiyoshi et al.
1989). In situ hybridisation, though, has detected no change in mRNA for 5-HTiB
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receptors in the SCN (Roca et al. 1993); however since this is a measure of receptor 
expression in the cell body it will not measure presyanptic 5-HT1B receptors. Thus the 
work in this thesis and evidence from published studies demonstrates a 24 hour 
variation in 5-HT 1B receptors.
The data presented in this thesis do not prove a circadian rhythm in 5-HT 1B 
function, but rather illustrate that 5-HTiB function varies over 24 hours. Further 
studies would be required to assess whether the observed variation is truly circadian.
In normal subjects 5-HT1B function correlates with 5-HT release. The results of 
the in vivo microdialysis studies demonstrate that autoreceptor function is higher when 
release is decreased. If the relationship between release and autoreceptor is changed, 
either by abnormal expression or by post-translational processing changes it might alter 
the circadian fluctuation in the autoreceptor, thus breaking down the feedback 
mechanism and changing the biophase concentration of 5-HT over 24 hours.
Role of 5-HT in the control of circadian rhythms
The circadian system can be thought of as consisting of three parts; an input to 
the pacemaker relaying information about the external environment, the pacemaker 
itself and outputs from the pacemaker to the integration/effector areas.
The main mammalian pacemaker is considered to be the SCN, an area of the 
anterior hypothalamus (Stephan and Zucker 1972; Rusak and Groos 1982; Ralph et al. 
1990). The SCN is a bilateral nucleus located at the base of the third ventricle above 
the optic chiasm which SCN receives external information via two pathways, the 
retinohypothalamic and geniculohypothalamic tracts, RHT and GHT respectively. The 
RHT is a direct pathway from the retina to the hypothalamus and is considered to be 
necessary for entrainment (Johnson et al. 1988), whilst the GHT is an indirect pathway 
passing from the retina to an area of the ventral lateral geniculate nucleus (vLGN) 
called the intergeniculate leaflet (IGL). Having synapsed in the IGL the pathway passes 
to the SCN; it is considered that part of the GHT is a collateral of the RHT (for a 
comprehensive review of the visual relays to the SCN see Card and Moore 1991). The
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GHT is thought to have a modulatory role, not being necessary for entrainment but 
rather relaying information about light intensities (Pickard et al. 1987). Both retinal 
afferents synapse in the ventral lateral portion of the SCN.
The SCN, which contains high levels of 5-HT (Saavedra et aL 1974) receives 
their most robust innervation from the RN. The DR projects to the SCN via the dorsal 
raphe periventricular tract and a projection from the DR that also innervates the IGL. 
Indeed collaterals of the same DR neuron can innervate both the SCN and IGL. The 
MR pathway passes in the median forebrain bundle to the SCN (Azmitia and Segal 
1978).
Serotonin has been implicated in the control of circadian rhythms for many 
years, although only recently have data indicating its true importance started to 
emerge. The results stem from three different types of experiment; depleting or 
increasing 5-HT throughout the brain in vivo, adminstration of 5-HT agonists in vivo 
and in vitro.
Whole animal studies
If the neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) is injected 
intraventricularly then it selectively destroys 5-HT neurons in the dorsal raphe (DR) 
and decreases 5-HT in DR projection areas (Dewar et al. 1992). It is important to note 
that the median raphe (MR) does not appear to be affected, so 5-HT will still be 
present in those areas that receive MR projection although the actual amount of 5-HT 
in each region will depend on the degree of innervation by the MR. Only two studies 
have thoroughly investigated the effect of 5,7-DHT on the circadian system by 
measuring the circadian pattern of wheel-running activity in hamsters. When entrained 
to a light-dark cycle, hamsters lesioned with 5,7-DHT began wheel running earlier and 
stopped wheel-running later than sham-operated hamsters (Smale et al. 1990; Morin 
and Blanchard 1991). When the hamsters were moved to constant light the total "day" 
length (circadian period, tau) of 5,7-DHT-lesioned hamsters was significantly longer 
compared to sham-operated hamsters. In constant light lesioned hamsters tended to
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become arrhythmic i.e. the activity was not clearly defined into bouts. When these 
hamsters were then moved to constant darkness lesioned hamsters took longer to 
resume a normal circadian pattern of activity than sham-operated control hamsters 
(Morin and Blanchard 1991). Re-entrainment to an 8  hour advance in the light-dark 
cycle was not smooth in 5,7-DHT-lesioned hamsters compared to sham-operated 
controls (Smale et al. 1990). When the hamsters were put into constant darkness the 
circadian period was more variable in lesioned hamsters, showing large increases and 
decreases. The re-establishment of a stable free-running rhythm in sham-operated 
hamsters was smooth and normal, however lesioned hamsters did not establish free- 
running rhythms smoothly and tended to lapse into a desynchronised state (Smale et al.
1990).
One measure of the circadian system is the phase response curve (PRC). The 
circadian wheel-running activity of hamsters kept in constant dark can be altered by 
delivering light pulses at specific times. Light pulses delivered early in the subjective 
night delay the hamster’s activity, whilst pulses delivered late in the subjective night 
advance the animal's wheel running activity; during the subjective day there is a dead 
zone where no change in activity is recorded. The phase shift i.e. the advance or delay 
in activity, in response to light pulses delivered at specific circadian times is plotted as a 
PRC. In 5,7-DHT lesioned hamsters the phase delays in response to light pulses 
delivered at CT13-15 were significantly greater than sham operated control hamsters. 
The whole PRC was shifted by about one hour, indicating that lesioned animals were 
sensitive to light for a prolonged time span (Morin and Blanchard 1991).
These studies show that DR 5-HT neurons are important for maintaining 
endogenous pacemaker function and entrainment. The role of the MR has not been 
fully investigated.
Penev and colleagues (1993) have shown that the onset and offset of wheel- 
running activity was advanced in entrained hamsters after reserpine treatment. It was 
also noted that in constant darkness there was an increase in free-running period. 
Moreover the PRC was altered follwing reserpine pre-treatment. The phase advance in
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locomotor activity after light pulses at CT19 was significantly greater than in control 
animals.
Increasing the level of 5-HT is achieved by chronic treatment with the MAO-A 
inhibitor, clorgyline. It should be noted that in hamsters 90% of the MAO is the A 
isoform so not only 5-HT but also NA and DA will be increased. When clorgyline was 
administered to hamsters kept in constant darkness it increased their circadian period 
and delayed their activity onset and offset (Duncan et al. 1988). If hamsters were 
clorgyline-treated, following entrainment to a light-dark cycle, their circadian period 
was also increased (Duncan et al. 1988). The pattern of activity in the dark phase was 
different in clorgyline-treated hamsters; the nocturnal activity of control hamsters was 
concentrated into the first portion of the dark phase, whilst clorgyline-treated animals 
were active throughout the dark phase (Duncan et al. 1988). The PRC of hamsters 
treated with clorgyline was significantly different from saline-treated hamsters. The 
maximum phase delay occurred 2  hours later and phase advances were not as great in 
clorgyline-treated animals (Duncan et al. 1988). Tamarkin and colleagues (1983) noted 
that under a light-dark cycle, clorgyline-treated hamsters had delayed activity onsets 
and offsets. The activity onsets were advanced throughout the course of the 
experiment but the hamsters never regained their pre-treatment activity onset times. 
The delay in activity onset brought about by clorgyline treatment was dose-dependent. 
If the beginning of the dark period was advanced by 2 hours, saline-treated hamsters 
entrained within 7 days; clorgyline-treated hamsters gradually advanced their activity 
onset but never to the same extent as saline-treated hamsters and never achieved a new 
entrained rhythm (Tamarkin et al. 1983). When hamsters were entrained to a light-dark 
cycle, then treated with clorgyline or saline and subsequently subjected to constant 
darkness the clorgyline-treated hamsters had further delayed activity onsets and offsets 
(Tamarkin et al. 1983).
The results of the above studies indicate that although 5-HT is not necessary 
for the generation of circadian rhythm it appears to play a role in modulating the effect 
of light on the circadian pacemaker, although the locus of action is not clear. One
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further experiemnt lends weight to the involvement of 5-HT in circadian rhythms. If 
RU24969 is infused directly into the SCN of entrained rats, their locomotor activity 
becomes arrhythmic (Martin and Marsden 1986b). This result also suggests that 
inhibition of 5-HT release abolishes entrainment in rats. The findings of Martin and 
Marsden (1986b) may help to explain the link between decreased 5-HT release, 
disturbed circadian rhythm and depression. Figure 48 shows the levels at which the 
serotoninergic system could affect the circadian system. In addition the DR has recently 
been shown to receive a direct retinal projection in rats (Shen and Semba 1994).
In vitro studies
The neuronal firing rate of SCN cells can be measured in vitro in slices of 
hypothalamus containing the SCN. In this system the cells display a circadian rhythm in 
their firing rate, as they do in vivo, and the firing rate remains stable for several days in 
vitro. If 5-HT is administered either as a microdrop onto the ventrolateral portion of 
the SCN (Medanic and Gillette 1992) or as a bath infusion (Shibata et al. 1992; Prosser 
et al. 1993) it can shift the circadian rhythm in SCN neuronal firing for up to 3 days 
after first administration. Applications during the light phase advance the neuronal 
firing rhythm (Medanic and Gillette 1992; Shibata et al. 1992; Prosser et al. 1993) and 
the effect is mimicked by 8 -OH-DPAT and 5-carboxamidotryptamine (5-CT) (Medanic 
and Gillette 1992) a selective 5-HT1A agonist and a 5 -H T j^  agonist respectively 
(van Winjgaarten et al. 1990). Quipazine (which has affinity for virtually every 5-HT 
receptor, the 5-HT transporter and a variety of other neurotransmitter receptors, van 
Wijngaarten et al. 1990) has also been shown to dose-dependendy phase advance the 
firing rhythm (Prosser et al. 1993), but unlike the above drugs it caused phase delays 
when administered during the dark phase. Shibata and colleagues (1992) showed small 
but non-significant phase delays in firing rate during the dark phase. The effects of 
quipazine during the light phase were antagonised by NAN190 (which also blocks a p  
adrenoceptors, van Wijngaarten et al. 1990), but interestingly neither of these 
antagonists blocked quipazine's effects during the dark phase. The field potentials after 









Figure 48. Schematic diagram of the circadian system indicating afferent pathways to the central 
circadian pacemaker, the suprachiasmatic nucleus (SCN). Information about the external environment 
reaches the SCN via two pathways from the retina; a direct projection from the retina to the SCN, the 
retinohypothalamic tract (RHT) and an indirect pathway that passes from the retina via the 
intergeniculate leaflet (IGL) to the SCN. In addtion, the SCN receives a robust projection from the 
dorsal and median raphe nuclei (DR and MR respectively). The DR itself receives an afferent from the 
retinal and can innervate the IGL, some of the axons being collaterals of those fibre passing to the 
SCN.
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incorporating the SCN. These field potentials have been shown to be inhibited by 5-HT 
and 8-OH-DPAT in a dose-dependent manner (Rea et al. 1993). This shows that 5-HT 
can directly modulate the RHT input to the SCN. The spontaneous and light-induced 
activity in firing rate of IGL cells was blocked by administration of 8-OH-DPAT in a 
dose-dependent manner (Ying et al 1993). The effect of 8-OH-DPAT was antagonised 
by the non-specific 5-HT antagonist metergoline but not a 5-HT1A antagonist 
Specific in vivo studies
Two in vivo studies have further implicated 5-HT in the mediation of circadian 
rhythms. Administration of 8-OH-DPAT during the light phase advances the wheel 
running activity of rats (Tominaga et al. 1992). In addition 8-OH-DPAT administration 
significantly accelerated the rate of re-entrainment to an 8 hour advance in the light- 
dark cycle (Tominaga et al. 1992). The light-induced phase shifts in hamster's activity 
described earlier (PRC) can be blocked by 8-OH-DPAT; both advances and delays 
being inhibited. In the SCN and vLGN post-synaptic neurons are more responsive to 5- 
HT when it is administered during the dark phase (Mason 1986). Interestingly when 
the SCN was lesioned the rhythm in responsiveness of vLGN neurons was abolished; 
however depleting 5-HT throughout the brain did not modify the circadian variation in 
sensitivity of SCN neurons (Mason 1986). Therefore these studies demonstrate that 
post-synaptic receptors profoundly alter circadian rhythms in neuronal firing or 
behaviour and hence potentially pacemaker activity. Extrapolation of my findings in the 
hypothalamus to the SCN in particular, suggest that if the rhythm in 5-HT release is 
modified as a result of manipualtion of 5-HT1B autoreceptor function, then circadian 
rhythms in SCN neuronal firing and behaviour might be affected.
The above in vivo and in vitro experimental data also imply that the effects of 
5-HT on circadian rhythms are mediated by a post-synaptic 5-H T^ receptor. Prosser 
and colleagues (1993) have demonstrated 5-H T^ binding sites in the SCN, though the 
number during the light phase and dark phase were reported to be the same. However 
Roca and co-workers (1993) could not detect any mRNA for 5-H T^ receptors in the 
SCN. This is interesting because it implies there are no post-synaptic 5-HT1A receptors
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on other cell bodies in the SCN, which is at odds with the findings of Prosser and 
colleagues. One possibility is that the terminal autoreceptor in the SCN is of the 5- 
HTia subtype; The evidence presented in this thesis, together with that of Martin and 
Marsden (1986a) and O'Connor and Kruk (1992) argues against this. The possibility 
that the 5-HTj A receptor is located presynapdcally on retinal afferent terminals 
themselves cannot be ruled out. A recently cloned 5-HT receptor, termed 5 -HT7 , might 
explain the discrepancy in the results. The new human receptor, cloned and 
characterised in 1993 by Bard and colleagues is positively coupled to adenylate cyclase 
by a G protein. This fact could explain the findings of Prosser and Gillette (1989) that 
cAMP and its analogues can phase shift the circadian rhythm of SCN neuronal firing in 
vitro. The new receptor, transfected in monkey kidney cells and shows high affinity for 
5-HT (Kj 8.1nM) in binding studies, additionally it is very sensitive to 5-CT (Kj 
0.93nM) and metergoline (Kj 6.4nM); however the receptor shows low affinity for 8 - 
OH-DPAT (Kj 466nM) (Bard et al. 1993). The new receptor has also been isolated 
from rat hypothalamic tissue (Lovenberg et al. 1993). It too shows highest affinity for 
5-CT (IC5 0  0.83nM), and relatively high affinity for methiothepin (IC5 0  1.3nM), 5-HT 
(IC5 0  9nM), 8 -OH-DPAT (IC5 0  98nM) and metergoline (IC5 Q 30nM). The receptor is 
found in the thalamus, hippocampus, cortex and various hypothalamic nuclei. However 
detection of mRNA for the 5 -HT7  receptor was not consistent in the SCN, being at the 
lower detection limit of the technique. Using the circadian rhythm in SCN neuronal 
firing in vitro, Lovenberg and workers (1993) found that the 8 -OH-DPAT-induced 
phase-shift in neuronal firing was unaffected by a 5-HT1A antagonist, but blocked by 
an antagonist which displays higher affinity for the 5-HT7  receptor than the 5-HTja 
receptor. This evidence implies that the effects of 5-HT on the circadian rhythm in 
neuronal firing are mediated by a 5-HT7  receptor.
The SCN can be divided into two portions on the basis of distinct 
neurotransmitter distribution. The dorsomedial section contains high levels of 
vasopression whilst the ventrolateral portion has one of the highest concentrations of 
vasoactive intestinal polypeptide (VIP) in the brain (Beinfield et al. 1984). Retinal
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afferents, from both the RHT and GHT, have been shown to terminate on VIP neurons 
in the ventrolateral SCN (Hisano et al. 1988; Ibata et al. 1988). The serotoninergic 
projection to the SCN terminates in the same area as retinal afferents and in addition 
VIP neurons are a prime target for 5-HT in the SCN (Bosler and Beaudet 1985). There 
are indications that NPY can alter 5-HT synthesis in the hypothalamus (Vallejo et al.
1987) and 5-HT terminals have been demonstrated to possess NPY heteroreceptors 
(Schlicker et al. 1991); NPY being the neurotransmitter of the GHT (Albers and Ferris 
1984). Thus 5-HT can modulate RHT neurotransmission, has close links with the GHT 
in the SCN and affects neurons in the IGL, placing it in an important position in one of 
the key areas of the circadian system. The function of the autoreceptor controlling 5- 
HT release is therefore very important since it will mediate the biophase concentration 
of 5-HT and thus control stimulation of post-synaptic neuronal elements, possibly 
involved in the circadian system.
Circadian rhythms and depression
The experimental evidence for circdian rhythm abnormalities in depression is 
reviewed in the Introduction (chapter 1). This section aims to provide a succinct 
review of the key findings.
Many studies have shown specific abnormalities in the circadian rhythms of 
different parameters in depressed patients. The circadian rhythm in plasma prolactin, 
corticotropin, cortisol, GH, thyrotropin and melatoninn is altered in depressives but 
there is no consensus as to the nautre of the change. Additionally body temperature, 
heart rate, sleep timing and architecture are all altered in depression, although again the 
precise changes vary significantly (Hallonquist et al. 1986; van cauter and Turek 1986; 
Goetze and Tolle 1987; Daimon et al. 1992). The circadian period of core body 
temperaturee tended to be longer in depressives (Daimon et al. 1992). the early 
morning increase in ACTH and nocturnal rise of prolactin and GH all occur earlier in 
depressed patients (van Cauter and Turek 1986). Interestingly the amplitude in the 
circadian rhythm of plasma 1-try is dampened in depressed patients (Candito et al. 
1992).
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This evidence demonstrates that circadian rhythms malfunction in depression 
but they do not indicate the locus of the abnormality.
Antidepressant drugs and 5-HTjb receptors
Several studies have investigated the effect of chronic antidepressant drugs on 
the terminal 5-HT autoreceptor. The results, though, are equivocal, in vitro studies 
have demonstrated down-regualtion of the autoreceptor (Maura and Raiteri 1984; 
Moret and Briley 1990; Blier and Bouchard 1994) but not always (Blier and Bouchard
1994), on the other hand chronic antidepressant treatment has been shown either to 
decrease (Johanning et al. 1992) or not to effect the number of 5-HTiB binding sites 
(Montero et al. 1991). Studies performed in vivo also provide conflicting evidence; 
Sleight and colleagues (1988) have provided proof that ther is no autoreceptor down- 
regulation after adminsitraitron of a reuptake inhibitor or a MOAI, conversely Blier and 
co-workers (1988) and Chaput et al. (1986) have demonstrated down-regulation after 
treatment with SSRIs but not a MAOI.
The experimental findings of this thesis agree with some of the in vitro findings. 
At a comparable time point (mid light) in the anterior hypothalamus the autoreceptor 
was unaffected by antidepresssant treatment. However in the whole hypothalamus and 
frontal cortex down-reglation was observed. Interestingly, at the same time point, up- 
regulation of 5-HT 1B receptors was witnessed in the hippocampus and striatum.
Antidepressant drugs and 24 hour variation in 5-HTi B receptor function
This thesis has demonstrated a time of day dependent up- and down-regulation 
in 5-HT1B receptor function following prolonged antidepressant adminsitration. This 
up- and down-regulation alters the 24 hour pattern of control the 5-HTJB receptor 
exerts on 5-HT synthesis and release, however the pattern in each brain region studied 
was affected differently.
It is not possible to compare these data with published results because this 
work is novel. The ability of antidepressant treatment to alter the 24 hour variation in
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binding of other receptor populations has been dewmonstrated before (Kafka et ah 
1981b; ODonahue et al. 1982; Wirz-Justice et al. 1983). However the data presented 
her are the first demonstration of chronic antidepressant-induced alteration in 5-HT1B 
control of synthesis and release over 24 hours.
Interaction between 5-HT, antidepressant drugs and circadain rhythms
Previous sections of this discussion have suggested how 5-HT1B autoreceptors 
may be defective in depression, the involvement of the 5-HT system in depression and 
circadian rhythms and finally how antidepressant drugs alter 5-HT autoreceptor 
function and change the relationship between 5-HT release and autoreceptor function.
To bring all these ideas together, the model developed proposes that 
antidepressant drugs when chronically administered, are effective in alleviating 
depression with a circadian element because they alter a malfunction in 5-HT1B 
autoreceptor control of synthesis and release by up- and down-regulating the 
autoreceptor in a time of day dependent fashion. This antidepressant-induced change in 
receptor function therefore alters the 5-HT input to the biological clock, in effect 
resetting the clock. This hypothesis is depicted in figure 49.
One interesting question that arises is that, if antidepressant drugs owe their 
clinical efficacy to their ability to reset circadian rhythms, why do all depressed patients 
show unequivocal signs of circadian rhythm abnormalities? Depressive illness in which 
altered circadian rhythms are implicated might represent a subpopulation of patients in 
whom there is a malfunction of the 5-HT system in key circadian "control centres", 
specifically, the IGL and SCN, in addition to its deficiency in other brain regions 
already mentioned. If less 5-HT were released in the SCN and IGL, because of 
autoreceptor supersensitivity (presynaptic 5-HT1B receptors have been detected in the 
LGN; Boschert et al. 1994), the modulatory role of 5-HT in these two key areas could 
be lost Chronic antidepressant treatment, by increasing the biophase level of 5-HT and 
resetting disturbed autoreceptor function could normalise the 5-HT input to these two 





Figure 49. Proposed model for the mechanism by which chronic antidepressant treatment resets 
circadian rhythms via an action at the 5-HT 1 3  autoreceptor. In depression a supersensitive 
autoreceptor is expressed which leads to feedback inhibition of 5-HT synthesis and release. This 
abnormality breaks down the feedbcak relationship between 5-HT release and autoreceptor function 
altering 5-HT release over 24 hours. The change in the 24 hour pattrn of release affects post-synpatic 
targets in such areas as the IGL and SCN thus affecting circadian rhythms. Administration of 
antidepressants (ADEP) up- or down-regulates the 5-HT autoreceptor in a time of day dependnet 
fashion, which normalises the 5-HT input to the circadian system and resets circdian rhythms thus 
alleviating depression.
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administration increases 5-HT levels only in specific brain regions. The data in this 
thesis and published work also indicate that 5-HT receptors in different brain regions of 
the same animal can be differentially affected after prolonged administration of the 
same antidepressant (Martin et al. 1992b; Blier and Bouchard 1994). The results of this 
study indicate that antidepressant treatment can reset 5-HT1b control of release and 
synthesis supporting this theory, although 5-HT function in these two areas was not 
actually assessed.
Two studies have specifically investigated the effect of chronic antidepressant 
treatment on responses to 5-HT in the IGL and SCN. In both cases the antidepressant 
was imipramine which inhibits the reuptake of both 5-HT and noradrenaline. Meijer 
and Groos (1988) found that chronic imipramine treatment decreased the spontaneous 
discharge rate of neurons in the SCN and vLGN areas equally during the dark phase 
and light phase. Harrington and Rusak (1991) also found that the discharge rate of IGL 
neurons was decreased after chronic imipramine treatment Both these lines of evidence 
indicate that chronic antidepressant treatment can alter 5-HT function in key areas of 
the circadian system which leads to an effect on the endogenous neuronal properties of 
these areas. The hypothesis could be tested by eliminating presynaptic 5-HT 
autoreceptors by infusion of antisense oligodeoxynucleotides (ODN) into the RN 
before antidepressant treatment. To verify which raphe input, the DR or the MR, was 
most important for the mediation of circadian rhythms the ODNs could be infused to 
either RN and the effect on activity rhythms, IGL and SCN neuronal firing measured.
Conclusion
This thesis has investigates the hypothesis that chronic antidepressant treatment 
alters 5-HT1B autoreceptor control of synthesis and release in a phase-dependent 
manner. The results of the work presented in this thesis agree with this hypothesis. 5- 
HT synthesis and release were influenced by a 5-HTjB receptor and the degree of 
control the receptro exerted varied signficantly over 24 hours. Chronic antidepressant 
treatment signficiantly altered the 24 hour pattern of control, causing both up- and
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down-regualtion. Moreover the effect of antidepressant treatment is not confined to 
those antidepressant drugs that only direcdy affect the 5-HT system; the results with 
desipramine implicate the noradrenergic system, at least in its ability to influence the 5- 
HT system. It can therefore be concluded that prolonged administration of 
antidepressant drugs affects the 24 hour control of synthesis and release.
On the basis of this conclusion I have developed a model to explain how 
antidepressant drugs alleviate depression with a circadian element Factors that affect 
autoreceptor function will influence autoreceptor control of the circadian biophase 5- 
HT level, in turn affecting 5-HT modulation of converging post-synaptic signals. In 
those depressive illnesses characterised by a malfunction of the circadian system 
antidepressant drugs affect the abnormal 5-HT1B autoreceptor control of 5-HT release 
and synthesis in key areas of the circadian system. This control could be exerted at the 
input level or within the SCN itself, or both. Thus the model proposed here could 
accommodate the range of hypotheses of circadian abnormality in the clock itself or the 
inputs to the clock.
167
Future work
The discussion of the results obtained using 5-HTPacc to asses TrOH activity 
highlights the great gaps in knowledge of the intracellular mechanisms affecting the 
central 5-HT system. Below are listed several suggestions of work that could be 
initiated to further the understanding of the 5-HT system.
+ It would be very useful have a measure the number and affinity of presynaptic 5- 
HT1 3  binding sites over 24 hours in all brain regions that receive a major 5-HT 
innervation. The numbers and affinity of somatodendritic and terminal heteroreceptors 
need to be assessed through the light-dark cycle. Further characterisation of these 
receptors and their effects on 5-HT synthesis and release over 24 hours in all brain 
regions would be very useful. Their anatomical location should be discovered to 
determine whether they are presynaptic heteroreceptors or not The effect of chronic 
antidepressant treatment, using antidepressant drugs from differing classes, on putative 
heteroreceptor control of 5-HT synthesis and release should be investigated through 
the light-dark cycle. All the experiments above should be conducted in entrained 
animals as well as animals freely-running in constant dark and constant light 
+ The precise anatomical location of the 5-HT1B receptor affecting 5-HT synthesis 
could be determined either by selective lesioning of different neurotransmitter systems 
or by inhibiting 5-HT1B receptor expression in 5-HT neurons.
+ The effect of differing types of antidepressant drugs on basal TrOH activity needs to 
be fully addressed both in vivo and in vitro, with tissue being taken from treated 
animals.
+ The intracellular factors controlling TrOH activity ought to be elucidated. Similarly 
the regulation of 5-HT1B receptor and TrOH expression needs to be deciphered. 
Measurement of the mRNA for 5 -HT1B receptors and TrOH, and the factors affecting 
their regulation needs to be assessed over 24 hours before and after chronic 
antidepressant treatment in specific brain regions.
+The adenylate cyclase type linked to 5-HTiB receptors needs to be investigated in all 
brain regions. The activity of adenylate cyclase, its stimulation of PKA and the activity
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of PKA all need to be measured over 24 hours before and after chronic antidepressant 
treatment.
Experiments, initially at mid and end dark, should be performed to complete the 
in vivo microdialysis study. The study could then be expanded to include antidepressant 
drugs from different classes and more time points.
More generally, the role presynaptic 5-HT autoreceptors play in affecting 
circadian rhythms should be investigated in the SCN and IGL.
Circadian measurements of 1-try levels in plasma, brain and 5-HT synthesis and 
release in depressed patients grouped according to the type of depression might help to 
provide more evidence for both a 5-HT involvement in different subtypes of depression 
including depression with a circadian element
The results of these findings should help to elucidate the control the terminal 5- 
HTjb autoreceptor exerts on the function of the 5-HT neuron, as well as helping to 
untangle how antidepressant drugs are effective in depression through the 5-HT 
system. Additionally it may help to understand how antidepressant drugs affect 
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One-way or two-way analysis of variance was performed to indicate whether 
there were any differences between groups compared. However ANOVA does not 
identify where the significant differences lie. To determine differences tests based on 
Studentised range (Q) tables were performed. The test allows the comparison of any 
group with any other and is therefore conservative to keep the overall significance 
level.
A variance estimate, both values being obtained from the ANOVA, is calculated 
from the formula:
variance estimate ( Ve) y  residual sum of squares 
yresidual degrees of freedom
A critical value is then calculated using the formula:
(1) Tukey method for equal group sizes
critical value=y Vg x Q 
n
(2) Tukey/Kramer method for unequal group sizes
critical valuej Ve x O/nj + i/a2 ) x Q
where n is the number observations per group and Q is derived from Studentised range 
(Q) tables from the residual degrees of freedom and the number of groups compared. 
Q values for P<0.05 and PO.Ol are obtained.
The differences between groups being compared are calculated and compared to 
the critical value. A difference greater than the critical value is considered significant at 
either the P<0.05 or P<0.01 level depending on the difference.
W
S tatistica l analysis and outcomes of 5-HTP accum ulation experim ents
Basal synthesis rate
The results of one-way ANOVA (time) on the variation in basal 5-HTP 
levels over 24 hours
Hypothalamus Hippocampus Frontal Cortex Striatum
df 3 3 J 3
F 28.8 40.5 29.5 116
P 1.8 x 10-7 1.1 xlO-7 1.5 x 10-7 8.1 x 10'13
i
Table Al. Accumulation of 5-HTP in four brain regions after decarboxylase inhibition. 
Values are expressed in ng 5-HTP/pg protein as mean±s.e.m., n= 6  for each time point 
and brain region, differences in levels were determined by one-way ANOVA followed 
by Q test, aP<0.01 mid light vs end dark, bP<0.05 end light vs mid dark, CP<0.05 end 
light vs end dark, dP<0.01 mid dark vs end dark, eP<0.01 mid light vs end light, 
fP<0.01 mid light vs end dark, SP<0.05 end light vs mid dark, hP<0.01 mid dark vs end 
dark, ip<0.01 mid light vs end dark, JPO.Ol end light vs end dark, kpO.Ol mid dark 
vs end dark, ^<0.01 mid light vs end light, mP<0.01 mid light vs end dark, nP<0.01 
end light vs mid dark, °P<0.01 end light vs end dark and PP<0.01 mid dark vs end 
dark.
ii
Table A l. Variation in 5-hydroxytryptophan accumulation over 24 hours in four brain regions
Brain Region Mid Light End Light M id  Dark End Dark
Hypothalamus 1.08±0.06a 0.94±0.04bc 1.15±0.06M 0.75±0.03acd
Hippocampus 6.7±0.3ef 4.65±0.2eS 5.9±0.48h
Frontal Cortex 7.0±0.3* 6.8±0.45i 6.3±0.4k 3.6*02**
Striatum 1.7±0.09Im 4.7±0.4lno 2.8±0.2nP 7.4±0.2moP
Pharm acological M anipulation
Results of two-way ANOVA (treatment (trt) and time) on vehicle control 
animals from RU24969 group and RU24969 +/- (±)cyanopindolol.____________
df F 1 P
Hypothalamus Trt 1 0.003 0.95
Time 3 21.5 5.4 x 10-7
Trt x Time 3 0 . 0 0 2 0.99
Hippocampus Trt 1 1.5 0.23
Time 3 327 1 . 6  x 1 0 - 19
Trt x Time 3 3.48 0.03
Frontal Cortex Trt 1 0.35 0.55
Time 3 66.5 8.9 x 10- 12
Trt x Time J 0.37 0.77
Striatum Trt 1 0.24 0.62
Time 3 1368 5.9 x 10-2 7
Trt x Time 3 3.74 0 . 0 2
The results of two-way ANOVA (treatment (Trt) and time) on the effect of 
pharmacological agents (RU24969, (±)cyanopindolol (CP) and (+)WAY100135 
(WAY)) on 5-HTP accumulation in the hypothalamus._______________________
RU24969 RU24969 +/- (±)CP RU24969+/-WAY
df F P df F P df F P
Trt 2 42.2 3.6 x 10" 10 2 4.7 0.015 2 18 1.1 xlO -5
Time 3 36.1 6 x 1 0 - 11 3 60 4.5 x 10- 14 3 13 0 . 0 0 0 1
Trt x Time 6 0.32 0.91 6 8.3 1 . 2  x 1 0 - 5 6 0.16 0.95
iv
The results of two-way ANOVA (treatment (Trt) and time) on the effect of 
pharmacological agents (RU24969, (±)cyanopindolol (CP) and (+)WAY100135 
(WAY)) on 5-HTP accumulation in the hippocampus.________________________
RU24969 RU24969 +/- (±)CP |  RU24969 +/- WAY |
df F ? df F P df F P
Trt 2 348 2.8 x 10-24 2 1.9 0.16 2 59 1.3 x 10-10
Time 3 713 4.2 x 10*32 3 47 1.5 x 10-12 3 75 9.7 x 10
Trt x Time 6 88 5.5 x 10-20 6 9.5 3.x 10^ 6 5.1 0.003
The results of two-way ANOVA (treatment (Trt) and time) on the effect of 
pharmacological agents (RU24969, (±)cyanopindolol (CP) and (+)WAY100135 
(WAY)) on 5-HTP accumulation in the frontal cortex.________________________
RU24969 RU24969 +/- (±)CP | RU24969 WAY
df F p df F P df F P
Trt 2 53 2.1 x 10*11 2 0.29 0.75 2 48 1.2 x lO*9
Time 3 159 8.2 x 10-21 *■>J 77 9.8 x 10-16 3 7.4 0.003
Trt x Time 6 3 . j 0.011 6 1.7 0.14 6 1.8 0.16
The results of two-way ANOVA (treatment (Trt) and time) on the effect of 
pharmacological agents (RU24969, (±)cyanopindolol (CP) and (+)WAY100135 
(WAY)) on 5-HTP accumulation in the striatum.____________________________
RU24969 j RU24969 +/- (±)CP RU24969 .+/- WAY
df F P df F P df F P
Trt 2 530 2.0 x 10-27 2 3.4 0.04 2 14.2 6.0 x 10-5
Time 3 8361 1.8 x 10-51 3 235 1.0 x 10-23 3 126 2.0 x 10-14
Trt x Time 6 76 5.6 x 10-19 6 3.8 0.004 6 0.93 0.46
v
Table A2. Effect of various manipulations on the accumulation of 5-HTP in the 
hypothalamus after decarboxylase inhibition. Values are expressed in ng 5-HTP/pg 
protein, as mean±s.e.m., n=4-8 depending on time point and treatment. For simplicity, 
values obtained from the control animals of each treatment group have been pooled 
and termed vehicle. Differences between treatments and time were determined by two- 
way ANOVA followed by Studentised range test, *P<0.05 vs pooled vehicle control 
**P<0.01 vs pooled vehicle control, aP<0.01 mid light vs mid dark, bp<0.01 mid light 
vs end dark. Data from experiments using WAY100135 have been normalised, see text 
on page 71 for details.
RU24969 vs group vehicle control P<0.001 with treatment, P<0.001 with time 
and Pns (P not significant) interaction; (±)Cyanopindolol + RU24969/ (± 
)cyanopindolol vs group vehicle control PO.05 with treatment, P<0.001 with time and 
PO.OOl interaction; WAY100135 + RU24969/ WAY100135 vs group vehicle control 
PO.OOl with treatment, PO.OOl with time and Pns interaction.
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Table A2. 5-Hydroxytryptophan accumulation in the hypothalamus
Time Point ■
Treatment Mid Light End Light Mid Dark End Dark
Vehicle 1.13±0.1 0.91±0.09 1.10±0.08 0.76±0.10
3mg/kg RU24969 1.08±0.05 0.87±0.02 1.14±0.05 0.73±0.06
9 mg/kg RU24969 0.80±0.01** 0.66±0.03** 0.84±0.06** 0.52±0.07**
3mg/kg (±)Cyctnopindolol + 
~ 9mg/kg RU24969
1.50±0.03**ab 0.90±0.01 1.21±0.05a 0.66±0.06b
3mg/kg (±) Cyanopindolol 1.13±0.1 1.00±0.03 1.07±0.03 0.80±0.02
5mg/kg WAY100135 + 
9mg/kg RU24969
0 .8 8 ±0 .0 2 ** 0.67±0.01** 0.78±0.03** 0.58±0.04*
5mg/kg WAY100135 1.08±0.1 0.87±0.03 1.02±0.03 0.81±0.07
Table A3. Effect of various manipulations on the accumulation of 5-HTP in the 
hippocampus after decarboxylase inhibition. Values are expressed in ng 5-HTP/pg 
protein, as mean±s.e.m., n=4-8 depending on time point and treatment. For simplicity, 
values obtained from the control animals of each treatment group have been pooled 
and termed vehicle. Differences with time and treatment were determined by two-way 
ANOVA followed by Studentised range test, *P<0.05 vs vehicle, **P<0.01 vs vehicle, 
a<P0.01 mid light vs mid dark, bP<0.01 end light vs mid dark, CP<0.05 end light vs end 
dark, dP<0.05 mid dark vs end dark, eP<0.01 mid light vs end light, *P<0.01 mid light 
vs mid dark, SPO.Ol mid light vs end dark, hpco.Ol end light vs mid dark and 
ipO.Olmid dark vs end dark. Data from experiments using WAY100135 have been 
normalised, see text on page 71 for details.
RU24969vs group vehicle control P<0.001 with treatment, PO.OOl with time 
and PO.OOl interaction; (±)Cyanopindolol + RU24969/ (±)cyanopindolol Pn.s. vs 
group vehicle control with treatment, PO.OOl with time and PO.OOl interaction; 
WAY100135 + RU24969/ WAY100135 vs group vehicle control PO.OOl with 
treatment, PO.OOl with time and PO.Ol interaction.
Table A3. 5-Hydroxytryptophan accumulation in the hippocampus
Time Point
Treatment Mid Light End Light Mid Dark End Dark
Vehicle 7.1±0.06 4.4±0.04 5.7±0.03 4.2±0.06
3mg/kg RU24969 7.3±0.02a 4.0±0.02*bc 4.2±0.1**abcd 4.2±0.2cd
9 mg/kg RU24969 5.1±0.01**efS 3.7±0.1**eh 2.8±0.03**fhi 3.8±0.01**8i
3mg/kg (±)Cycmopindolol + 
9 mg/kg RU24969
7.3±0.6 4.3±0.1 5.4±0.3 4.2±0.2
3mg/kg (±)Cycinopindolol 6.2±0.3 5.7±0.2* 5.1±0.1 5.5±0.3**
5mg/kg WAY100135 + 
9mg/kg RU24969
5.2±0.1 ** 3.5±0.2** 2.9±0.1** 3.6±0.1*
5mg/kg WAY100135 7.2±0.2 4.4±0.1 5.2±0.4 4.8±0.4
-  -
Table A4. Effect of various manipulations on the accumulation of 5-HTP in the 
frontal cortex after decarboxylase inhibition. Values are expressed in ng 5-HTP/pg 
protein, as mean±s.e.m., n=4-8 depending on time point and treatment. For simplicity, 
values obtained from the control animals of each treatment group have been pooled 
and termed vehicle. Differences with treatment and time were determined by two-way 
ANOVA followed by Studentised range test, *PO.05 vs vehicle, **P<0.01 vs vehicle, 
aP<0.01 mid light vs end light bP<0.05 end light vs end dark, CP<0.01 end light vs mid 
dark, dP<0.01 end light vs end dark. Data from experiments using WAY100135 have 
been normalised, see text on page 71 for details.
RU24969 vs group vehicle control PO.OOl with treatment, PO.OOl with 
time and PO.05 interaction; (±)Cyanopindolol + RU24969/ (±)cyanopindolol vs 
group vehicle control Pn.s. with treatment, PO.OOl with time and Pn.s. interaction; 
WAY100135 + RU24969/ WAY100135 vs group vehicle control PO.OOl with 
treatment, PO.05 with time and Pn.s. interaction.
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Table A4. 5-Hydroxytryptophan accumulation in the frontal cortex.
Time Point
....................................................... . ....................................................................................................
Treatment Mid Light End Light Mid Dcn'k End Dark
Vehicle 7.1±0.4 7.0±0.2 6.6±0.1 3.8±0.3
3mg/kg RU24969 7.0±0.4a 5.9±0.5**ab 7.2±0.1 3.6±0.04b
9mg/kg RU24969 5.6±0.2** 4.9±0.1**cd 5.6±0.2**c 2.9±0.1*d
Smg/kg (±) Cyanopindolol + 
9mg/kg RU24969
6.4±0.4 7.1±0.4 6.1±0.2 3.9±0.1
Smg/kg (±) Cyanopindolol 6.7±0.4 6.5±0.2 6.0±0.1 4.1±0.1
5mg WAY100135 + 9mg/kg 
RU24969
5.9±0.1** 4.5±0.2** 4.9±0.2** 2.9±0.3*
5mg/kg WAYJ00135 7.4±0.6 5.7±0.2 6.9±0.1 3.8±0.1 |
Table A5. Effect of various manipulations on the accumulation of 5-HTP in the 
striatum after decarboxylase inhibition. Values are expressed in ng 5-HTP/pg protein, 
as mean±s.e.m., n=4-8 depending on time point and treatment. For simplicity, values 
obtained from the control animals of each treatment group have been pooled and 
termed vehicle. Differences with time and treatment were analysed by two-way 
ANOVA followed by Studentised range test *P<0.05 vs vehicle, **P<0.01 vs vehicle, 
aP<0.05 mid light vs end light, bP<0.05 mid light vs mid dark, CP<0.05 end light vs end 
dark, dP<0.05 mid dark vs end dark, eP<0.01 mid light vs end light, fpO.Ol mid light 
vs mid dark, 8PO.01 mid light vs end dark and hP<0.05 end light vs mid dark, *PO.01 
end light vs end dark, JPO.Ol mid dark vs end dark, kPO.Ol mid light vs end dark, 
lP<0.001 end light vs end dark, mP<0.001 mid dark vs end dark, nP<0.05 end light vs 
end dark. Data from experiments using WAY100135 have been normalised, see text on 
page 71 for details.
RU24969 vs group vehicle control PO.OOl with treatment, PO.OOl with time 
and PO.OOl interaction; (±)Cyanopindolol + RU24969/ (±)cyanopindolol vs group 
vehicle control PO.OOl with treatment, PO.OOl with time and Pn.s. interaction; 
WAY100135 + RU24969/ WAY100135 vs group vehicle control PO.05 with 
treatment, PO.OOl with time and PO.Ol interaction.
Table A5. 5-Hydroxytryptophan accumulation in the striatum.
Time Point
Treatment Mid Light End Light Mid Dark End Dark
Vehicle 1.8±0.03 4.9±0.01 3.0±0.03 7.7±0.05
Smg/kg RU24969 1.6±0.06*ab 4.7±0.03ac 3.1±0.1bd 8 .0 ±0 .1 cd
9mg/kg RU24969 1.5±0.06**ef8 4.1±0.2**ehi 2 .0 ±0 .1 **flli 6.1±0.06**gy
Smg/kg (±)Cyanopindolol + 
9mg/kg RU24969
1.9±0.1k 5.1dt0.1] 3.1±0.1m 5.8±0.3**klm
Smg/kg (±) Cyanopindolol 1 .8 ±0 . 1 4.6±0.5n 2.9±0.2 6.5±0.3*n
5mg/kg WAY1001S5 + 
9mg/kg RU24969
1.6±0.08** 3.9±0.1** 1.9±0.1** 5.8±0.4**
5mg/kg WAY1001S5 1 .8 ±0 . 1 4.6±0.5 2.9±0.2 7.4±0.3
Chronic antidepressant treatment
Results of one-way ANOVA (time) om 5-HTP accumulation after chronic 
antidepressant treatment at end light_____________________________________
Hypothalamus Hippocampus Frontal Cortex Striatum
df 2 2 2 2
F 0.81 0.40 0.004 111.8
P 0.47 0.67 1.0 4.4 x 10-7
Results of two-way ANOVA (treatment (trt) and time) on the effect of 
chronic antidepressant treatment on the RU24969-induced suppression of 5-HTP 
accumulation.
df F P
Hypothalamus Trt 2 0.96 0.39
Time 3 41.8 8  x 1 0 - 12
Trt x Time 6 1 2 . 6 1.3 x 10-7
Hippocampus Trt 2 0.7 0.47
Time J 63.3 2  x 1 0 - 14
Trt x Time 6 6 . 0 0 . 0 0 0 2
Frontal Cortex Trt 2 33.1 6.98 x 10-9
Time 3 439 2 . 1 1  x 1 0 * 2 8
Trt x Time 6 37.6 4.52 xlO - 14
Striatum Trt 2 10.3 0.0003
Time 3 632 3.5 x 10-31
Trt x Time 6 2 0 . 6 2 . 6  x 1 0 - 10
Table A6 . Effect of chronic antidepressant treatment on the response to 9mg/kg i.p. 
RU24969 in the hypothalamus. Data is expressed in ng 5-HTP/pg protein, as 
mean±s.e.m., n=4 depending on each time point and treatment. Differences with 
treatment and time were determined by two-way ANOVA with post hoc Studentised 
range test, **P<0.01 vs saline-treated + 9mg/kg RU24969 aP<0.01 mid light vs end 
light, bP<0.01 mid light vs mid dark.
Basal 5-HTP levels were unaltered after chronic desipramine or paroxetine 
treatment (F2 9=4.25, variance ratio 0.80). The effect of chronic antidepressant 
treatment significantly altered the response to RU24969 P<0.05 with treatment, 
PO.OOl with time and PO.OOl interaction.
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Table A6. Effect o f chronic antidepressant treatment on the response to RU24969 in the hypothalamus.
Tim e
T rea tm en t Mi
Saline + RL 1249690.72±0.05 0.69±0.03
Pointr u i u i
MidDark 
0.92±0.01 0.6±0.01
Paroxetine + RU24969 0.69±0.03 0.80±0.04* 0.93±0.01 0.65±0.07





Table A7. Effect of chronic antidepressant treatment on the response to 9mg/kg i.p. 
RU24969 in the hippocampus. Values are expressed in ng 5-HTP/pg protein or "̂ as a 
% of the saline value since analysis was not performed on the same HPLC system, as 
mean±s.e.m., n=4-6 depending on time point and treatment. Differences with treatment 
and time were determined by two-way ANOVA followed by Studentised range test, 
*P<0.05 compared to saline-treated + 9mg/kg RU24969, aP<0.01 mid light vs end 
light, bp<0.01 mid light vs mid dark, CP<0.01 mid light vs end dark.
Basal 5-HTP levels were unaltered after chronic desipramine or paroxetine 
treatment (F2 >i 2 =3 .8 8 , variance ratio 0.41). The effect of chronic antidepressant 
treatment significantly altered the response to RU24969 P<0.05 with treatment, 




Table A7. Effect o f chronic antidepressant treatment on the response to RU24969 in the hippocampus.
Tim e Point
=====
Mid DarkEnd LightMid IJghtTreatment
3.3±0.33.0±0.03Saline + RU24969 4.1±0.25.5±0.4
4.1 ±0.02* *abcParoxetine + RU24969




Table A8. Effect of chronic antidepressant treatment on the response to 9mg/kg i.p. 
RU24969 in the frontal cortex. Values are expressed in ng 5-HTP/pg protein or ^as a 
% of the saline value since analysis was not performed on the same HPLC system, as 
mean±s.e.m., n=4-6 depending on time point and treatment. Differences with treatment 
and time were determined by two-way ANOVA followed by Studentised range test, 
**P<0.01 vs saline-treated + 9mg/kg RU24969, aP<0.01 mid light vs mid dark, 
bp<0.01 mid light vs end dark, CP<0.01 end light vs mid dark, dP<0.01 end light vs end 
dark, eP<0.01 mid light vs mid dark, *P<0.01 end light vs mid dark, SP<0.01 mid dark 
vs end dark.
Basal 5-HTP levels were unaltered after chronic desipramine or paroxetine 
treatment (F2 i2=3.88, variance ratio 0.41). The effect of chronic antidepressant 
treatment significantly altered the response to RU24969 P<0.05 with treatment, 
P<0.001 with time and P<0.001 interaction.
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Table A8. Effect o f chronic antidepressant treatment on the response to RU24969 in the frontal cortex.
Time Point
Treatment Mid Light* End Light M 'dDark
Saline + RU24969 5.4±0.2 4.3*0.05 5.1±0.1 3.4±0.1
r —....... - — ----  - ■ -ir - ---  ■ - ...... -....  -
Paroxetine + RU24969 6.3±0.03**ab 5.0*0.01 **c 5.3±0.01acd 3.5±0.04bd
---- ----------------------------------------





Table A9. Effect of chronic antidepressant treatment on the response to 9mg/kg 
RU24969 in the striatum. Values are expressed in ng 5-HTP/pg protein or ^as a % of 
the saline value since analysis was not performed on the same HPLC system, as 
mean±s.e.m., n=3-6. Differences with treatment and time were determined by two-way 
ANOVA followed by Studentised range test, *P<0.05 vs saline-treated + 9mg/kg 
RU24969, **P<0.01 vs untreated + 9mg/kg RU24969, aP<0.01 mid light vs end dark, 
bp<0.01 end light vs end dark, CP<0.01 mid dark vs end dark.
Basal 5-HTP levels were unaltered after chronic desipramine or paroxetine 
treatment compared to saline-treated animals (1^9=4.25, variance ratio 111.8, the 
significance was found to stem from a significant difference between 5-HTP levels in 
paroxetine-treated animals vs desipramine-treated animals.). The effect of chronic 
antidepressant treatment significantly altered the response to RU24969 P<0.001 with 





Table A9. Effect of chronic antidepressant treatment on the response to RU24969 in the striatum.
Time Point ■ , ■ : ■' 1 : ■ ' ' . ' ■ • ^
Treatment Mid Light End Light M id Dark End Dark
Saline + RU24969 1.7±0.08 4.0±0.1 2.1±0.2 6.8±0.4
Paroxetine + RU24969 1.1±0.04** 4.8±0.01** 2.5±0.01 6.4±0.07




In vivo microdialysis 
Control vs calcium free buffer:
PO.OOl with treatment, P<0.01 with time and PO.OOl interaction. 
Control vs InM 8-OH-DPAT:
Pn.s. with treatment, P<0.05 with time and Pn.s. interaction.
Control vs 0.1 nM RU24969:
PO.OOl with treatment, PO.Ol with time and P<0.01 interaction. 
Control vs InM RU24969:
PO.OOl with treatment, Pn.s. with time and PO.Ol interaction. 
Control vs 5nM RU24969:
PO.OOl with treatment, Pn.s. with time and PO.05 interaction. 
Control vs lOuM RU24969:
PO.OOl with treatment, P<n.s. with time and PO.OOl interaction. 
Control vs InM methiothenin:
PO.OOl with treatment, PO.Ol with time and P<n.s.
Control vs lOnM methiothepin:
PO.OOl with treatment, PO.Ol with time and P n.s. interaction. 
InM RU24969 vs InM methiothepin + InM RU24969:
PO.OOl with treatment, Pn.s. with time and PO.05 interaction. 
5nM RU24969 vs lOnM methiothepin + 5nM RU24969:
PO.OOl with treatment, Pn.s. with time and Pn.s. interaction.
Mid light control vs 5nM RU24969:
PO.OOl with treatment, PO.Ol with time and PO.OOl interaction. 
End light vs 5nM RU24969:
PO.OOl with treatment, PO.OOl with time and PO.OOl interaction. 
Mid light saline-treated vs antidepressant-treated:
PO.OOl with treatment, PO.OOl with time and PO.05 interaction. 
End light saline-treated vs antidepressant-treated:
PO.OOl with treatment, PO.OOl with time and Pn.s. interaction.
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Table A10. Results of in vivo microdialysis experiments. Values are expressed in % 
control values as mean±s.e.m., for n see graphs on pages 128.
xxiv
Time (nuns)
Treatment -30 -15 0 15 30 45 60 75 90
Pooled control 101±0.2 99±0.2 96±0.4 102±0.8 84±0.3 85±0.7 85±0.5 86±0.5 72±0.4
Ca++free 105±0.7 95±0.7 63±3.7 11±3.7 5±1.2 2±0.6 9.5±1.4 70±1.9 55±2.7
1/uM 8-OH-DPAT 101±0.8 99±0.8 96±1.2 103±2.5 98±1.2 92±1.3 95±2.4 105±4.6 76±0.7
O.lpM RU24969 102±2.4 98±2.4 11 ±9.1 46±3.3 45±6.6 58±3.0 67±4.6 60±3.6 92±7.4
IpM  RU24969 104±1.0 96±1.0 61±2.0 61±2.0 47±4.0 53±3.0 53±2.0 63±0.8 66±2.0
5juM RU24969 101±1.7 99±1.7 66±1.0 59±1.9 48±3.0 44±1.7 49±2.2 61±5.2 37±2.2
lOpM RU24969 102±0.9 98±0.2 81±2.0 60±2.0 35±2.0 41±4.0 49±3.0 58±2.0 65±1.0
1 pM  Methiothepin 98±1.8 102±1.8 110±3.6 116±5.2 113=1=4.2 115±5.8 113±3.4 107±3.4 99±1.9
1 OpM Methiothepin 100±0.8 100±0.8 95±2.1 149±11 238±8.3 221±9.8 242±7.1 153±7.4 130±1.5
1 pM  Methiothepin ± 
1 pMRU24969
99±3.1 101±3.1 114±2.6 76±7.0 73±7.0 87±4.0 108±6.0 107±7.0 75±2.0
J
■ / ■ ■ . :
Time (mins)
Treatment -30 -15 0 15 30 45 60 75 90
1 OpM Methiothepin 
+ 5pM RU24969
102±0.2 98±0.2 102±4.6 115±6.4 83±3.8 131±6.7 122±6.0 122±7.8 137±6.8
Mid light control 101±0.8 99±0.8 97±4.4 100±1.7 92±l.5 97±1.3 99±1.7 88±1.5 84±1.4
5/iM RU24969 100±0.9 100±0.9 87±2.8 58±2.3 48±1.1 35±3.3 31 ±2.1 39±0.4 88±3.2
Saline-treated + 
5fiM RU24969
97±0.5 103±0.5 79±1.7 70±1.0 65±1.7 61±2.9 54±2.9 89±4.3 129±3.8
Paroxetine-treated + 
5pM RU24969
103±0.3 97±0.3 81±1.7 71±1.5 62±1.3 53±1.7 53±2.6 98±4.0 131±5.8
Desipramine-treated 
± 5pMRU24969
102±1.9 98±1.9 71±1.6 52±1.4 54±1.7 55±1.5 49±1.7 55±1.4 67±2.9
Time (mins)
Treatment -30 -15 0 15 30 45 60 75 90
End light control 102±0.5 98±0.5 98±1.2 104±1.2 92±1.2 98±1.2 93±1.0 79±1.5 82±1.5
5/uM RU24969 101±0.7 99±0.7 84±1.4 60±l.0 36±3 9±2.2 0±0.0 0±0.0 o±o.o
Saline-treated + 
5pM RU24969
101±0.7 99±0.7 80±2.0 69±3.9 57±2.5 40±1.9 28±2.6 1. 2=t 1.2 1.2±1.2
Paroxetine-treated + 
5pM RU24969
98±0.2 102±0.2 69±2.4 65±2.0 71±3.1 86±3.1 88±3.1 92±0.5 92±0.8
Desipramine-treated 
+ 5pM RU24969
102±0.8 98±0.8 82±6.7 72±7.4 53±5.0 30±1.8 17±0.9 7±0.8 8±0.9
I
